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Abstract
Methylation of cytosine is an epigenetic mark essential for many cellular and
developmental processes. How methylation is interpreted into transcriptional regulation is not fully
understood, but previous studies have found that this process involves the methyl-CpG binding
domain (MBD) family of proteins. Three MBD proteins, MeCP2, MBD1 and MBD2, specifically
bind methylated cytosines and recruit different co-repressor complexes to regulate transcription
and chromatin states. Genetic studies also linked MeCP2 and MBD1 to neurodevelopmental
disorders in humans and mice. However, a role for MBD2 in the brain has not been described. In
this work, we characterized the phenotypes of mice lacking MBD2. We found that, unlike MeCP2
and MBD1, Mbd2 null mice behave similarly to wildtype littermates, with the exception of mildly
altered nesting and locomotor activity and reduced body weight. To investigate the underlying
cause of different functional requirements for the MBDs, we generated knockin mice in which
endogenous MBD2 and MBD1 are biotin-tagged. We systematically compared the spatiotemporal
expression patterns of the MBDs and found that MeCP2, MBD1 and MBD3 are primarily
expressed in the brain. In contrast, MBD2 is widely expressed throughout the body at young and
adult ages. In addition, the expression of MBD2 is upregulated in adult spleen and small intestine
compared to younger ages, while MBD1 and MBD3 are only enriched at early ages in the brain.
We also determined that MBD2 interacts with the NuRD complex ubiquitously across tissues. We
conclude that MBD2 is likely dispensable for brain function and instead may mediate NuRDrelated
functions primarily in peripheral tissues. Our study provides novel genetic tools and
reveals new directions to investigate MBD2 functions in vivo.
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ABSTRACT
INSIGHTS INTO MBD2 FUNCTION REVEALED BY A NOVEL
GENETIC TAGGING APPROACH
Kathleen H. Wood
Zhaolan Zhou, Ph.D.

Methylation of cytosine is an epigenetic mark essential for many cellular and
developmental processes. How methylation is interpreted into transcriptional regulation is not fully
understood, but previous studies have found that this process involves the methyl-CpG binding
domain (MBD) family of proteins. Three MBD proteins, MeCP2, MBD1 and MBD2, specifically
bind methylated cytosines and recruit different co-repressor complexes to regulate transcription
and chromatin states. Genetic studies also linked MeCP2 and MBD1 to neurodevelopmental
disorders in humans and mice. However, a role for MBD2 in the brain has not been described. In
this work, we characterized the phenotypes of mice lacking MBD2. We found that, unlike MeCP2
and MBD1, Mbd2 null mice behave similarly to wildtype littermates, with the exception of mildly
altered nesting and locomotor activity and reduced body weight. To investigate the underlying
cause of different functional requirements for the MBDs, we generated knockin mice in which
endogenous MBD2 and MBD1 are biotin-tagged. We systematically compared the spatiotemporal
expression patterns of the MBDs and found that MeCP2, MBD1 and MBD3 are primarily
expressed in the brain. In contrast, MBD2 is widely expressed throughout the body at young and
adult ages. In addition, the expression of MBD2 is upregulated in adult spleen and small intestine
compared to younger ages, while MBD1 and MBD3 are only enriched at early ages in the brain.
We also determined that MBD2 interacts with the NuRD complex ubiquitously across tissues. We
conclude that MBD2 is likely dispensable for brain function and instead may mediate NuRDrelated functions primarily in peripheral tissues. Our study provides novel genetic tools and
reveals new directions to investigate MBD2 functions in vivo.
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CHAPTER 1: Introduction
Adapted from: Wood KH and Zhou Z. Emerging Molecular and Biological Functions of MBD2, a
Reader of DNA Methylation. Frontiers in Genetics. Submitted.

DNA METHYLATION AND ITS READERS

Establishment of DNA methylation and oxidized forms
DNA methylation at the 5’ position of cytosine (mC) is a chemical modification that is
essential for mammalian viability and development (Smith and Meissner, 2013; Suzuki and Bird,
2008). DNA methylation at CpG dinucleotides (mCG) has historically been associated with gene
repression; however, recent advances have revealed a complex role for DNA methylation in
regards to its dynamic turnover, cell type specific distribution patterns and effect on transcriptional
regulation (Suzuki and Bird, 2008). DNA is methylated by the de novo methyltransferases
DNMT3A and DNMT3B (Okano et al., 1999), in association with DNMT3L (Bourc’his et al., 2001),
and the mark is maintained through cell division by the maintenance methyltransferase DNMT1
(Yoder and Bestor, 1998). Passive demethylation occurs in the absence of DNMT activity as cells
divide without maintenance methylation (Chen et al., 2003). Active demethylation also occurs
through the conversion of mC to hydroxymethylcytosine (hmC) by the ten-eleven translocation
(TET) family of proteins (Tahiliani et al., 2009). hmC can be further oxidized by the TET proteins
to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011), which is then modified
by thymine-DNA glycosylase (TDG) and can be replaced with an unmodified cytosine through
base excision repair (BER) mechanisms (He et al., 2011). Alternatively, hmC can lead to passive
demethylation even in cells expressing the maintenance methyltransferase DNMT1, as it is a
poor substrate for this enzyme (Hashimoto et al., 2012a).These processes together complete the
cycle of cytosine modification (Figure 1.1).
Methylation and its oxidized forms are also found outside of the CpG context (mCH) in
many cell types (Lister et al., 2009; Schultz et al., 2015). While mCG is the most abundant
1

modification, both mCH and hmC are also detected across tissues and are highly enriched in
embryonic stem cells (ESCs) and the brain (Lister et al., 2009, 2013; Schultz et al., 2015). The
distribution of these modifications is developmentally dynamic and cell-type specific, but the
mechanisms that direct the precise establishment of these patterns have yet to be fully
determined (Pastor et al., 2013; Schübeler, 2015). It is critical to gain further understanding of the
mechanisms of DNA methylation because these findings will in turn aid in our elucidation of other
biological processes, including the differentiation of pluripotent cells, neuronal development and
function, and tumorigenesis, amongst many others.

DNA methylation and transcriptional regulation
It is well established that methylation affects transcriptional regulation differently
depending on the genomic context. Most CpG sites in the mammalian genome are methylated,
with the exception of CpG-dense, hypomethylated domains at putative regulatory elements or
promoter regions called CpG islands (CGI) (Deaton and Bird, 2011). A subset of CGIs are highly
methylated and induce transcriptional silencing of the associated gene with cell-type specificity
(Deaton and Bird, 2011; Illingworth et al., 2008). Highly methylated CGIs also correspond to
regions with long-term or constitutive silencing, such as imprinted genes (Li et al., 1993), the
inactive X chromosome (Csankovszki et al., 2001), and endogenous retroviruses (Walsh et al.,
1998). In contrast, increased mCG and particularly mCH density across the gene body is
associated with transcriptional activation (Maunakea et al., 2010; Mo et al., 2015; Yang et al.,
2014b). hmC is also associated with active regulatory and transcribed regions and is dynamically
regulated throughout development (Lister et al., 2013; Pastor et al., 2011; Stroud et al., 2011).
DNA methylation is intimately linked to other epigenetic factors and together these
mechanisms comprise the chromatin state and direct gene expression programs (reviewed in
(Chen and Dent, 2014). However, it is not clear how or in what order histone modifications and
DNA methylation are established and how they influence each other (Cedar and Bergman, 2009;
Schübeler, 2015; Spruijt and Vermeulen, 2014; Suzuki and Bird, 2008). Different histone marks
2

correlate with different regions of chromatin, such as promoters, enhancers and coding regions
(Kim and Shiekhattar, 2015). Different histone modifications also direct the binding of many
factors to DNA and can affect DNA methylation deposition by the differential recruitment of
DNMTs (Baubec et al., 2015; Eberl et al., 2013; Noh et al., 2015). Conversely, DNA methylation,
or the absence of methylation at CGIs, can direct the establishment of different histone marks
(Thomson et al., 2010).
DNA methylation can also directly determine how and where protein factors bind to DNA.
Transcription factors can be repelled by methylation at promoters (Blattler and Farnham, 2013;
Domcke et al., 2015), but can also bind to methylation without having repressive activity (Figure
1.2.A-C) (Spruijt and Vermeulen, 2014). Finally, mC and its oxidized forms are bound specifically
by several classes of proteins referred to as ‘readers’ of methylation, which can in turn recruit
other chromatin-modifying proteins to DNA amongst other diverse functions (Spruijt et al., 2013).
These studies have made it apparent that DNA methylation is an integral and dynamic part of
chromatin and transcriptional regulation, far from its originally presumed role as a simple
transcriptional repressor.

Readers of DNA methylation
The readers of methylation are a key component of epigenetic regulation as they function
at the intersection of several critical mechanisms that affect transcriptional regulation. The reader
proteins include the methyl-CpG binding domain (MBD), Kaiso, and SET- and Ring fingerassociated (SRA) domain and other protein families, some of which have cell-type specificity
(Filion et al., 2006; Hendrich and Bird, 1998; Prokhortchouk et al., 2001; Spruijt et al., 2013;
Unoki et al., 2004). The readers of methylation may induce transcriptional silencing by blocking
transcription or other activating protein factors from binding to DNA (Figure 1.2.D), or by inducing
chromatin remodeling through their binding partners (Du et al., 2015). However, there is evidence
that readers of methylation, particularly certain MBD proteins, are also found at actively
transcribed genes in promoters or intragenic sites, although the effect of this binding on
3

transcriptional regulation is not fully understood (Baubec et al., 2013; Günther et al., 2013)
(Figure 1.2.E,F). These findings show that the readers of methylation and its derivatives are
dynamic and developmentally regulated and therefore are essential to our understanding of
epigenetic processes. Despite many biochemical studies on proteins that bind to methylation, the
precise functions of these proteins in vivo remain unclear. In particular, the functions of the MBD
family of proteins have been of great interest because these proteins have been genetically linked
to disease in both humans and mouse models (Du et al., 2015).

The methyl-CpG binding domain family of proteins
Of the DNA methylation readers, the methyl-CpG binding domain (MBD) family
represents a group of proteins that generally act as intermediates between methylation and other
chromatin and histone modifying protein complexes. Members of the MBD protein family are
essential for varied biological processes, such as embryogenesis and brain function and have
been studied in human patients and animal models (Amir et al., 1999; Du et al., 2015; Hendrich et
al., 2001). The first MBD protein identified was MeCP2 (Lewis et al., 1992), after which six
additional proteins containing the conserved MBD were described to make up the canonical MBD
family (Figure 1.3) (Baymaz et al., 2014; Hendrich and Bird, 1998). An additional four proteins,
SETDB1/2 and BAZ2A/B, contain a phylogenetically distinct MBD and are therefore not included
in the MBD family (Hendrich and Tweedie, 2003). The non-MBD readers of methylation recognize
mCG through other protein domains, such as the SRA domain or zinc finger domains in Krüppel
or Kaiso-related proteins (Filion et al., 2006; Prokhortchouk et al., 2001; Spruijt et al., 2013; Unoki
et al., 2004).
Despite the name, in fact not all members of this family bind to mCG with exclusivity, or
at all. Instead, the MBD proteins have distinct DNA-binding properties that may contribute to their
respective functions. Early studies showed that only certain MBD proteins, including MeCP2,
MBD1, MBD2 and MBD4, are localized to hypermethylated major satellite regions (Hendrich and
Bird, 1998; Nan et al., 1997). More detailed biochemical analysis demonstrated that all the MBD
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proteins, with the exception of MBD3, MBD5, and MBD6, bind with high affinity to mCG
(Hashimoto et al., 2012a). It was later shown that MBD1 is the only MBD protein with
demonstrated affinity for unmodified cytosines, which is mediated through two or three
alternatively spliced CxxC-type zinc finger domains (Jørgensen et al., 2004). MBD4 binds to
methylated DNA and has DNA glycosylase activity that is unique in the MBD family (Hashimoto et
al., 2012b). The most recently described MBD proteins, MBD5 and MBD6, are localized at
pericentric heterchromatin but do not specifically bind methylated DNA (Laget et al., 2010).
Whether or not any MBD proteins can specifically bind to hmC has been a source of
controversy; however, it seems that none bind to hmC preferentially over mCG or unmodified
cytosine (Hashimoto et al., 2012a; Spruijt et al., 2013). MeCP2 was reported to bind hmC (Mellén
et al., 2012), but a closer examination showed that MeCP2 specifically binds hmC at CpA, but not
CpG, dinucleotides in addition to binding to methylation in CpG and CpA contexts (Gabel et al.,
2015; Guo et al., 2014). MBD3 has been linked to hmC and Tet protein function in ESCs,
suggesting that MBD3 may be specifically targeted to hydroxymethylation (Yildirim et al., 2011).
However, in vitro studies have not detected a specific interaction between MBD3 and hmC and
instead show MBD3 binding to mC, hmC and unmodified C with relatively low, equal affinity
(Hashimoto et al., 2012a; Spruijt et al., 2013).
The MBD proteins were first described as mediators of transcriptional repression that
bind to methylated DNA and recruit various chromatin-modifying or co-repressor protein
complexes (Feng and Zhang, 2001; Nan et al., 1998; Ng et al., 1999, 2000). However, only
MeCP2, MBD1, and MBD2 fit this model precisely by recruiting co-repressor complexes through
their transcriptional repression domains (TRDs) (Figure 1.3). Additionally, each of these proteins
has distinct functions. Both MBD2 and MBD3 are part of the nucleosome remodeling and histone
deacetylation (NuRD) protein complex (Feng and Zhang, 2001; Le Guezennec et al., 2006).
However, MBD2 binds to mCG while MBD3 has a point mutation in the MBD that abolishes
specific binding to methylated DNA (Saito and Ishikawa, 2002). MeCP2 associates with the
Sin3A, coREST and NCoR co-repressor complexes, but has also been linked to heterochromatin
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formation, long-range chromatin looping, and alternative splicing (Agarwal et al., 2007; Ballas et
al., 2005; Ebert et al., 2013; Kernohan et al., 2014; Lyst et al., 2013; Maunakea et al., 2013; Nan
et al., 1998). MBD1 functions in transcriptional repression and replication-dependent
heterochromatin formation (Fujita et al., 2003b, 2003c; Ng et al., 2000). Therefore, although
MeCP2, MBD1 and MBD2 are superficially similar, these proteins have distinctive DNA binding
properties, protein associations, and functions, and should be considered separately but in
context of each other. In this study, we have focused on MBD2 with the goal of characterizing
MBD2 in vivo functions through phenotypic, molecular, and gene expression analyses.

MOLECULAR FUNCTIONS OF MBD2

Evolutionary origins of MBD proteins
MBD2 and MBD3 are the two most closely related mammalian MBD proteins, with
identical genomic structure and over 70% identical amino acid sequences (Hendrich et al., 1999).
These two MBD proteins presumably arose through a gene duplication event approximately
concurrent with the separation of the ancestral vertebrate lineage. They also likely correspond to
the ancestral MBD protein because the single MBD2/3 form found in invertebrates is the only
MBD-containing protein identified in this lineage. The other MBD proteins are unique to
vertebrates and either arose from further gene duplication events of the ancestral MBD2/3, or
from an orphan MBD-like protein (Hendrich and Tweedie, 2003). The functions of MBD2/3 are
highly conserved from invertebrates to vertebrates with some important distinctions. For example,
the Drosophila melanogaster MBD2/3 orthologue interacts with components of the NuRD
complex to mediate transcriptional repression (Ballestar et al., 2001), but binds preferentially to
mCH instead of mCG (Marhold et al., 2004). There is also some variation amongst vertebrates in
the number and structure of the MBD2/3 genes. The African clawed frog (Xenopus laevis) and
zebrafish (Danio rerio) each have two forms of MBD3, one of which does bind mCG, and one
form corresponding more closely to mammalian MBD2 (Hendrich and Tweedie, 2003; Wade et
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al., 1999). In contrast, mammals have one MBD2 gene with methylation-specific binding
capability and one MBD3 gene that does not bind to methylation, each with several alternatively
spliced or translated isoforms (Hendrich et al., 1999; Hendrich and Bird, 1998).

MBD2 gene and protein structure
Mammalian MBD2 was identified in a search for proteins containing the conserved MBD
(Hendrich and Bird, 1998). MBD2 and MBD3 are on different chromosomes in humans and mice,
but have a highly similar genomic structure, further indicating the occurrence of an ancestral gene
duplication event (Hendrich et al., 1999; Hendrich and Tweedie, 2003). Murine MBD2 is encoded
by six coding and one non-coding exons, with the MBD spanning exons 2 and 3, and has three
isoforms: MBD2a, MBD2b, and MBD2c (also known as MBD2t) (Figure 1.4.A) (Hendrich et al.,
1999; Hendrich and Bird, 1998). The distinctions between the isoforms of MBD2 correspond to
different functions, and are therefore critical for the understanding of MBD protein function in vivo.
MBD2a and MBD2b arise from two alternative translation start sites and differ only in the
inclusion of a GR-rich N-terminal domain in MBD2a (Figure 1.4.B). Both isoforms contain the full
MBD and C-terminal TRD, which is essential for MBD2 interactions with co-repressor protein
complexes, including the NuRD complex (Boeke et al., 2000).
The inclusion of the GR-rich domain in MBD2a may have important functional
consequences, as post-translational methylation of this region affects interactions with DNA and
NuRD (Tan and Nakielny, 2006). Furthermore, the GR-rich domain also mediates MBD2
interactions with RNA (Jeffery and Nakielny, 2004). MBD2a protein consistently appears as a
doublet in western blot analyses, suggesting that a fourth alternatively spliced, translated,
modified, or cleaved isoform may be present (Ng et al., 1999). The C-terminal TRD region of
MBD2 includes two domains that interact with different members of the NuRD complex. The
intrinsically disordered region immediately downstream of the MBD interacts directly with the
NuRD components RBBP4/7, HDAC1/2 and MTA1/2/3 (Desai et al., 2015), while a coiled-coil
domain mediates interactions with p66α and p66β (later renamed GATAD2a and GATAD2b)
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(Feng and Zhang, 2001; Gnanapragasam et al., 2011). The third isoform, MBD2c or MBD2t,
utilizes an alternative third exon and produces a truncated protein that includes the N-terminal
GR-rich domain and the MBD, without the C-terminal TRD (Figure 1.4.B) (Hendrich and Bird,
1998). This isoform is expressed exclusively in the testes and ESCs and does not interact with
the NuRD complex, with important functional consequences particularly for pluripotent stem cells
(Baubec et al., 2013; Hendrich and Bird, 1998; Lu et al., 2014).

MBD2 and NuRD
MBD2 was first described as part of a methylation-binding protein named MeCP1
(Meehan et al., 1989), which was later resolved to be the components of the NuRD complex in
addition to MBD2 (Ng et al., 1999; Zhang et al., 1999). The composition and functions of the
NuRD complex are conserved from mammals to other vertebrates and insects (Marhold et al.,
2004; Wade et al., 1999). NuRD consists of the ATP-dependent remodeling enzymes CHD3/4,
histone deacetylases HDAC1/2, histone chaperones RBBP4/7, and DNA binding proteins
GATAD2A/B and MTA1/2/3 in addition to MBD2 and MBD3 (Torchy et al., 2015). NuRD has both
ATP-dependent nucleosome remodeling and histone deacetylase activity (Basta and Rauchman,
2015). Early studies of MBD protein function focused on the transcriptional repressive activities of
NuRD. The first model of MBD2 function proposed that MBD2 recruits NuRD to methylated sites
to induce histone-deacetylase-dependent transcriptional silencing and chromatin compaction
(Figure 1.5.A) (Ng et al., 1999). In this simplified model, reduced DNA methylation density
corresponds to less MBD2/NuRD binding activity, increased histone acetylation and more open
chromatin allowing for active transcription (Figure 1.5.B). This activity was observed in numerous
studies examining repression of methylated reporter constructs and endogenous methylated
promoters of several genes, particularly those related to cancer (Auriol et al., 2005; Chatagnon et
al., 2009; Feng and Zhang, 2001; Ng et al., 1999; Ramírez et al., 2012).
Despite the biochemical evidence for this model of MBD2/NuRD mediated transcriptional
repression, many studies now suggest that this model does not constitute the full activity of
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MBD2/NuRD. NuRD unexpectedly has both repressive and activating effects on transcription,
and may be better described as a modulator of transcriptional activity (Reynolds et al., 2013).
Furthermore, it has been challenging to identify specific methylated genes that are targeted for
regulation by MBD2 when studying transcriptome changes on a genome-wide scale. Upon loss of
MBD2, both upregulation and downregulation occurs and it is difficult to distinguish direct from
indirect effects, implying that MBD2-mediated transcriptional regulation may be context-specific
(Günther et al., 2013; Lopez-Serra et al., 2008; Stefanska et al., 2013). By correlating MBD2
binding sites determined by chromatin immunoprecipitation (ChIP) with differentially expressed
genes upon knockdown of MBD2, several studies support the model that loss of MBD2 primarily
results in derepression of lowly expressed genes (Devailly et al., 2015; Günther et al., 2013).
One possible explanation for the subtle gene regulation by MBD2 is that the interactions
between MBD2 and NuRD are more complicated than originally realized. This may be due to
different isoforms of MBD2, of which only two interact with NuRD, and post-translational
modifications of MBD2 that can also affect NuRD interactions (Baubec et al., 2013; Tan and
Nakielny, 2006). Recent findings are in opposition to the original model which proposed that
MBD2 recruits NuRD to methylated sites (Ng et al., 1999). Surprisingly, NuRD shows less than
expected co-occupancy with MBD2 at methylated regions (Figure 1.6.A). MBD2 is also found at
unmethylated, active regions and requires interaction with the NuRD complex for this localization
(Baubec et al., 2013). These findings suggest NuRD is recruiting MBD2 to unmethylated sites
where it would otherwise not bind (Figure 1.6.B). It is plausible that MBD2b, which has the Cterminal TRD, interacts with NuRD and methylated and unmethylated DNA in a similar manner to
MBD2a (Figure 1.6.C,D). In contrast, MBD2c, which does not interact with NuRD due to the
absence of the TRD, may still bind methylated sites without NuRD but is absent from
unmethylated sites (Figure 1.6.E,F) (Baubec et al., 2013). These findings support the view that
MBD2, through its interactions with NuRD, may be involved in transcriptional activation as well as
repression (Baubec et al., 2013; Reynolds et al., 2013).
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The other critical factor that may be affecting MBD2 function is the role of MBD3 in
complex with NuRD. MBD3 was identified as an essential member of the NuRD complex with
transcriptional repressive activity, despite not binding to methylated DNA (Wade et al., 1999).
Two further studies gave strong indication that MBD2 and MBD3 may have very different
molecular functions in vivo. First, NuRD incorporates MBD2 or MBD3 into mutually exclusive
complexes (Le Guezennec et al., 2006) and second, genetic studies of mice show distinctly
different null phenotypes for each gene (Hendrich et al., 2001). MBD3 is considered to be a core
NuRD component with repressive activity (Morey et al., 2008; Saito and Ishikawa, 2002; Wade et
al., 1999), but its exact functions within NuRD and the functional mechanisms of NuRD assembly
with either MBD2 or MBD3 are unknown.
It is clear that MBD2/NuRD and MBD3/NuRD have distinct genome-wide distributions
(Baubec et al., 2013; Günther et al., 2013) and different functions, particularly in ESCs (Gu et al.,
2011; Kaji et al., 2006; Lu et al., 2014). Together these findings suggest that transcriptional
regulation by MBD2 is more dynamic and multifaceted than originally proposed, and this may
help explain why direct targets of MBD2 regulation have been difficult to identify in vivo. Further
work is required to determine the dynamics of MBD2, MBD3 and NuRD recruitment to chromatin
and how MBD2 may function within and also independently of NuRD.

MBD2 and other protein complex interactions
Although MBD2 is usually associated with the NuRD co-repressor complex, there is
increasing evidence that MBD2 functions may rely on interactions with several other diverse
protein complexes. Several of these interactions directly affect MBD2 binding to NuRD, and it is
possible that they also mediate NuRD-independent functions. The most well described example
is the post-translational methylation of MBD2 by PRMT1 and PRMT5 (Le Guezennec et al., 2006;
Tan and Nakielny, 2006). Methylation of the N-terminal RG-rich region of MBD2a (Figure
1.7.A,B), and presumably MBD2c although this has not been shown directly (Figure 1.7.C,D),
reduces the affinity of MBD2 for the NuRD complex and for methylated DNA. Importantly, these
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interactions are MBD2-specific because no PRMT proteins are associated with MBD3/NuRD (Le
Guezennec et al., 2006). Methylation of histone H4 by PRMT1 or PRMT5 produces
transcriptionally active or repressed chromatin, respectively (Nicholson et al., 2009). It is unknown
if either PRMT protein modifies chromatin in addition to MBD2 where MBD2/NuRD is bound, or if
these functions are independent from each other.
There is also evidence that MBD2 interacts with other chromatin- or transcriptionregulating protein complexes besides NuRD. MBD2 can form a complex with TACC3 and the
histone acetyltransferase pCAF to activate transcription (Angrisano et al., 2006). Another study
showed that MBD2a, but not MBD2b, reactivates transcription of unmethylated, cAMP-responsive
genes through interactions with RNA helicase A, part of the CREB transcriptional coactivator
complex (Fujita et al., 2003a). Interestingly, when MBD2 is associated with either of these protein
complexes it is not bound to histone deacetylases, which are key components of the NuRD
complex. It is not clear if these interactions represent additional NuRD-independent functions of
MBD2, or if they only serve to mediate MBD2-NuRD interactions.
Finally, there is evidence that MBD2 has a role in cell cycle progression. MBD2 was
found to associate with the transcription factor histone nuclear factor P (HiNF-P, also known as
MIZF), which regulates transcription of histone H4 genes at the G1/S phase transition (Mitra et
al., 2003; Sekimata et al., 2001). Another group found that MBD2 immunoprecipitates with and
co-localizes with DNMT1 at replication foci (Tatematsu et al., 2000). However, a more recent
study demonstrated that MBD2 and other MBD proteins are delayed in their recruitment to
chromatin after DNA replication, as opposed to binding concurrently or soon after replication
(Alabert et al., 2014). Further work is necessary to resolve the many remaining questions
surrounding the mechanisms of MBD2 function both in association with and independent of the
NuRD complex. The majority of studies on MBD2 protein complex interactions have been
performed in cell culture systems, and there is little information on these mechanisms in a
relevant biological context.
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DNA binding properties and genome-wide localization of MBD2
Several MBD proteins have different DNA-binding properties that may be related to their
different functions in vivo, such as MeCP2 binding to non-CpG methylation, which is abundant in
neurons (Gabel et al., 2015). MBD2 binds specifically to mCG, and there has been no
demonstrated affinity for methylation in mCH contexts, hmC or unmodified cytosine (Hashimoto et
al., 2012a; Spruijt et al., 2013). Interestingly, MBD2 also binds to mRNA and siRNA with high
affinity in an MBD-independent manner through its basic N-terminal RG repeats in vitro (Jeffery
and Nakielny, 2004). One candidate for regulation by MBD2 is the lncRNA Xist, which is derepressed in the absence of MBD2, but not other MBD proteins (Barr et al., 2007). However, this
repression is maintained through transcriptional silencing of the methylated Xist locus, and it is
unknown if MBD2 also interacts with the Xist lncRNA directly.
The binding of MBD2 to methylated sites depends on the presence of an intact MBD and
the methylating activities of the DNMT proteins (Baubec et al., 2013). Several studies have
examined MBD2 binding to specific loci such as the methylated regulatory regions of BRCA1 or
Foxp3 (Auriol et al., 2005; Wang et al., 2013), but only a few attempts have been made to
determine the genome-wide distribution of MBD2. These experiments are complicated by the fact
that DNA methylation patterns are dynamic and cell-type specific (Schultz et al., 2015) and
antibodies to MBD2 are generally unreliable; therefore all ChIP data to date have been acquired
using cell culture or biochemical tagging approaches (Baubec et al., 2013; Chatagnon et al.,
2011; Devailly et al., 2015; Günther et al., 2013; Menafra et al., 2014).
Studies in HeLa cells (Chatagnon et al., 2011; Günther et al., 2013), mouse ESCs
(Baubec et al., 2013), and breast cancer cell lines (Devailly et al., 2015; Menafra et al., 2014) all
showed that MBD2 localization is highly correlated with methylation, as expected, with no
detectable sequence specificity. MBD2 is enriched at transcription start sites, promoters, and
exons that coincide with methylated CGIs (Baubec et al., 2013; Günther et al., 2013; Menafra et
al., 2014). Highly methylated sites that have low mCG density, such as most repetitive regions
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and low-CpG promoters, introns and intergenic regions, show low or no enrichment for MBD2
(Baubec et al., 2013; Günther et al., 2013).
Surprisingly, MBD2 was also detected at unmethylated sites including intermediate- and
high-CpG promoters that correlate with the presence of activating histone marks. The MBD2c
isoform, which lacks the C-terminal region that interacts with NuRD, was lost from these regions
but retained at methylated sites, which suggests that MBD2 localization to unmethylated sites is
NuRD-dependent. MBD2 binding to unmethylated promoters is also associated with tissuespecific regulatory regions and low levels of gene expression (Baubec et al., 2013; Günther et al.,
2013; Menafra et al., 2014).
In contrast, MBD3 binding, similar to NuRD, is not correlated with methylation and
instead is enriched at transcriptionally active, open chromatin (Baubec et al., 2013; Günther et al.,
2013). Despite evidence from several studies that MBD2/NuRD and MBD3/NuRD are localized at
active chromatin, biochemical evidence shows that NuRD is repelled by the activating histone
mark H3K4me3 (Eberl et al., 2013). Therefore, the mechanisms of MBD2/NuRD recruitment and
distribution on chromatin remain poorly understood. Additionally, the dynamics and biological
consequences of NuRD formation with either MBD2 or MBD3 are unclear, particularly in the in
vivo cellular context.

BIOLOGICAL FUNCTIONS OF MBD2

Neuronal functions of the MBD protein family
Epigenetic mechanisms in the brain are distinctive because DNA methylation changes
dynamically throughout development and in learning and memory processes (Heyward and
Sweatt, 2015; Lister et al., 2013; Szulwach et al., 2011). The highly complex network of diverse
neuronal subtypes have distinct epigenomic and transcriptional profiles (Mo et al., 2015), further
suggesting that epigenetic regulation is essential for the maintenance and function of the brain.
Most MBD proteins are associated with neuronal functions in both humans and mice. The most
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well studied example is MECP2, which when mutated, deleted, or duplicated causes the
neurodevelopmental disorder Rett syndrome (Amir et al., 1999; Pohodich and Zoghbi, 2015).
Loss of MBD5 is the causative factor in 2q23.1 microdeletion syndrome, characterized by
intellectual disability, behavioral problems and seizures (Talkowski et al., 2011). Mutations in the
other MBD proteins have not been definitively shown to cause specific disorders in humans, but
have been correlatively linked to autism spectrum disorder (ASD) (Cukier et al., 2010, 2012; Li et
al., 2005).
Mouse models with deletion of Mecp2 or Mbd5 closely recapitulate the symptoms of the
respective human disorders, reflecting the conserved functions of these proteins (Camarena et
al., 2014; Guy et al., 2001). Mice with mutation, deletion or duplication of Mecp2 show changes in
many phenotypes associated with the human disorder, including decreased anxiety-related
phenotypes, impaired motor ability, reduced sociability, deficits in learning and memory, seizures,
respiratory abnormalities, and premature lethality (Bissonnette et al., 2014; Goffin et al., 2012).
Mice with loss of Mbd1 show many of the same phenotypes as Mecp2 mice that are commonly
associated with ASDs in humans, including changes in anxiety-related phenotypes, decreased
sociability and impaired learning and memory (Allan et al., 2008; Zhao et al., 2003).
Furthermore, the NuRD complex and MBD3 also have important neuronal functions.
Mbd3 constitutive null mice are embryonic lethal (Hendrich et al., 2001), but a Mbd3 brain-specific
conditional null mouse has defects in cortical thickness and neuronal differentiation and is
neonatal lethal (Knock et al., 2015). In addition, a recent study identified a brain-specific isoform
of the NuRD component CHD5 which interacts with MBD3, but not MBD2, which suggests that
MBD3 has brain-specific functions distinct from MBD2 (Potts et al., 2011). The NuRD complex is
also essential in the brain. Genetic deletion of NuRD complex component CHD4, which disrupts
the NuRD complex, affects gene expression programs in the cerebellum that regulate synaptic
differentiation (Yamada et al., 2014).
In contrast to the relatively severe phenotypes of the other MBD protein null mice, Mbd2
null mice are viable and fertile and the only reported behavioral phenotype is a maternal nurturing
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deficit (Hendrich et al., 2001). It has been speculated that MBD2 may also have brain-specific
functions judging by the essential role of the other closely-related MBD proteins in the brain (Du
et al., 2015). A role for MBD2 in several other peripheral cell types have reported, including
embryonic stem cells and various cells of the immune system, but the effect of these functions on
any phenotypes of Mbd2 mice have not been fully characterized (Cook et al., 2015; Lu et al.,
2014; Wang et al., 2013).

Isoform-specific roles of MBD2 in pluripotent cells
The maintenance, proliferation and differentiation of pluripotent cells is highly dependent
on epigenetic mechanisms (Meissner, 2010). It is clear that MBD3 has an essential role in
pluripotent ESCs because Mbd3 null mice are early embryonic lethal (Hendrich et al., 2001). In
contrast, mice with loss of each other MBD protein are viable, albeit with a range of phenotypic
severity (Du et al., 2015). Recent work has revealed an important role for MBD2 in pluripotent
cells. MBD2 is more lowly expressed in ESCs compared to MBD3 (Lu et al., 2014) and was
initially thought to repress reprogramming of somatic to induced pluripotent stem (iPS) cells (Lee
et al., 2013). However, further efforts found that differentially spliced isoforms of MBD2 actually
have a role in both repression and promotion of reprogramming to pluripotency in human
pluripotent stem cells (hPSCs) (Lu et al., 2014). MBD2a, the longest isoform that includes both
the N-terminal GR-rich domain and C-terminal TRD, is specifically enriched in differentiated
fibroblasts (DFs) while alternatively spliced MBD2c, which lacks the TRD, is enriched in hPSCs.
Overexpression of MBD2a in hPSCs disrupts pluripotency presumably by mediating NuRD
targeting to the OCT4 and NANOG promoter regions and downregulating their expression. In
contrast, MBD2c is also bound at these promoters but does not interact with NuRD.
Overexpression of MBD2c together with other reprogramming factors in DFs actually enhances
reprogramming efficiency. The authors conclude that MBD2a and MBD2c mediate the balance
between proliferation and differentiation of hPSCs (Lu et al., 2014).
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It is unclear why Mbd2 constitutive null mice are viable and fertile when there is a role for
MBD2 and NuRD in pluripotent cells (Hendrich et al., 2001; Lu et al., 2014; Reynolds et al.,
2012). Similarly to the brain, it is possible that MBD3 may be sufficient to mediate NuRD-related
functions during embryogenesis. However, a genetic interaction between Mbd2 and Mbd3 argues
that MBD3 cannot fully compensate for loss of MBD2 (Hendrich et al., 2001). The role of MBD3 in
pluripotent cells has been better studied but is not fully understood. MBD3-deficent blastocysts
fail to develop mature epiblast after implantation, accompanied by significant gene expression
changes, suggesting that MBD3 is required for differentiation (Kaji et al., 2006, 2007). These
findings were supported by a study that showed that NuRD, with MBD3, is required to
dynamically regulate expression of pluripotency genes in ESCs in order to transition to
differentiation (Reynolds et al., 2012). The function of MBD3 in reprogramming of differentiated
somatic cells to iPS cells has been controversial. Two studies found that removal of NuRD
increased reprogramming efficiency (Luo et al., 2013; Rais et al., 2013), while another study
supports that NuRD is essential for reprogramming (Dos Santos et al., 2014). These conflicting
results suggest that MBD3/NuRD may have different context-specific effects on differentiation,
but further studies are needed to resolve this question.

Emerging roles for MBD2 in immunity
There is strong evidence that DNA methylation and other epigenetic mechanisms are
essential in hematopoiesis and differentiation of myeloid and lymphoid cell lineages (ÁlvarezErrico et al., 2014; Shih et al., 2014). For example, CD4+ T cells undergo extensive
transcriptional, chromatin remodeling and DNA methylation changes during maturation (Komori et
al., 2015). NuRD, MBD2 and MBD3 have roles in multiple lymphoid cell populations (Dege and
Hagman, 2014a). The core NuRD component CHD4 is required for the maintenance and
differentiation of hematopoietic stem cells (Yoshida et al., 2008). However, a specific role for
MBD2 in these cells and other early progenitors has not been described. Mbd2 null mice have
unaltered lymphoid organs and major lymphocyte subsets, suggesting that MBD2 may not be
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required at early stages of hematopoiesis (Hutchins et al., 2002). In B cells, the NuRD complex
interacts with various transcription factors to mediate temporal changes in development and
differentiation (Gao et al., 2009; Musselman et al., 2012). Transcriptional regulation of the B-cell
specific Cd79a gene involves MBD2-dependent CHD4/NuRD recruitment, but whether B cells are
broadly affected in Mbd2 null mice is unknown (Ramírez et al., 2012).
The functions of NuRD and MBD2 in several T cell populations have been studied more
extensively. Loss of MBD2 has been linked to changes in proliferation or maturation of multiple T
cell populations. These changes may arise from altered expression of several critical factors,
some of which are controlled by differentially methylated regulatory regions. For example, loss of
MBD2 or NuRD components CHD4 or MTA2 skews CD4+ T cell polarization towards Th2
populations, with implications for pathogen resistance (Hosokawa et al., 2013; Hutchins et al.,
2002, 2005; Lu et al., 2008). One study proposed that these changes may occur because
MBD2/NuRD regulates expression from the Th2 cytokine locus, which is demethylated during
Th2 cell differentiation (Aoki et al., 2009).
Interestingly, MBD2 also indirectly affects CD4+ T cell maturation by regulating gene
expression programs in dendritic cells, which are required to direct T helper cell maturation (Cook
et al., 2015). The maturation of CD8+ T cell populations into effector and memory cells after
acute viral infection is also directly affected by loss of MBD2, consistent with MBD2 regulating
expression of surface markers and cytokines (Kersh, 2006). Finally, MBD2 regulates the
expression of the master T regulatory (Treg) cell transcription factor Foxp3 (Lal et al., 2009;
Wang et al., 2013). MBD2 binds to a Treg-specific demethylation region (TSDR) upstream of
Foxp3 that becomes demethylated in thymus-derived natural Tregs. MBD2 promotes the Tet2mediated demethylation of the TSDR in Treg cells. Consequently, Mbd2 null mice show
decreased Treg numbers and impaired Treg suppressive function in addition to retaining
methylation at the TSDR (Wang et al., 2013).
Disruptions to the NuRD complex are detrimental to immunity, as evidenced by a study
that showed mice with loss of MTA2 develop a severe lupus-like autoimmune disease (Lu et al.,
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2008). Although loss of MBD2 results in reduced numbers of Treg cells, Mbd2 null mice
surprisingly do not develop autoimmunity possibly because their T effector cells are less
responsive to stimulation and more susceptible to Treg suppression (Wang et al., 2013). In fact,
loss of MBD2 is protective against experimental autoimmune encephalomyelitis, a model of T cell
mediated autoimmunity and demyelinating diseases of the central nervous system (Zhong et al.,
2014). In human patients, increased levels of MBD2 and global demethylation in CD4+ T cells
has been observed in several autoimmune disorders, including systemic lupus erythematosus
(Balada et al., 2007; Liu et al., 2011), systemic sclerosis, dermatomyositis (Lei et al., 2009) and
MBD2 was determined to be a susceptibility locus for psoriasis (Tsoi et al., 2012). These human
and mouse studies point to MBD2/NuRD being an essential regulator of immune function with
therapeutic potential. However, considerable effort is required to fully understand the complexities
of MBD2 function in immunity at the cellular and systemic levels.

Implications for MBD2 function in cancer
Factors that shape the epigenome have been studied extensively in regards to cancer
initiation, progression and treatments (Baylin and Jones, 2011). The NuRD complex is thought to
mediate tumorigenesis by modifying expression or activities of transcription factors linked to
cancer, targeting hypermethylated tumor suppressor genes for transcriptional silencing, and
maintaining genomic stability (Lai and Wade, 2011). Many studies have attempted to link loss of
MBD2 or MBD3 to significantly increased cancer predisposition in human patients, but evidence
for this is limited. Studies of MBD2 and MBD3 in cancer have therefore focused on their potential
as therapeutic targets. However, concerns have been raised regarding the feasibility of directly
targeting these proteins and possible off-target effects (Parry and Clarke, 2011).
MBD2 has been studied particularly in the context of colorectal cancer, but questions
remain as to the specific role of MBD2 in tumor initiation or progression. MBD2 is required for
regulation of gene expression in the gastrointestinal tract, as Mbd2 null mice show altered spatial
expression of several genes in the small intestine and colon (Berger et al., 2007). Loss of MBD2
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is protective against tumorigenesis specifically in Apc

Min/+

colorectal tumorigenesis (Sansom et al., 2003). The Apc

mice, a mouse model of sporadic

Min/+

mouse develops tumors due to

significantly upregulated Wnt signaling (Sansom, 2004), which is downregulated in the absence
of MBD2 (Phesse et al., 2008). While these results suggest targeting MBD2 may have
therapeutic potential for colorectal cancer, further investigations show that the downregulation of
Wnt signaling may not be related to MBD2-specific functions. First, Mbd2 null mice in a wildtype
background do not show any changes in intestinal histology or Wnt signaling (Phesse et al.,
2008). More importantly, similar downregulation of Wnt signaling and reduced tumorigenesis
occurs when perturbing several other chromatin binding or modifying factors, including the
DNMTs (Cai et al., 2014), the methylation-binding protein Kaiso (Prokhortchouk et al., 2006), and
the chromatin remodeling factor Brg1 (Holik et al., 2014). In contrast, MBD3 is more likely to have
a direct function in the gastrointestinal tract. Loss of MBD3 specifically in the gut results in
increased tumorigenesis induced by inflammation through the upregulation of targets of the AP-1
transcription factor (Aguilera et al., 2011). It is currently unknown if these pathways are also
affected by loss of MBD2.
MBD2 may directly affect tumorigenesis because reduced expression of MBD2 inhibits
tumor growth in cultured cell lines and in human cancer cell xenografts in mice (Campbell et al.,
2004). One way this could occur is through the de-repression of tumor suppressor genes. MBD2
binds to hypermethylated promoters of tumor suppressor genes and contributes to their
transcriptional silencing, which has been shown to occur in multiple human cancer cell lines
(Lopez-Serra et al., 2008). Therefore, loss of MBD2 may be protective against tumorigenesis by
relieving transcriptional repression of hypermethylated tumor suppressor genes such as
p14(ARF) and p16(INK4A) that commonly show aberrant methylation in colon cancer cells
(Magdinier and Wolffe, 2001; Martin et al., 2008). Similar mechanisms have been observed in
glioma cells (Zhu et al., 2011) and breast cancer cells (Mian et al., 2011).
Interestingly, MBD2 has been shown to directly repress human telomerase reverse
transcriptase (hTERT) in several cancer cell types (Chatagnon et al., 2009). hTERT is usually
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hypermethylated and silenced, but is expressed in most cancer cells and therefore, in regards to
this mechanism, loss of MBD2 may encourage tumor growth. However, loss of MBD2 has
complex effects on gene expression with both upregulation and downregulation of many genes in
breast cancer and liver cancer cell lines (Devailly et al., 2015; Stefanska et al., 2013).
Downregulation of certain genes in the absence of MBD2 may be protective against
tumorigenesis. In prostate cancer cells, loss of MBD2 suppresses tumor growth through
hypermethylation and silencing of pro-metastatic genes (Shukeir et al., 2006). These complexities
indicate that identification and manipulation of specific therapeutic pathways targeted via MBD2
will be challenging. Furthermore, the majority of these studies have identified misregulation of a
single locus in cultured cells and do not fully address the role of MBD2 in a biological, cellular
context.
Studies of MBD2 in human cancer patients also point to MBD2 as a potential regulator of
tumorigenesis. The finding that the 18q21 locus that includes Mbd2 is deleted in 70% of human
colorectal cancers (Fearon et al., 1990) led to speculation that Mbd2 could be a candidate tumor
suppressor gene itself. However, further investigation showed that only the deleted in colon
cancer (DCC) gene at this locus is likely to be directly linked to cancer progression. All other
neighboring genes, including Mbd2, are rarely affected by hypermethylation or point mutations in
colorectal cancer (Bader et al., 2003; Derks et al., 2009). Mbd3 is also generally unaffected by
mutations or epigenetic changes in colon cancer (Zhu et al., 2004).
Despite the absence of mutations in MBD2 or MBD3 in cancer patients, there is evidence
that these genes show altered regulation in tumors. Both MBD2 and MBD3 are downregulated in
multiple human tumor types, but it is not clear what effect this has on tumor progression (Kanai et
al., 1999; Müller-Tidow et al., 2001; Pontes et al., 2014). Studies of MBD2 in breast cancer have
produced conflicting results. One study found that MBD2 is upregulated in breast tumors (Billard
et al., 2002), while another found no difference (Müller et al., 2003). Analysis of single nucleotide
polymorphisms in Mbd2 and breast cancer were similarly difficult to interpret, although some
weak associations were detected (Sapkota et al., 2014; Zhu et al., 2005). Because MBD2
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appears to have variable or context specific effects on tumorigenesis, significant further
investigations into the molecular mechanisms of MBD2 function must be undertaken to identify
potential therapeutic targets associated with these functions.

THE CHARACTERIZATION OF MBD2 FUNCTIONS IN VIVO

Of the MBD family proteins, considerable efforts have been made to understand the
functions of MeCP2 because mutations in this protein are genetically linked to neurological
disease (Pohodich and Zoghbi, 2015). MBD1, MBD3 and MBD5 have also been the subject of
many mouse model studies with implications for brain development and embryogenesis
(Camarena et al., 2014; Yildirim et al., 2011, 3; Zhao et al., 2003). In contrast, MBD2 functions
have been examined almost exclusively using cultured cells (Feng and Zhang, 2001; Ng et al.,
1999). These studies have shed light on important biochemical attributes of MBD2, but the
functions of MBD2 in vivo remain largely unexplored.
Previous work has shown that Mbd2 null mice are viable and fertile with only a reported
nurturing deficit (Hendrich et al., 2001). This scenario raises significant questions about MBD2
function in vivo. It is surprising that MBD2 is the most highly conserved MBD protein in mammals
with reported functions in immune and ESCs, yet in contrast to the other MBD proteins, loss of
MBD2 does not result in overt or specific phenotypes (Cook et al., 2015; Lu et al., 2014; Wang et
al., 2013). The most common explanation put forth for this observation is that the other MBD
proteins are compensating for the loss of MBD2 functions. However, the fact that the MBD
proteins have distinct DNA binding properties and protein associations does not support this
hypothesis (Du et al., 2015). Even MBD3, arguably the best candidate for MBD2 compensation
due to their common association with NuRD, has distinctly different DNA-binding properties and
is unlikely to recapitulate the role of MBD2 (Baubec et al., 2013; Hendrich et al., 2001). Therefore,
there likely remain many unrealized functions for MBD2 in vivo. Previous studies have pointed to
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a role for MBD2 in immunity (Wang et al., 2013), the gastrointestinal system (Berger et al., 2007),
and in tumorigenesis (Sansom et al., 2003), all with significant implications for human disease.
In this study, we sought to expand our understanding of MBD2 in vivo functions with two
parallel genetic approaches. First, we characterized multiple aspects of the Mbd2 null mouse
phenotype, beginning with phenotypes that have been observed in other MBD protein null mice
(Chapter 2) (Guy et al., 2001; Zhao et al., 2003). Second, in order to analyze MBD2 in vivo
functions, we developed a novel transgenic mouse lines expressing biotin-tagged alleles of
endogenous MBD2 and systematically compared the spatiotemporal expression of MBD2 in
context of the other MBD proteins (Chapter 3). Together, this work identifies previously
uncharacterized in vivo aspects of MBD2 function and new directions for further studies.
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CHAPTER 1 FIGURES

Figure 1.1. The cytosine modification cycle.
Unmodified cytosine is methylated by the DNA methyltransferase proteins DNMT1, DNMT3A and
DNMT3B. 5-methyl cytosine is oxidized by TET1, TET2, or TET3 to 5-hydroxymethylcytosine.
Further oxidation of hydroxymethylcytosine by the TET proteins yields 5-formylcytosine and 5carboxylcytosine. 5-carboxylcytosine is converted to an unmodified cytosine by thymine-DNA
glycosylases (TDG) and base excision repair (BER) pathways.
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Figure 1.2. Models of DNA methylation affecting transcription factor recruitment.
(A) The binding of transcription factors at hypomethylated regulatory regions drives transcriptional
activation. (B) Activating transcription factors are blocked from binding to hypermethylated
regulatory regions, resulting in transcriptional silencing. (C) Methylation-specific transcription
factors may bind hypermethylated regulatory regions to activate transcription. (D) Methyl-CpG
binding domain (MBD) proteins can bind mCG-dense regions and block transcription factor
binding, leading to transcriptional silencing. MBD proteins may bind to actively transcribed genes
at intragenic (E) or promoter (F) sites, but the effect of this binding on transcriptional regulation is
unclear.
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Figure 1.3. The methyl-CpG binding domain (MBD) family of proteins.
All MBD family proteins contain a highly conserved methyl-CpG binding domain (blue box) in
addition to other functional domains. The MBD of MBD3 has a point mutation (*) that abolishes
methyl-CpG binding. MBD5 and MBD6 do not specifically bind methyl-CpG (lighter blue box).
MeCP2, MBD1 and MBD2 contain C-terminal transcriptional repression domains (TRD) that
interact with co-repressor protein complexes (orange box). MBD1 has CxxC-type zinc finger
domains which mediate DNA binding. MBD2 has an N-terminal glycine/arginine rich domain
(yellow box) and a C-terminal coiled-coil domain, which is also found in MBD3 (green box). The
functions of MBD4 are mediated through a C-terminal glycosylase domain (red box). Both MBD5
and MBD6 contain proline rich domains (tan box) while MBD5 has a PWWP motif (purple box)
that binds methylated histones.
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Figure 1.4. The isoforms of MBD2 contain different functional domains.
(A) The Mbd2 transcript has seven exons, with non-coding regions (smaller gray box) in exons 1,
6 and 7. Coding regions are contained in exons 1-6 (white and filled boxes). The methyl-CpG
binding domain (MBD, blue box) is split between exons 2 and 3 with the glycine/arginine rich
region (yellow box) in exon 1. There are two translation start sites corresponding to MBD2a and
MBD2b, respectively. MBD2c includes an alternatively spliced exon (striped box) between exons
2 and 3. (B) MBD2a utilizes the first translation start site and includes the G/R rich domain, MBD
and C-terminal transcriptional repression domain (TRD). Translation of MBD2b excludes the Nterminal G/R rich domain. MBD2c includes the alternatively spliced exon and does not contain the
C-terminal TRD.
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Figure 1.5. Simplified model of transcriptional regulation by MBD2 and NuRD.
(A) MBD2 binds to mCG-dense regions as a component of the NuRD complex, which induces
histone deacetylation and chromatin compaction (large arrows) leading to transcriptional
silencing. (B) At transcriptionally active sites, MBD2/NuRD is replaced by histone
acetyltransferases and activating transcription factors to induce histone acetylation and open,
active chromatin.

27

Figure 1.6. DNA binding dynamics of MBD2 isoforms and NuRD.
(A) MBD2a binds to methyl-CpG dense sites with the NuRD complex. (B) At unmethylated sites,
MBD2 recruitment to DNA is dependent on interactions with NuRD through the C-terminal
transcriptional repression domain (TRD). (C) Similarly to MBD2a, MBD2b binds to methyl-CpG
dense sites with NuRD and may be recruited to unmethylated sites via interaction with NuRD (D)
MBD2c lacks the C-terminal TRD and does not interact with NuRD. Therefore, MBD2c may bind
methylated sites without NuRD (E) and, in this model, would not be recruited to unmethylated
sites by NuRD (F).
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Figure 1.7. DNA binding dynamics of MBD2 depend on post-translational modifications.
(A) MBD2a and NuRD binding to methylated sites results in nucleosome remodeling (large
arrows) and deacetylation, producing transcriptional silencing. (B) Post-translational methylation
of the N-terminal glycine/arginine rich region of MBD2a by PRMT1/5 reduces the affinity of
MBD2a for NuRD and methylated DNA and may not produce transcriptional repression. (C)
MBD2c does not interact with the NuRD complex but does bind methylated DNA. It is not fully
understood how this binding may affect transcriptional regulation. (D) MBD2c has the N-terminal
G/R rich domain, but it is not clear if it is also methylated by PRMT1/5 and if this modification
would affect DNA binding similarly to MBD2a.
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CHAPTER 2: Phenotypic characterization of Mbd2 Null Mice
Adapted from: Wood, K. H., Johnson, B. S., Welsh, S. A., Lee, J. Y., Cui, Y., Krizman, E.,
Brodkin, E. S., Blendy, J. A., Robinson, M. B., Bartolomei, M. S., Zhou, Z. Tagging methyl-CpG
binding domain proteins reveals different spatiotemporal expression and supports distinct
functions. Epigenomics. In Press.

ABSTRACT

Methylation of cytosine is an epigenetic mark that is essential for many biological
processes, including brain development and function. The methyl-CpG binding domain (MBD)
family of proteins specifically bind methylated cytosines and recruit different co-repressor
complexes to regulate transcription and chromatin state. Genetic studies have linked the MBD
proteins MeCP2 and MBD1 to neurodevelopmental disorders related to autism spectrum disorder
(ASD) in humans and mice. However, a role for MBD2 in the brain has not been described. In this
study, we characterized the behavioral phenotypes of mice lacking MBD2. We found that, in
contrast to MeCP2 and MBD1, Mbd2 null mice are largely similar to control littermates, with mildly
altered home-cage activity, nesting and body weight. To further investigate these phenotypes, we
examined gene expression changes in the striatum and hypothalamus of Mbd2 null mice and
also quantified the levels of biogenic amines in the cortex and striatum. Our results show that a
small number of genes show altered expression in the striatum and hypothalamus and that
biogenic amine levels are equivalent to wildtype littermates. We conclude that, in contrast to the
closely related proteins MeCP2 and MBD1, MBD2 appears to be dispensable for brain functions
at the age that we examined.
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INTRODUCTION

Epigenetic mechanisms, including DNA methylation, are essential for proper brain
function. DNA methylation at CpG and CpH sites and hydroxymethylation change dynamically in
the brain throughout development concurrently with maturation of synapses (Lister et al., 2013).
In the mature brain, synaptic plasticity and learning and memory processes are dependent on
epigenetic mechanisms (Feng et al., 2010; Heyward and Sweatt, 2015). Furthermore, epigenetic
mechanisms are linked to the vast diversity of neuronal cell types, each with unique
transcriptional programs and functional properties (Mo et al., 2015).
Genetic studies of MBD proteins in humans and animal models have demonstrated a
critical role for this protein family in the brain (Allan et al., 2008; Amir et al., 1999; Cukier et al.,
2010, 2012; Guy et al., 2001; Zhao et al., 2003). Mutations in several MBD proteins have been
identified in individuals with autism spectrum disorder (ASD), although further work is needed to
determine if these mutations are causative (Cukier et al., 2010, 2012). MeCP2 and MBD5 are
linked to the specific neurological diseases Rett syndrome and 2q23.1 microdeletion syndrome,
respectively (Amir et al., 1999; Talkowski et al., 2011), both of which are closely recapitulated in
mouse models with deletion or mutation of each gene (Camarena et al., 2014; Goffin et al.,
2012). Mbd1 null mice also exhibit behavioral phenotypes that mimic features of ASD such as
learning and memory deficits, reduced sociability, and changes in anxiety-related phenotypes
(Allan et al., 2008; Zhao et al., 2003). Furthermore, MBD3 and multiple components of the MBDassociated co-repressor complexes, such as NuRD, Sin3A, and NCoR/SMRT, also have critical
roles in the brain (Knock et al., 2015; McQuown et al., 2011; Potts et al., 2011; Schoch and Abel,
2014; Yamada et al., 2014).
Given the similarities between the MBD proteins and the link between MBD proteins and
neurodevelopmental disorders, we hypothesized that MBD2 may also have a role in brain
-/-

function. Although a nurturing deficit has been reported in Mbd2 null (Mbd2 ) mice (Hendrich et
al., 2001), the extent to which loss of MBD2 leads to other behavioral phenotypes related to brain
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-/-

function has yet to be determined. We carried out behavioral characterization of Mbd2 mice
similar to studies of Mecp2 and Mbd1 null mice (Allan et al., 2008; Goffin et al., 2012). Many of
-/-

the phenotypes we found in Mbd2 mice are seen in mice with genetic or pharmacological
disruption to striatal dopamine (Palmiter, 2008). In order to determine if these systems are
affected by loss of MBD2, we asked if loss of MBD2 affects biogenic amine levels or gene
expression in the striatum. We also assessed hypothalamic neuropeptide expression to
-/-

investigate if the low body weight observed in Mbd2 mice has neurological etiologies. We found
-/-

that Mbd2 mice are equivalent to wildtype and heterozygous littermates on most measures,
including behavioral assays, differentially expressed genes, and levels of biogenic amines.
Therefore, our results indicate that MBD2, unlike the closely related proteins MeCP2 and MBD1,
is largely dispensable for brain functions and behaviors examined in this study.

METHODS

Animal Husbandry
All experiments were conducted in accordance with the ethical guidelines of the US National
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of
the University of Pennsylvania. All mice were housed in a standard 12 h light/12 h dark cycle with
access to ample amounts of food and water. All experiments were performed on mice on a
congenic sv129:C57BL/6J background unless otherwise stated. All assays were performed on
-/-

male littermates aged 2-3 months. Mice deficient in MBD2 (Mbd2 ) are previously described
-/-

(Hendrich et al., 2001). All Mbd2 mice, wildtype and heterozygous littermates were bred from
heterozygous parents to avoid any confounding effects from nurturing deficits reported in Mbd2

-/-

dams (Hendrich et al., 2001). Male and female mice were weighed weekly beginning at postnatal
-/-

day 14. Mice deficient in MBD1 (Mbd1 ) are previously described (Zhao et al., 2003). Mice were
genotyped using a PCR-based strategy to detect mutant and wildtype alleles of Mbd2 and Mbd1.
The genotyping primer sequences are listed in Table 2.1.
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Table 2.1. Mbd2 and Mbd1 null mice genotyping primer sequences.
Primers

Sequences

Product size

Mbd2 knockout allele
genotyping

5’-ACGCTGGCCTAGTGCCGTGC-3’
5’-TTGTGGTTGTGCTCAGTTC-3’
5’-TCCGCAAACTTCTATTTCTG-3’

Wildtype: 631bp
Mbd2 knockout: 200bp

Mbd1 knockout allele
genotyping

5’-TCTTCTCAGACTGAGAAGGGTGA-3’
5’-CACTGAACATTGCCCAGAGCACA-3’
5’-AAACGGCGGATTGACCGTAATGG-3’

Wildtype: 300bp
Mbd2 knockout: 500bp

Behavioral Assays
All animal behavioral studies and video analysis were performed blinded to genotype. Mice were
allowed to habituate to the testing room for a minimum of 30 minutes before testing began for all
assays. Each test was performed at the same time of day. All equipment was thoroughly cleaned
between trials. Tests were performed in the following order with less stressful assays performed
first: zero maze, social approach, locomotor, Barnes maze, accelerating rotarod, fear
conditioning.

Locomotor
Locomotor activity was measured by the number of infrared beam breaks in a photobeam frame
(Med Associates). Mice were individually placed into a home cage-like environment with clean
bedding surrounded by the infrared photobeam frame. Activity was quantified as the total number
of beam breaks over one sixty-minute trial.

Accelerating Rotarod
Mice were place on an accelerating rotarod apparatus (Med Associates) for 16 trials (4 trials a
day for 4 consecutive days). Each trial lasted a maximum of 5 minutes while the rod accelerated
from 4 to 40 rpm. Mice were allowed to rest for at least 15 minutes between trials. The time and
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rpm at which the mouse fell off the apparatus or completed a full rotation while gripping the rod
was recorded.

Zero Maze
The elevated Zero Maze (Stoelting) consists of a circular platform with two open quadrants and
two walled (closed) quadrants. Mice were placed in the center of one closed quadrant and
allowed to freely explore for 5 minutes. Video recordings of each trial were hand-scored for time
spent in open and closed quadrants.

Social Approach Test
The social approach test was performed in a three-chambered apparatus as previously described
(Fairless et al., 2011). Mice were tested in a box with walls partially dividing the chamber into
three areas: center, left and right. Two identical clear Plexiglas cylinders with holes were placed
in the left and right sides. During the first habituation phase, the test mouse was placed into the
center of the box and allowed to freely explore the three chambers with empty cylinders for 10
minutes. During the second social test phase, an unfamiliar stimulus mouse (adult male
gonadectomized A/J mouse; The Jackson Laboratory) was placed into one cylinder in the
designated social chamber. A novel plastic object (paperweight) was simultaneously placed into
the other cylinder in the designated non-social chamber. The test mouse was then allowed to
explore freely for 10 minutes. Left and right chambers were designated as social or non-social
chambers alternately for each trial before the trial began. Video recordings of each trial were
analyzed with TopScan software (Clever Systems) for the time the mouse spent in each chamber
and the time spent directly sniffing the cylinders during each test phase.

Olfaction
Mice were tested for their ability to distinguish between neutral and social odors using a
previously described protocol with modification (Yang and Crawley, 2009). Mice were placed
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individually into a clean cage with bedding and presented with cotton-tipped wooden applicators
dipped in water, almond extract, or bedding of an unfamiliar cage. Each stimulus scent was
presented for 1 minute with a 1-minute inter-trial interval. Time spent sniffing was defined as time
the animal spent oriented with its nose 2 cm or closer to the cotton tip with scent.

Buried food retrieval
Mice were tested for their ability to find a small piece of hidden food using a previously described
protocol with modifications (Yang and Crawley, 2009). For two consecutive days before testing,
single-housed mice were presented with a piece of novel palatable food (one piece of sweetened
cereal). Mice that did not consume the cereal by the next day were excluded from the study. To
test the mice, a piece of cereal was buried under clean bedding in a new cage in a randomly
determined corner. Mice were placed in the new cage and the amount of time needed to find and
begin eating the buried food was recorded.

Nesting
Nesting behavior was assessed using the scoring system previously described (Deacon, 2006).
Mice were single housed with clean bedding and provided with a pressed square of cotton.
Twenty-four hours later, nests were assigned a score of 0 (no nest building behavior observed) to
5 (cup shaped nest with high walls, all material used).

Barnes Maze
Mice were tested for spatial learning and memory using a Barnes maze (Sunyer et al., 2007)
(San Diego Instruments), which consists of a white circular platform (36 inch diameter) with 20
holes (2 inch diameter) around the perimeter. An escape box was located under the target hole.
Entry into off-target holes was blocked by a piece of black Plexiglas. The platform was 36 inches
above the floor and four distinct visual cues were placed on the walls surrounding the platform.
During each trial, the test mouse was allowed to explore the maze until the mouse found and
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entered the escape box or for a maximum of 150 seconds. If the mouse did not enter the escape
box at the completion of the trial, it was gently guided into the box by the experimenter and
allowed to remain there for 1 minute before returning to its home cage. Mice were trained in one
trial per day for four consecutive days. Trials were video recorded and analyzed with TopScan
software (Clever Systems). Measures quantified included primary latency (time to initially reach
the target hole) and total latency (time to enter escape box through target hole), and number of
errors (visits to non-target holes).

Fear conditioning
On the training day, mice were placed in individual chambers (Med Associates) for two minutes
followed by a loud tone (85 dB, 2 kHz) for 20 seconds, co-terminating with a two second, 0.75-mA
foot shock. Mice were left undisturbed for two minutes, after which a second tone-shock pairing
was delivered. Mice were returned to their home cage 90 seconds after the second shock.
Twenty-four hours later, mice were tested for context-dependent memory by being placed into the
same testing chambers without a tone or shock for 5 minutes. One hour later, mice were tested
for cued memory by being placed into a novel chamber for two minutes and playing the same
loud tone without shock for one minute. Freezing behavior, defined as no movement except for
respiration, was analyzed with FreezeScan NI version 2.0.

Food Intake
Single-housed male mice were each given 150g of standard chow in their home cages. Mice had
unrestricted access to food and water during testing. For two consecutive days, food was
removed, weighed, and carefully replaced to habituate mice to this process. Measurements from
the first two days were not included in the analysis. Food was removed, weighed, and replaced
for five consecutive days following habituation and mice were weighed on the final testing day.

Quantitative reverse transcription PCR
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Total RNA was isolated using Trizol reagent (Invitrogen) and treated with TURBO DNase
(Ambion). cDNA was generated from 1 µg of total RNA by random hexamer priming using
SuperScriptIII reverse transcriptase (Invitrogen). Quantitative PCR (qPCR) was performed on 10
ng of the resulting cDNA using SYBR Green detection (Applied Biosystems). All qPCR primer
pairs are exon-spanning and listed in Table 2.2. Gapdh was used as an internal normalization
control.

Table 2.2. Primers used for RT-qPCR.
Gene

Forward Primer

Reverse Primer

Agrp

5’-TAGATCCACAGAACCGCGAGT-3’

5’-GAAGCGGCAGTAGCACGTA-3’

Npy

5’-CTCCGCTCTGCGACACTAC-3’

5’-AGGGTCTTCAAGCCTTGTTCT-3’

Pomc

5’-CTGGAGACGCCCGTGTTTC-3’

5’-TGGACTCGGCTCTGGACTG-3’

Mbd2

5’- AACTGGAGGAGGCACTGATG-3’

5’- GGGGAAGGTCAGTCGAAAGT-3’

Mecp2

5’-CATACATAGGTCCCCGGTCA-3’

5’-CAGGCAAAGCAGAAACATCA-3’

Gapdh

5’-GATGCCCCCATGTTTGTGAT-3’

5’-GGTCATGAGCCCTTCCACAAT-3’

HPLC analysis of monoamine levels
Brain tissues were resected on ice, weighed, and immediately frozen in liquid nitrogen. Samples
were sonicated on ice for 10 sec in homogenizing buffer containing 250nM 3,4dihydroxybenzylamine as an internal standard, followed by centrifugation at 14,000 rpm at 0°C for
20 min. Levels of monoamines were determined using HPLC with standard methods as described
previously (Howerton et al., 2014). The standard curve was from 0-10 pmol for each monoamine.
Data acquisition and analysis was performed by blinded to genotype.

RNA-seq
Total RNA was isolated using Trizol reagent (Invitrogen) and treated with TURBO DNase
(Ambion). 2µg of total RNA was used as input with the TruSeq Stranded mRNA Library Prep Kit
(Illumina) according to the manufacturer’s instructions. Samples were sequenced to an
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approximate depth of 50 million reads per sample at 100 nucleotides using the HiSeq 2000
(Illumina). The raw FASTQ files of the RNA-seq were mapped using STAR program (Dobin et al.,
2013) under the parameters of "--outFilterMultimapNmax 1 --outFilterMismatchNmax 3". Number
of reads for each gene was counted using in house Perl programs. Differentially expressed genes
were identified by edgeR (Robinson et al., 2010) with a false discovery rate (FDR) < 0.05.

Statistics
Statistical analysis was performed using Prism 6.0 (GraphPad Software). Individual statistical
tests are stated in the figure legends.

RESULTS

Behavioral characterization of Mbd2 null mice
Given that genetic studies of humans and mice have linked several MBD proteins to ASD
and neurodevelopmental disorders, we hypothesized that MBD2 may also have a critical role in
brain function and that loss of MBD2 would result in behavioral phenotypes similar to those
observed in Mecp2 or Mbd1 null mice (Allan et al., 2008; Camarena et al., 2014, 5; Du et al.,
-/-

2015; Guy et al., 2001). Although an Mbd2 null mouse (Mbd2 ) has been generated, the only
reported phenotype is a pup nurturing and retrieval deficit (Hendrich et al., 2001) and a full
phenotypic characterization has not been reported. In this mouse, exon 2 of Mbd2 is replaced
with a promoterless 7kb β-Geo LacZ cassette, removing most of the conserved MBD (Hendrich et
al., 2001). Small amounts of read-through transcript are present, but no full-length protein of
either MBD2 isoform (MBD2a and MBD2b) is detectable, indicating this is a null allele (Hendrich
et al., 2001). We focused our analysis on behavioral phenotypes that are affected in mouse
models of ASDs, such as Mecp2 or Mbd1 null mice, and assessed motor function, anxiety-related
behaviors, sociability, and learning and memory (Allan et al., 2008; Goffin et al., 2012; Pasciuto et
al., 2015).
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Changes in locomotor activity have been observed in Mecp2 null mice (Goffin et al.,
-/-

2012) so we quantified the locomotor activity of Mbd2 mice in a home-cage like environment.
-/-

We found that Mbd2 mice show significantly reduced locomotor activity compared to wildtype
+/+

+/-

(Mbd2 ) and heterozygous (Mbd2 ) littermates (Figure 2.1.A). We then asked if the observed
hypoactivity could be attributed to motor impairments, as motor function is also affected in Mecp2
null mice (Goffin et al., 2012). We tested motor coordination and learning in a rotarod task, in
which mice were challenged to stay on an accelerating rod for 16 total trials over four days. All
genotypes showed comparable improvement in this task over each trial and testing day,
-/-

indicating that motor coordination and learning is not impaired in Mbd2 mice (Figure 2.1.B).
Anxiety-related phenotypes are altered in both Mecp2 and Mbd1 null mice (Allan et al., 2008;
Goffin et al., 2012). Therefore, we used a zero maze to assess anxiety, a task that takes
advantage of a mouse’s innate preference for enclosed spaces. Mice that spend increased time
in the open arm of the maze are inferred to have decreased anxiety-related behavior (Crawley,
-/-

2007). We found Mbd2 mice displayed a preference for the closed arm that was equivalent to
control littermates, indicating that anxiety-related behavior is not affected by the loss of MBD2
(Figure 2.1.C).
-/-

We next assessed whether Mbd2 mice exhibited several autistic-like phenotypes that
have been shown to be affected in mice lacking MeCP2 or MBD1 (Allan et al., 2008; Goffin et al.,
2012). Impaired social interaction is a common feature of ASDs and is recapitulated in numerous
mouse models (Fairless et al., 2011; Pasciuto et al., 2015). Mice are inherently social animals
and most mice prefer to interact with other mice (Fairless et al., 2011). We tested sociability of
-/-

Mbd2 mice using the social approach test in a three-chambered apparatus (Figure 2.1.D). This
assay tests the preference of the test mouse to interact with a novel social stimulus (unfamiliar
+/+

mouse) or novel object. In the first habituation phase of the test, Mbd2 , Mbd2

+/-

and Mbd2

-/-

mice showed no significant difference in time spent sniffing two empty cylinders. At the start of
the second phase of the test, a novel stimulus mouse and novel object were introduced to the
+/+

+/-

-/-

cylinders. We found no significant difference between Mbd2 , Mbd2 , and Mbd2 littermates in
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the amount of time spent sniffing the social stimulus mouse, suggesting sociability is not affected
by the loss of MBD2.
Detection of olfactory cues is essential for many murine behaviors including social
interactions. MBD2 and MeCP2 deficient mice have impairments in differentiation or proliferation
of olfactory receptor neurons, but it is unknown if olfaction is affected (Macdonald et al., 2010).
Impairment in olfactory ability may affect outcomes in the sociability assay and other behavior
-/-

tests. Therefore, we evaluated olfaction by testing whether Mbd2 mice can distinguish between
scent cues in a swab-sniff test (Figure 2.1.E). We found that all genotypes spent more time
sniffing a social scent versus neutral water or almond scents as expected, indicating these mice
-/-

have the olfactory ability to distinguish between scents. However, Mbd2 mice spent significantly
less time sniffing a social scent than wildtype littermates. This result may be due to decreased
-/-

home-cage activity (Figure 2.1.A) because there is a trend for Mbd2 mice to spend less time
sniffing the neutral scent swabs as well. Alternatively, this result may indicate olfactory
impairment. To distinguish between these possibilities, we performed a secondary olfaction test in
which we quantified the time needed for mice to find and retrieve a buried piece of food in a clean
-/-

home cage (Figure 2.1.F). Mbd2 mice found and retrieved the hidden food as quickly as
littermates, indicating these mice can detect and respond to olfactory cues similarly to littermates.
We next assayed nest building as test that is commonly used to assess home cage
behaviors. Nesting is a spontaneous, complex behavior and is considered to be an indicator of
home-cage social behavior and general welfare in mice (Deacon, 2006). Nesting is affected by
neurological and as well as external factors affecting behavior. Several mouse models of ASD
and neurodegenerative disease and mice experiencing social defeat have impaired nesting
-/-

activity (Jirkof, 2014; Otabi et al., 2015; Pasciuto et al., 2015). We found that Mbd2 mice show
impaired nest building activity in contrast to wildtype and heterozygous littermates (Figure 2.1.G).
Together with the reduced home-cage locomotor activity (Figure 2.1.A), these findings indicate
-/-

that Mbd2 mice have altered home-cage behaviors but the exact etiologies of these changes in
behavior are difficult to determine.
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Deficits in learning and memory have been found in numerous mouse models of ASDs
and have also been observed in mice lacking MeCP2 or MBD1 (Allan et al., 2008; Goffin et al.,
-/-

2012; Pasciuto et al., 2015). To determine if Mbd2 mice have a similar phenotype, we tested
spatial learning and memory using the Barnes maze paradigm over four consecutive training
-/-

days. Mbd2 mice showed a slight but significant increase in the time needed to initially reach the
target hole on the second training day (primary latency, Figure 2.1.H), but equal time to enter the
target hole and complete the trial on all testing days (total latency, Figure 2.1.I) compared to
wildtype and heterozygous littermates. The increase in primary latency time on the second
training day is unlikely to reflect significant changes in learning and memory because Mbd2

-/-

mice are comparable to control littermates on all other measures in this assay, including the
number of errors made on all days (total number of visits to non-target holes, Figure 2.1.J).
As the Barnes maze paradigm primarily tests hippocampal-dependent spatial memory,
-/-

we also sought to determine if other aspects of learning and memory are affected in Mbd2 mice.
The fear conditioning test assesses amygdala-dependent cued memory in addition to amygdalaand hippocampus-dependent contextual memory (Crawley, 2007). During training, there were no
significant differences between genotypes in freezing behavior before or after the foot shock
-/-

(Figure 2.1.K). On the testing day, Mbd2 mice showed significantly less cue-dependent freezing
behavior than wildtype and heterozygous littermates, but equivalent context-dependent freezing
behavior. Although these findings may be indicative of a mild learning and memory phenotype,
the altered home-cage activity levels (Figure 2.1.A) may confound the results obtained here.
Furthermore, the absence of a significant phenotype in the Barnes maze analysis (Figure 2.1.H-J)
support that these findings may be attributed to differences in activity rather than learning and
memory phenotypes.
-/-

In summary, we found that Mbd2 mice are equivalent to wildtype and heterozygous
littermates on most measures tested, with the notable exception of homecage locomotor activity
and nest building. These results are in contrast to mice lacking MeCP2 or MBD1, which show
significant alterations in locomotor activity, sociability, anxiety-related behaviors and deficits in
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learning and memory (Allan et al., 2008; Goffin et al., 2012). Therefore we conclude that unlike
most MBD proteins, MBD2 does not have a major impact on brain functions that underlie many
key behavioral phenotypes relevant to ASD.

-/-

Mbd2 mice have reduced body weight and decreased food intake associated with altered
hypothalamic neuropeptide expression
-/-

Although Mbd2 mice are viable and fertile as previously reported (Hendrich et al., 2001),
+/+

+/-

we noticed that these mice have reduced reproductive ability. We also weighed Mbd2 , Mbd2 ,
-/-

-/-

and Mbd2 male and female littermates and found that Mbd2 males and females have subtle
but significantly lower body weights beginning at 4 and 6 weeks of age, respectively (Figure
2.2.A,B). Loss of MeCP2 and MBD1 both affect brain weight, as well (Goffin et al., 2012; Zhao et
-/-

al., 2003). Therefore, we tested if brain weight is affected in Mbd2 mice and compared these
-/-

values to total body weight. We observed that Mbd2 male mice have slightly but significantly
decreased brain weight, but have increased brain weight as a percentage of body weight
compared to littermates (Figure 2.2.C,D). This finding suggests that the low brain weight of Mbd2
/-

-

mice is likely due to loss of overall body mass.
-/-

To further explore the low body weight observed in Mbd2 mice, we next measured daily
-/-

food intake for each genotype. We found that male Mbd2 mice consume less food per day
compared to wildtype and heterozygous littermates (Figure 2.2.E). However, when food
-/-

consumption is normalized to body weight, Mbd2 mice consume comparable amounts of food
for their body size as littermates (Figure 2.2.F). These findings are in contrast to mice with Mecp2
mutations, which show increasing phenotypic severity with age in addition to significantly reduced
body and brain weight (Goffin et al., 2012).
-/-

We then asked if the low body weight observed in Mbd2 mice has a neuronal origin.
Neuronal systems sense levels of circulating hormones such as leptin and insulin and nutrient
signals in order to regulate body energy stores and feeding activity (Schwartz, 2005). The arcuate
nucleus of the hypothalamus contains several populations of neurons including the orexigenic
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agouti-related peptide (AgRP)–neuropeptide Y (NPY) neurons that stimulate food intake and
reduce energy expenditure and the anorxegenic proopiomelanocortin (POMC) neurons that
reduce appetite and stimulate energy expenditure. Lower levels of body fat and caloric intake are
associated with reduced levels of leptin, which in turn increases expression of Agrp and Npy and
downregulates expression of Pomc (Yi and Tschop, 2012) (Figure 2.3.A). Changes in expression
of these peptides are therefore indicative of hypothalamic sensing of an energy imbalance.
However, this does not reveal the etiology of the imbalance, which may be affected by neuronal
factors such as reduced dopamine signaling (Yang et al., 2014a) or extrinsic factors such as a
high fat diet (Schwartz, 2005).
We examined the expression levels of the orexigenic peptides Agrp and Npy and
-/-

anorexigenic peptide Pomc and in the hypothalamus of three-month old wildtype and Mbd2 mice
using RT-qPCR (Figure 2.3.B). As a control, we also determined that Mbd2 expression is
-/-

significantly reduced and Mecp2 expression is unchanged in Mbd2 mice, as expected. In Mbd2
/-

-

mice, Pomc is significantly downregulated, which indicates hypothalamic sensing of a energy or

nutrient deficit. Unexpectedly, Agrp and Npy expression show no statistically significant
-/-

differences between wildtype and Mbd2 mice and in fact show a trend towards down regulation.
-/-

Together, these results signify that Mbd2 mice are sensing a nutrient deficit but are not
motivated neurochemically to increase their food consumption.

-/-

Mbd2 mice have equivalent biogenic amine content and few differentially expressed
genes in the striatum compared to wildtype littermates
-/-

Although Mbd2 mice are comparable to control littermates on most measures, we next
sought to determine if the observed changes in locomotor activity, body weight, and impaired
nesting behavior are linked to any alterations in biogenic amine levels. Genetic or
pharmacological disruption of biogenic amine levels, particularly striatal dopamine, is associated
with many of these phenotypes, including low body weight, hypophagia, hypoactivity, and
impairments in nesting and pup nurturing (Henschen et al., 2013; Palmiter, 2008; Yang et al.,
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2014a). We performed HPLC analysis to measure the abundance of essential monoamines and
-/-

their metabolites in the cortex and striatum of wildtype and Mbd2 littermates (Figure 2.4.A,B).
These include norepinephrine (NE), dopamine (DA) and its metabolites 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), serotonin (5-HT) and its
metabolite 5-hydroxyindoleacetic acid (5-HIAA). We found that none of the measured biogenic
-/-

amine levels in the cortex and striatum are altered in Mbd2 mice compared to wildtype
littermates. Therefore, the loss of MBD2 is unlikely to affect monoamine signaling in the brain, in
contrast to the essential role of MeCP2 in regulating these systems (Panayotis et al., 2011).
In addition to examining biogenic amines particularly in the striatum, we also sought to
determine if loss of MBD2 is associated with significant changes in gene expression in the brain.
We assessed differentially expressed genes (DEGs) in the striatum of adult wildtype and Mbd2

-/-

littermates, as disruption to striatal signaling and particularly dopamine is associated with many of
-/-

the phenotypes observed in Mbd2 mice (Henschen et al., 2013; Palmiter, 2008; Yang et al.,
2014a). We performed poly-A selected mRNA-seq and first analyzed the total number of reads
and mapped reads (Table 2.3). As an additional experimental verification, we determined that
-/-

there are no reads mapped to exon 2 of Mbd2 in Mbd2 mice, as this exon is deleted (Hendrich
et al., 2001) (Figure 2.5).
We found a total of 38 DEGs using an FDR value of <0.05, including 21 genes
upregulated and 17, including Mbd2, downregulated. Of these DEGs, 18 genes showed greater
-/-

than 2-fold change in expression comparing wildtype to Mbd2 mice (Figure 2.6). The DEGs
have diverse functions with no significant enrichment for any gene ontology terms (data not
shown, Figure 2.7). Although several genes have been linked to ASDs, it is not clear if MBD2 is
directly regulating expression of these genes or if the DEGs are secondary effects of MBD2
function in other cell types or systems. In either scenario, further work is required to determine the
biological implications of altered expression of these genes and whether they contribute to the
-/-

phenotypes observed in Mbd2 mice.
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-/-

Table 2.3. Total and uniquely mapped reads from wildtype and Mbd2 poly-A selected
RNA-seq in the striatum.
Sample

Total Reads

Uniquely Mapped Reads

Wildtype Replicate 1

57,648,692

49,232,956 (85.40%)

Wildtype Replicate 2

51,110,555

43,509,724 (85.13%)

-/-

66,516,889

56,179,825 (84.46%)

-/-

44,545,090

37,886,828 (85.05%)

Mbd2 Replicate 1
Mbd2 Replicate 2

DISCUSSION

In this study, we show that loss of MBD2, relative to MeCP2 and MBD1, surprisingly has
only a minor impact on brain function. We present the first behavioral characterization of Mbd2

-/-

mice, with emphasis on phenotypes affected by loss of related proteins MeCP2 or MBD1 (Allan et
al., 2008; Goffin et al., 2012). In addition to behavior, we also assessed whether loss of MBD2
affects hypothalamic and striatal gene expression and biogenic amine levels in the striatum.
Unexpectedly, we found that loss of MBD2 results in few subtle behavioral phenotypes.
-/-

Most behavioral measures were generally unaffected in Mbd2 mice compared to wildtype and
heterozygous littermates, including motor coordination and learning, anxiety-related behaviors,
sociability, olfaction, and spatial and contextual learning and memory (Figure 2.1). In contrast,
mice with loss of MeCP2 or MBD1 show significant deficits on the majority of these measures
-/-

(Allan et al., 2008; Goffin et al., 2012). We found that Mbd2 mice are hypoactive in a home-cage
environment (Figure 2.1.A) and show significant differences to littermates in measures of nest
-/-

building and olfaction (Figure 2.1.E,G). Specifically, we observed that Mbd2 mice spend
significantly less time engaged in sniffing behavior of a social scent during a test of olfactory
-/-

discrimination (Figure 2.1.E). Finally, Mbd2 mice show reduced cue-dependent freezing
behavior in a fear conditioning assay (Figure 2.1.K).
-/-

Despite finding statistically significant differences between Mbd2 mice and control
littermates on several tests, the results of all tests as a whole must be considered before
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interpreting results of individual tests as discrete behavioral phenotypes. Most importantly, the
hypoactivity phenotype (Figure 2.1.A) complicates the interpretation of several tests that depend
on activity levels, in particular nesting, the swab sniff olfaction test, and fear conditioning.
Phenotypes such as hypoactivity, nesting, and low body weight are multigenic and complex in
nature and therefore it is challenging to determine the precise etiologies of these phenotypes
(Gaskill et al., 2013; Reed et al., 2008; Tou and Wade, 2002). Furthermore, low body weight
(Figure 2.2.A,B) is inexorably linked to activity levels, and therefore must also be considered in
interpretation of these phenotypes (Tou and Wade, 2002).
Changes in body weight have been observed in over 30% of viable, single-gene null
mice, which illustrates the sensitivity of this phenotype to genetic perturbations in multiple cellular
processes (Reed et al., 2008). While hypoactivity has been observed in several mouse models of
ASD including Mecp2 null mice, in these mice hypoactivity is accompanied by significant deficits
in other behavioral measures such as learning and memory deficits or seizures, supporting a
neuronal etiology (Goffin et al., 2012; Pasciuto et al., 2015). The origins of changes in nesting
behavior are similarly challenging to classify in this scenario. Nesting can be affected by a range
of experimental factors, such as genetic models of neurodegenerative disease, pharmacological
treatments, or external factors such as stress arising from social defeat (Jirkof, 2014; Otabi et al.,
2015; Pasciuto et al., 2015). Therefore, we conclude that the nesting deficits observed in Mbd2

-/-

mice are likely related to the overall reduced home cage activity levels (Figure 2.1.A), but we
-/-

cannot precisely determine the cause of impaired nesting in Mbd2 mice without further
additional experiments.
-/-

We found that Mbd2 mice spend significantly less time sniffing a social scent during a
test of olfaction than control littermates (Figure 2.1.E). However, we expect that this finding does
-/-

not indicate that olfactory ability is impaired in Mbd2 mice to the extent that it would affect
-/-

behaviors for the following reasons. First, Mbd2 mice show a trend of spending less time sniffing
overall during the water and almond phases of this test, indicating that the decreased sniffing of
the social scent may be more indicative of lower overall home cage activity levels (Figure 2.1.A)
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rather than a true olfactory deficit. This conjecture is supported by our findings that there is no
significant difference between genotypes in time spent sniffing a cylinder containing a novel
stimulus animal in a sociability assay (Figure 2.1.D) or the buried food retrieval assay, an
independent olfaction test (Figure 2.1.F).
-/-

Similarly, we found subtle changes between Mbd2 mice and control littermates in the
Barnes maze assay and cued fear conditioning (Figure 2.1.H-K), but we hypothesize that these
results may be linked to reduced overall activity levels rather than representing specific deficits in
learning and memory. In the Barnes maze assay, if spatial memory were directly affected in
-/-

Mbd2 mice, we would expect to see increased primary and total latency on additional training
-/-

days (Figure 2.1.H,I) or increased errors (Figure 2.1.J). However, Mbd2 mice are equivalent to
control littermates on all measures with the exception of primary latency on the second training
day (Figure 2.1.H), indicating that spatial memory is likely unaffected. In a fear-conditioning
-/-

assay, we found that Mbd2 mice show significantly more time freezing in response to cue, but
not a context, associated with an aversive foot shock (Figure 2.1.K). The results on this assay are
-/-

difficult to interpret because Mbd2 mice show a trend of reduced freezing behavior during the
training phase after the foot shock, although this difference is not statistically significant. The
readout for this assay, freezing behavior, is also activity-dependent and the overall decreased
-/-

activity levels in Mbd2 mice may confound the results. Therefore, this assay must be repeated to
-/-

ensure that Mbd2 mice have an equivalent pain threshold and freezing response to control
littermates.
-/-

In summary, Mbd2 mice show subtle phenotypes on several measures but several of
these results may be indicative of overall reduced activity levels rather than additional, specific
phenotypes related to brain function. The phenotypes that are clearly affected, including homecage activity, nesting and body weight, are complex and multigenic in nature and may have nonneuronal etiologies. Therefore, in the absence of additional changes in behavior, striatal gene
expression changes, or biogenic amine levels, we expect that the observed subtle behavioral
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phenotypes are likely not neuronal in origin. We conclude that, unlike most MBD proteins, MBD2
is largely not required for brain functions that affect behavioral outcomes examined here.
We also found that loss of MBD2 results in subtle, but significantly decreased body
-/-

weight (Figure 2.2A,B). Although Mbd2 mice eat less food per day, they consume equivalent
food normalized to body weight as wildtype littermates (Figure 2.2.E,F). These findings support
-/-

the conclusion that low body weight is established early in Mbd2 mice after weaning, after which
-/-

Mbd2 mice stabilize and continue to eat a sufficient amount of calories to maintain their body
-/-

weight at steady state (Figure 2.2.A,B). Although Mbd2 mice maintain their body weights, they
do show altered expression levels of the hypothalamic peptide Pomc (Figure 2.3.B). Reduced
Pomc expression is generally caused by reduced levels of serum leptin associated with reduced
adipose tissue. Downregulation of Pomc expression is usually accompanied by increased
expression of the orexigenic peptides Npy and Agrp, which together stimulate increased food
-/-

intake and reduced energy expenditure (Myers et al., 2008). Paradoxically, Mbd2 mice show a
trend, although not statistically significant, for downregulation of hypothalamic Agrp and Npy
(Figure 2.3.B). This finding may indicate that loss of MBD2 is directly affecting hypothalamic gene
-/-

expression. Alternatively, energy homeostasis pathways may be affected in Mbd2 mice at one
or multiple different areas, including the liver or levels of circulating hormones, for example. Due
to the absence of significant behavioral phenotypes, striatal gene expression changes, or
-/-

biogenic amine levels in Mbd2 mice, we hypothesize that the reduced Pomc expression is likely
due to changes in peripheral tissues and pathways and does not reflect a specific hypothalamic
function for MBD2.
To determine if loss of MBD2 affects brain function at the molecular or cellular level, we
assessed biogenic amine levels in the striatum and cortex and also looked for gene expression
changes in the striatum. We choose to examine the striatum because genetic or pharmacological
disruptions to this system, and particularly striatal dopamine signaling, produce phenotypes
-/-

similar to those seen in Mbd2 mice, including hypoactivity, low body weight, hypophagia, and
altered nurturing behavior (Bromberg-Martin et al., 2010; Henschen et al., 2013; Palmiter, 2008).
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We did not find any significant alterations in the levels of biogenic amines and their metabolites in
-/-

the striatum or cortex of Mbd2 mice, unlike what has been observed in Mecp2 or Mbd1 null mice
(Figure 2.4.A,B) (Allan et al., 2008; Panayotis et al., 2011). These results indicate that the
-/-

phenotypes of Mbd2 mice are likely not related to changes in biogenic amine signaling pathways
such as striatal dopamine, and instead may have more complex or non-neuronal origins.
In addition to assessing levels of biogenic amines in the striatum, we also sought to
determine if gene expression is altered in the striatum upon loss of MBD2. The striatal DEGs in
-/-

Mbd2 mice have diverse functions (Figure 2.7). Several of the DEGs have been linked to brainspecific functions related to ASD. Mutations in Grin2b, an NMDA receptor subunit, are associated
with intellectual disability, ASD and seizures (Endele et al., 2010). Engrailed homeobox factor 2
(En2) is upregulated during CNS development and is also linked to neurological phenotypes in
mouse models and human patients (Benayed et al., 2005; Cheh et al., 2006). Several DEGs point
-/-

to increased inflammatory stress in Mbd2 mice. For example, lipocalin2 (Lcn2) is upregulated in
the prefrontal cortex and hippocampus in response to stress or neural injury such as stroke and
elevated transthyretin (Ttr), the primary transporter of thyroid hormone and retinol in the cerebral
spinal fluid, is used clinically as a marker of inflammatory stress (Buxbaum and Reixach, 2009;
Lee et al., 2009). While these findings indicate directions for future investigations, it is unclear if
expression levels of the DEGs are directly affected by MBD2-mediated transcriptional
mechanisms or if these are secondary effects of loss of MBD2 in other cell types or systems. Due
to the absence of notable behavioral phenotypes and unchanged biogenic amine levels in the
-/-

striatum of Mbd2 mice, the DEGs observed are likely to be secondary effects of loss of MBD2
rather than an indication of brain-specific MBD2 functions.
-/-

Although these phenotypes of Mbd2 mice are complex, additional experiments would
clarify these findings. First, despite the absence of robust behavioral phenotypes, a subtler
-/-

neuronal cellular phenotype may be present in Mbd2 mice. One study found that olfactory
-/-

receptor neurons in Mbd2 mice show enhanced proliferation but reduced lifespan and
differentiation capability (Macdonald et al., 2010). However, it is unclear how or if this cellular
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phenotype may affect olfactory function as we did not detect a notable difference in odor-induced
behaviors in these mice on several independent tests (Figure 2.1.D-F). It is therefore possible
that additional cellular phenotypes may be present without significantly affecting the behaviors
examined in this study in adult mice.
-/-

Because Mbd2 mice have significantly decreased home-cage activity and reduced body
weight (Figure 2.1.A, Figure 2.2.A,B), these phenotypes may confound the interpretation of
several other behavior tests performed in this study that rely on mobility and activity. Therefore, to
-/-

better understand the phenotype of Mbd2 mice it would be beneficial to perform additional tests
that do not directly or indirectly measure activity levels as an output. For example, prepulse
inhibition can be used to assess deficits in sensorimotor gating and is affected by loss of MBD1 in
mice (Allan et al., 2008). Alternatively, the Y-maze spontaneous alteration test assesses spatial
cognition but does not depend on the subject mouse’s speed to reach a target, as does the
Barnes maze (Crawley, 2007).
Another approach to study the effects of loss of MBD2 would be to perform the tests
described here on mice with conditional loss or rescue of MBD2. It is likely that several of the
-/-

phenotypes of Mbd2 mice such as low body weight and hypoactivity are interrelated and may
even have a synergistic effect. By genetically isolating MBD2 functions to a specific cell type or
tissue, it may be possible to determine which phenotypes are direct consequences of loss of
MBD2 and which may be secondary effects. For example, an Mbd2 conditional null and/or rescue
-/-

mouse would be beneficial to study the low body weight phenotype of Mbd2 mice. If a brainspecific Mbd2 null mouse also had low body weight, this would be strong evidence that this
phenotype is neuronal in origin and may be primarily attributed to misregulation in the
hypothalamus, for example. Alternatively, this phenotype could be due to a gastrointestinalrelated MBD2 function that could be explored through an intestine epithelial cell-specific loss of
MBD2.
In summary, we found that loss of MBD2 results in subtle phenotypes including low body
weight, hypoactivity, and deficits in nesting behavior. We also determined that loss of MBD2
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reduces expression of the anorexigenic hypothalamic peptide Pomc and affects expression of a
limited number of genes in the striatum. However, additional experiments are required to assess
if expression of these differentially expressed genes is directly regulated by MBD2-dependent
mechanisms, or if these findings represent secondary effects of loss of MBD2. The limited
number of genes affected and the equivalent levels of biogenic amines in the brain of Mbd2

-/-

mice support the hypothesis that these are likely to be indirect effects. We conclude that, in
contrast to MeCP2 or MBD1, MBD2 is generally not required for the behavioral outcomes and
brain functions examined in this study.
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CHAPTER 2 FIGURES

-/-

Figure 2.1. Behavioral characterization of Mbd2 mice compared to wildtype and
heterozygous littermates.
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-/-

Figure 2.1 Behavioral characterization of Mbd2 mice compared to wildtype and
heterozygous littermates.
-/(A) Mbd2 mice are hypoactive as measured by the number of infrared beam breaks in a homecage like environment over sixty minutes (n = 14 per genotype, **P < 0.01, *P < 0.05, one-way
-/ANOVA with Tukey’s test). (B) Mbd2 mice perform similarly to littermates in the rotarod task
indicating unaffected motor coordination or learning (n = 14 per genotype, two-way ANOVA). (C)
-/Mbd2 mice have unaltered anxiety-related behavior in a zero maze assay (n = 14 per genotype,
-/one-way ANOVA of time in open arm). (D) Sociability of Mbd2 mice was assessed in the social
approach test in a three-chambered apparatus. All genotypes show equal preference between
two empty cylinders (left and right) during the habituation phase. All genotypes show equivalent
+/+
increased preference for a social stimulus (mouse) versus a non-social stimulus (object) (Mbd2
+/-/and Mbd2 n = 13, Mbd2 n = 14, two-way ANOVA). (E) The ability to distinguish between
neutral (water and almond) and social scents was determined by assessing time spent sniffing a
swab with each scent. All genotypes have increased interaction (sniffing) with a social scent
-/compared to neutral scents, but Mbd2 show significantly less time sniffing a social scent (n = 12
per genotype, P < 0.0001 effect of scent, P < 0.001 effect of genotype, **P < 0.01, two-way
-/ANOVA with Tukey’s test). (F) Mbd2 mice take equivalent time to littermates to find and retrieve
+/+
-/+/a buried piece of food in a home-cage like environment (Mbd2 and Mbd2 n = 13, Mbd2 n =
-/11, ns not significant, one-way ANOVA). (G) Mbd2 mice have significantly impaired nest+/+
+/-/building behavior (Mbd2 n = 22, Mbd2 n = 19, Mbd2 n = 18, **P < 0.01, one-way ANOVA
with Tukey’s test). (H-J) Spatial learning and memory were assessed using a Barnes maze
-/paradigm. Mbd2 mice show a slight but significant delay to initially reach a target escape hole on
the second training day (primary latency, H), but equivalent time to enter the escape hole (total
-/latency, I) during four days of training. Mbd2 mice made comparable numbers of errors to
+/+
+/control littermates (visits to non-target hole, J) during all training days (Mbd2 n = 22, Mbd2 n =
-/19, Mbd2 n = 18, *P <0.05, two-way ANOVA with Tukey’s test). (K) In a fear conditioning
learning and memory assay, all genotypes responded with equivalent freezing behavior to a
-/paired tone-footshock. Mbd2 mice showed significantly less freezing behavior in response to a
cued stimulus, but equivalent freezing behavior to a contextual stimulus compared to control
+/+
-/+/littermates (Mbd2 and Mbd2 n = 14, Mbd2 n = 12, *P <0.05, two-way ANOVA with Tukey’s
test). All data are presented as mean ±SEM.

53

-/-

Figure 2.2. Mbd2 mice show decreased body and brain weight associated with reduced
food intake.
-/+/+
+/(A) Male Mbd2 mice have decreased body weight compared to Mbd2 and Mbd2 littermates
-/(n = 10 per genotype, P < 0.01, interaction, two-way ANOVA). Mbd2 weight was significantly
decreased at 4 weeks continuing to 18 weeks postnatal (**P < 0.01, two-way ANOVA with
-/Tukey’s test). (B) Female Mbd2 mice have decreased body weight (n = 10 per genotype, P <
-/0.001, interaction, two-way ANOVA). Mbd2 weight was significantly decreased at 6 weeks
continuing to 8 weeks postnatal (***P < 0.001, two-way ANOVA with Tukey’s test). (C) 13-week
-/+/+
+/old male Mbd2 mice have significantly decreased brain weight (Mbd2 and Mbd2 n = 11,
-/-/Mbd2 n = 12, **P < 0.01, one-way ANOVA with Tukey’s test). (D) 13-week old male Mbd2 mice
+/+
+/have significantly increased brain weight as a percentage of body weight (Mbd2 and Mbd2 n
-/-/= 11, Mbd2 n = 12, **P < 0.01, one-way ANOVA with Tukey’s test). (E) 8 week old male Mbd2
mice consume significantly less food per day on an unrestricted diet of standard chow, but (F)
+/+
+/-/consume equivalent food normalized to body weight (Mbd2 and Mbd2 , n = 5, Mbd2 n = 8, *
P <0.05, ns not significant, one-way ANOVA with Tukey’s test). All data are presented as mean
±SEM.
54

-/-

Figure 2.3. Hypothalamic neuropeptide expression in Mbd2 mice.
(A) Simplified diagram of the orexigenic AgRP-NPY and anorexigenic POMC neurons in the
arcuate nucleus of the hypothalamus, which contribute to the regulation of food intake and energy
expenditure. (B) The relative expression levels of Agrp and Npy in the hypothalamus are
-/equivalent between wildtype and Mbd2 mice, but Pomc is significantly downregulated. Mbd2 is
-/significantly downregulated and Mecp2 expression is unaffected in Mbd2 mice, as expected
+/+
-/(Mbd2 and Mbd2 n = 5, unpaired two-tailed t test with Holm-Sidak multiple comparison
correction). All data are presented as mean ±SEM.
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-/-

Figure 2.4. Mbd2 mice have equivalent biogenic amine content to wildtype littermates.
HPLC analysis showed equivalent levels of biogenic amines and their metabolites in the cortex
+/+
-/+/+
-/(A) and striatum (B) between 12 week old male Mbd2 and Mbd2 mice (Mbd2 n = 6, Mbd2
n = 8, unpaired two-tailed t test with Holm-Sidak multiple comparison correction). All data are
presented as mean ±SEM.
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-/-

Figure 2.5. RNA-seq from the striatum of Mbd2 mice confirms loss of Mbd2 exon 2 and
expression of full-length transcript.
-/RNA-seq tracks from two wildtype replicates (blue) and two Mbd2 (KO) replicates shows a loss
-/of reads corresponding to exon 2, which is deleted in Mbd2 mice. Small amounts of readthrough transcript are detectable in the KO samples, as reported (Hendrich et al., 2001).

-/-

Figure 2.6. Differentially expressed genes in the striatum of Mbd2 mice compared to
wildtype littermates.
-/MA plot showing differential gene expression and abundance from RNA-seq analysis of Mbd2
versus wildtype striatal tissue. Genes that are significantly differentially expressed (FDR < 0.05)
are labeled in red. Selected and discussed genes are labeled.
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-/-

Table 2.4. List of differentially expressed genes in the striatum of Mbd2 mice compared to
wildtype littermates.
All significantly DEGs (FDR < 0.05) and predicted functions are listed. Significantly differentially
expressed genes with FC > log(1) are labeled in red.
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CHAPTER 3: Genetic tagging of MBD2 reveals different spatiotemporal
expression and supports distinct functions from related MBD proteins
Adapted from: Wood, K. H., Johnson, B. S., Welsh, S. A., Lee, J. Y., Cui, Y., Krizman, E.,
Brodkin, E. S., Blendy, J. A., Robinson, M. B., Bartolomei, M. S., Zhou, Z. Tagging methyl-CpG
binding domain proteins reveals different spatiotemporal expression and supports distinct
functions. Epigenomics. In Press.

ABSTRACT

DNA methylation and other epigenetic mechanisms are necessary to maintain cell-type
specific gene expression programs and the chromatin state. However, it is not understood how
DNA methylation is linked to the regulation of transcription and histone modifications. Previous
biochemical studies have shown the methyl-DNA binding domain (MBD) family of proteins can
bind to methylated DNA and recruit various co-repressor complexes to mediate transcriptional
regulation. However, the in vivo roles of these proteins in a cellular context and their
spatiotemporal expression patterns have not been fully determined. The study of the MBD
proteins in vivo, and especially MBD2, has been limited by the lack of reliable antibodies. To
overcome this limitation, we generated novel transgenic mice with endogenous MBD2 or MBD1
tagged with biotin. This approach allowed us to isolate biotin-tagged MBD2 for multiple
applications to characterize MBD2 in vivo functions in the context of the MBD protein family. We
were also able to reliably distinguish multiple isoforms of tagged MBD2, which may have distinct
biological properties. We determined that MBD2 interacts with the NuRD complex in multiple
tissues in vivo. We also found that MBD2 is broadly expressed throughout multiple tissues at
young and adult ages, in contrast to related proteins MBD1, MeCP2, and MBD3, which are
primarily expressed in the brain. Our findings support a critical role for MBD2 in peripheral tissues
and reveal new directions and genetic tools for the study of MBD protein in vivo functions.
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INTRODUCTION

Epigenetic mechanisms, including DNA methylation, are essential for the maintenance of
chromatin state and gene expression programs (Smith and Meissner, 2013; Suzuki and Bird,
2008). The mechanism by which DNA methylation is interpreted into transcriptional output is not
fully understood, but involves protein ‘readers’ that bind to methylated sites (Du et al., 2015).
These readers include the methyl-CpG binding domain (MBD) family of proteins, comprised of
methyl-CpG binding protein 2 (MeCP2) and MBDs 1-6 (Du et al., 2015; Hendrich and Bird, 1998).
The MBD is a highly conserved domain originally identified for its ability to specifically bind mCG
sites (Meehan et al., 1989). Most MBD proteins, with the exception of MBD3, MBD5 and MBD6,
bind to DNA in a methylation density-dependent manner when expressed in ESCs (Baubec et al.,
2013).
Biochemical studies support the role of MBD proteins in mediating transcriptional
repression through the recruitment of various co-repressor complexes (Feng and Zhang, 2001;
Nan et al., 1998; Ng et al., 2000). MBD2 or MBD3 are incorporated into mutually exclusive
complexes with the Mi2/nucleosome remodeling and deacetylase (NuRD) complex, while MeCP2
associates with the repressive Sin3A and NCoR/SMRT complexes (Ebert et al., 2013; Le
Guezennec et al., 2006; Lyst et al., 2013; Nan et al., 1998; Ng et al., 1999). MBD1 interacts with
several heterochromatin-associated proteins, including repressive histone methyltransferases
(Fujita et al., 2003c; Ichimura et al., 2005; Reese et al., 2003; Sarraf and Stancheva, 2004).
However, the functional outcomes of these interactions in a cellular context have not yet been
fully characterized.
The study of MBD protein functions in vivo has been severely limited by the lack of
appropriate antibodies. Consequentially, the majority of studies on MBD proteins, and especially
MBD2, have relied on the use of tagged alleles overexpressed in cultured cells to perform various
experiments such as chromatin immunoprecipitation and sequencing (ChIP-seq), amongst other
applications (Baubec et al., 2013). While these studies provide insight into molecular mechanisms
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of MBD protein function, they do not fully address MBD protein function in a complex,
differentiated cellular context in vivo.
In order to examine MBD functions in vivo, it is also necessary to identify the specific
tissues or cell types where the MBD proteins are expressed. MBD expression at the
transcriptional level has been assessed in several tissues for MeCP2, MBD1 and MBD2
(Hendrich and Bird, 1998; Roloff et al., 2003). However, a closer analysis of MeCP2 expression
showed that MeCP2 protein levels do not correlate with transcript abundance in mouse or human
tissues, indicating that significant post-transcriptional regulation may be occurring (Shahbazian et
al., 2002). Phenotypic data must also be carefully evaluated to determine the cell-type specific
functions of MBD proteins. For example, MeCP2 loss-of-function phenotypes in non-neuronal
tissues may be occurring due to non-cell-autonomous effects that are neuronal in origin, as was
recently shown in a study of muscle (Conti et al., 2015). However, a comprehensive analysis of
MBD protein expression in tissues of interest has not been possible due to limitations of currently
available antibodies, especially for MBD2.
In this study, we sought to explore the functions of MBD2 in vivo in the context of the
other MBD family proteins. To investigate the underlying causes of the distinct behavioral and
physiological outcomes of Mecp2, Mbd1, and Mbd2 null mice, we generated mouse lines with
gene replacement alleles expressing endogenous MBD2 or MBD1 tagged with biotin. We used
these mice to systematically identify the in vivo binding partners, genomic localization, and
spatiotemporal expression patterns of MBD2 in the context of the MBD protein family. Our
findings reveal new insights and directions and provide novel genetic tools for the study of MBD2
function in vivo.

METHODS

Animal Husbandry
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All experiments were conducted in accordance with the ethical guidelines of the US National
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of
the University of Pennsylvania. All mice were housed in a standard 12 h light/12 h dark cycle with
access to ample amounts of food and water. All experiments were performed on mice on a
congenic sv129:C57BL/6J background unless otherwise stated. All assays were performed on
-/-

-/-

male littermates aged 2-3 months. Mice deficient in MBD2 (Mbd2 ) or MBD1 (Mbd1 ) are
previously described (Hendrich et al., 2001; Zhao et al., 2003) and were genotyped using a PCRbased strategy (Chapter 2 Methods).

Generation of Tavi-tagged mice
The targeting constructs used for homologous recombination in ESCs were cloned in two arms by
PCR amplification of sv129 genomic DNA. The primer sequences used to PCR amplify the 5’ and
3’ arms of Mbd2 and Mbd1, respectively, and the Tavi oligo are listed in Table 3.1.

Table 3.1. Primers used to generate targeting constructs for Tavi-tagged alleles of Mbd2
and Mbd1.
Primer

Forward Primer

Reverse Primer

Mbd2 5’ arm

5’-GTTTGGCTTAACACATCTCAACC-3’

5’-GGATGAGTCAGGACAGAGGAGTA-3’

Mbd2 3’ arm

5’-GAAGCTCAGGGTATGGTCTCAC-3’

5’-AAAGTATCACGCTCTGGTCCAT-3’

Mbd1 5’ arm

5’-GCTGCAGATCCAGACCTTTC-3’

5’-TCCCTCATCCGAGTGTTCTC-3’

Mbd1 3’ arm

5’-AAAAGCTGGTCCCACTCTCC-3’

5’-ATTTGGGCAGGCAACACAAG-3’

Tavi oligo

5’-GGGAAAACCTGTATTTTCAGGGCGCC
GGCCTGAACGACATCTTCGAGCTCAGAA
AATCGAATGGCACGAATAGGTT-3’

5’-AACCTATTCGTGCCATTCGATTTTCTG
AGCCTCGAAGATGTCGTTCAGGCCGGC
GCCCTGAAAATACAGGTTTTCCCGC-3’

The Tavi oligo contained a 5’ SacII restriction site overhang and a 3’ HpaI restriction site
overhang and a stop codon directly upstream of the 3’ HpaI site overhang. Insertional
mutagenesis was then used to introduce SacII and HpaI restriction sites into exon 6 of Mbd2 and
exon 15 of Mbd1 in the respective targeting constructs. These sites were immediately upstream
of the stop codon in order to ligate the Tavi tag oligo in the correct orientation at the C terminus of
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each gene. After ligation of the Tavi oligo into the 3’arm of each construct, each arm was cloned
into a vector containing a loxP-flanked neomycin cassette (Neo) and a diphtheria toxin A
negative-selection cassette. Each targeting construct was confirmed by sequencing, linearized
using NotI and subsequently electroporated into sv129 mouse ESCs. Two ESC clones each of
Mbd2

Tavi

and Mbd1

Tavi

were independently injected into C57BL/6 blastocysts and subsequently

transferred to pseudopregnant females. The resulting chimeric offspring were mated with
C57BL/6J EIIa-Cre mice (The Jackson Laboratory) for embryonic deletion of the Neo cassette,
and the agouti offspring were screened by PCR genotyping to confirm germ line transmission of
the Mbd2

Tavi

or Mbd1

Tavi

. Germline transmitted Mbd2

Tavi

or Mbd1

Tavi

mice were backcrossed to

C57BL/6J for at least 5 generations. Mice were genotyped using a PCR-based strategy to detect
wildtype and Tavi-tagged alleles of Mbd2 and Mbd1. The genotyping primers sequences are
listed in Table 3.2.

Table 3.2. Primers used to genotype Mbd2
Primers

Tavi

and Mbd1

Tavi

mice.

Sequences

Product Size

Tavi

5’- AAAGGCAAACAGGTCAGCCATTCC-3’
5’- ACAGGAAGAGCGAGTCCAACAAGT-3’

Wildtype: 473bp
Tavi
Mbd2 : 557bp

Tavi

5’-TTCCCACAGAGAACACTCGGATGA-3’
5’-TAGCAGGTCTTCAGCACACTTGGA-3’

Wildtype: 535bp
Tavi
Mbd1 : 619bp

Mbd2
Mbd1

Nuclear extract preparation
Tissues were minced on ice and homogenized in ice-cold lysis buffer (10mM HEPES pH 7.9,
1.5mM MgCl2, 10mM KCl, 0.5% NP-40, 0.2mM EDTA, protease inhibitors). Nuclei were pelleted,
washed and resuspended in nuclear extract (NE) buffer (20mM HEPES pH7.9, 1.5mM MgCl2,
500mM KCl, 0.2mM EDTA, 10% glycerol, protease inhibitors). Nuclei were incubated in NE buffer
at 4°C for two hours with rotation. Samples were cleared by ultracentrifugation with TLA 100.3
rotor (Beckman Optima TL) at 4°C for 30 minutes and the supernatant taken for nuclear extract.
Protein concentration was quantified using a modified Bradford assay (Bio-Rad).
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Western blot
Western blots were carried out and imaged with the LI-COR Odyssey Clx Infrared Imaging
System following manufacturer’s protocols. 50ug of nuclear extract was loaded per lane.
Antibodies and dilutions used in this study are as follows: Avi tag, Abcam ab106159, 1:5000
(listed as anti-BirA, detects the minimal peptide substrate of biotin ligase BirA regardless of
biotinylation status); Sin3A, Thermo Scientific PA1-870, 1:500; HDAC1, Abcam Ab7028, 1:2000;
HDAC2, Cell Signaling 5113, 1:2000; HDAC3, Santa Cruz sc-11417, 1:1000; LaminB1, Santa
Cruz sc-30264, 1:1000; TBLR1, Bethyl A300-408A, 1:1000; Chd4, Abcam ab70469, 1:1000;
MTA2, Santa Cruz sc-9447, 1:200; H3, Abcam ab1791, 1:2000; MBD2, Diagenode CS-098-100,
1:500; MBD1, Santa Cruz sc-10751, 1:200; MBD3, Santa Cruz sc-9402, 1:200; MeCP2, rabbit
polyclonal antibody directed to the C-terminus of MeCP2, 1:1,000 (Zhou et al., 2006). Secondary
antibodies are as follows: Streptavidin DyLight 800 conjugated, Thermo Scientific, 1:1000;
donkey anti-rabbit IRDye 680RD, donkey anti-mouse IRDye 800CW, donkey anti-goat IRDye
800CW, all from LI-COR Biosciences, 1:10,000.

Immunoprecipitation
1mg of nuclear extract was adjusted to 300µl total volume with NE buffer to perform IP in
duplicate. Protein G Dynabeads or Streptavidin M-280 Dynabeads (Life Technologies) were
washed three times in PBS with 0.1% Tween-20 and 0.1% BSA. Nuclear extracts were cleared
for 30 minutes at 4°C with 25µl Protein G Dynabeads. For streptavidin pulldown, 50µl of
streptavidin Dynabeads were added to the nuclear extract and incubated at 4°C for two hours
with rotation. For antibody immunoprecipitation, 5µg of antibody was added to nuclear extract and
incubated overnight at 4°C with rotation. 50µl of Protein G beads were blocked in wash buffer
overnight at 4°C with rotation. Blocked beads were incubated with antibody-conjugated nuclear
extract in the morning for two hours at 4°C with rotation. Beads were washed four times in PBS
with 0.1% Tween-20 and split into two equal volumes. Each sample was resuspended in 25µl
loading buffer with 50mM DTT and boiled for 10 minutes at 95°C prior to loading on gel.
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Chromatin immunoprecipitation and qPCR
Tissue was suspended in 10ml ice-cold crosslinking buffer (10mM HEPES pH 7.5, 100mM NaCl,
1mM EDTA, 1mM EGTA, 1% formaldehyde) and homogenized with a Polytron tissue
homogenizer (VWR). Homogenized tissue was rotated at room temperature for 5 minutes after
which glycine was immediately added to a final concentration of 0.125M. Tissue was washed
twice with ice-cold PBS, resuspended in lysis buffer 1 (50mM HEPES pH 7.5, 140mM NaCl, 1mM
EDTA, 1mM EGTA, 0.25% Triton X-100, 0.5% NP-40, 10% glycerol, protease inhibitors) and
dounced to lyse cells. Pelleted nuclei were washed and resuspended in lysis buffer 2 (10mM Tris
pH 8.0, 1mM EDTA, 1mM EGTA, 0.25% SDS, protease inhibitors) and incubated on ice for 20
minutes to lyse nuclei. Chromatin was sheared using a Covaris S220 to approximately 200500bp. Chromatin shearing efficiency was analyzed using agarose gel electrophoresis. 100µg of
chromatin was diluted with lysis buffer without SDS to a final SDS concentration of 0.1% and 5µg
was reserved as input. Chromatin was precleared with Protein A Dynabeads (Life Technologies)
for 30 minutes with rotation at 4°C. For TEV protease pre-treatment, chromatin was incubated at
this point with 20 units of TEV protease (Sigma-Aldrich) for 3 hours at 16°C before proceeding.
Chromatin was incubated with 5µg of antibody or IgG control, or with 50µl of streptavidin
Dynabeads overnight at 4°C with rotation. For antibody ChIP, 30µl of Protein A Dynabeads were
washed and blocked overnight at 4°C with rotation in blocking buffer (1% BSA in TBST). For
antibody ChIP, chromatin was incubated for 3 hours at 4°C with blocked Protein A beads. The
antibodies used for ChIP are anti-histone H3 (acetyl K27) (Abcam ab4729), anti-histone H3 (trimethyl K4) (Abcam ab8580) and normal rabbit IgG (Cell Signaling 2729). Beads were washed as
follows: once with low salt buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X100, 0.1% DOC), once with high salt buffer (50mM HEPES pH 7.5, 500mM NaCl, 1mM EDTA,
1% Triton X-100, 0.1% DOC), once with LiCl buffer (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.5%
DOC, 0.5% NP-40, 250mM LiCl), and twice with TE buffer (10mM Tris pH 8.0, 1mM EDTA). Input
and IP chromatin was eluted in 100µl elution buffer (50mM Tris pH 8.0, 10mM EDTA, 1% SDS)
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overnight at 65°C to reverse crosslinks. DNA was treated with RNase A and proteinase K before
phenol-chloroform purification following standard methods. DNA was quantified by Qubit
Fluorometric Quantitation (Thermo Fisher Scientific). ChIP DNA was analyzed by qPCR using
SYBR Green detection (Applied Biosystems) with the primers listed in Table 3.3.

Table 3.3. Primers used for ChIP-qPCR.
Locus

Forward Primer

Reverse Primer

5’- CCATCACGTCCTCCATCATC -3’

5’- CAGTCGGAAACTGGGAAGG-3’

5’- AGTGTCTACACCGCGGGAAT-3’

5’- CTGGCACAGCCAACTTTACG-3’

IAP
element

5’- GCTTTCGTTTTTGGGGCTTGG -3’

5’- CTTACTCCGCGTTCTCACGAC-3’

Chr6 Gene
Desert

5’- GGGAGAGAGTGATAGTCCAAGA -3’

5’- CTTTGGTAGAAGAGAATGGTGTTTG-3’

Gapdh
Promoter
Actb
Promoter

Fractionation of small intestine and colon crypts and protein lysate preparation
The gastrointestinal tract was dissected on ice, cut longitudinally and washed in cold PBS. The
villi of the small intestine were gently scraped off using a glass coverslip. Remaining tissue was
minced and incubated in ice-cold 5mM EDTA/PBS for 30 minutes with pipetting every 5 minutes
to release crypt cells. After letting tissue settle to bottom of tube, the supernatant was filtered
through a 70µm filter and transferred to a new tube. This was repeated with additional PBS until
100µl of supernatant was collected and cells were pelleted. Whole cell protein lysates were
prepared by incubating cells in RIPA buffer (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.5mM EGTA,
1% Triton X-100, 0.1% DOC, 0.1% SDS, 140mM NaCl) with dounce homogenization. Samples
were cleared by centrifugation and quantified using a modified Bradford Assay (Bio-Rad).

Brain histology
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Mice were anesthetized with 1.25% Avertin (wt/vol), transcardially perfused with 4%
paraformaldehyde (wt/vol), and brains were post-fixed for 2 hours at 4°C. Brains were washed in
PBS, cryoprotected in 30% sucrose/PBS at 4°C overnight, and snap frozen in OCT mounting
medium (Sakura Finetek). Frozen tissue was cryosectioned at 20µm and mounted on glass slides
for staining. For β-galactosidase (β-gal) staining, sections were incubated in X-gal staining
solution (5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM MgCl2, 0.01% DOC, 0.02% NP-40, 1mg/ml Xgal in PBS) overnight at 37°C. Slides were rinsed five times in PBS and coverslipped. For Nissl
staining, mounted frozen sections were dehydrated in ethanol and xylene, rehydrated, incubated
in cresyl violet acetate solution (0.1% cresyl violet, 0.25% glacial acetic acid (v/v)) for 10 minutes
at room temperature, rinsed, dehydrated and coverslipped.

Gastrointestinal tract histology
Small intestine and colon was cut longitudinally and washed in ice-cold PBS. Fresh tissue was
snap-frozen in OCT mounting medium (Sakura Finetek), cryosectioned at 20µm and mounted on
slides for staining. β-gal staining was performed as described for brain tissue. Sections were
counter-stained with nuclear fast red (Sigma-Aldrich) following manufacturer’s protocols.

RESULTS

Generation of gene replacement alleles expressing biotin-tagged MBD2 or MBD1
Given that previous studies linked MeCP2 and MBD1 to brain function in both humans
and mice (Allan et al., 2008; Cukier et al., 2010; Goffin et al., 2012; Guy et al., 2001), it is
surprising that mice lacking MBD2 are equivalent to control littermates on most measures,
including behavior, gene expression, and biogenic amine levels (Chapter 2). MBD2 likely has
critical functions in other tissues and systems, such as the gastrointestinal and immune systems
(Cook et al., 2015; Sansom et al., 2003; Wang et al., 2013), that may contribute to the
hypoactivity, impaired nesting and nurturing (Hendrich et al., 2001), and low body weight
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phenotypes observed in Mbd2 null mice. However, the study of MBD2 functions in vivo has been
impeded by the lack of reliable antibodies that specifically recognize MBD2.
To overcome these limitations, we took a genetic approach and developed gene
replacement alleles tagging MBD2 with a biotinylation consensus sequence derived from the E.
coli biotin ligase, BirA (Figure 3.1). The tag was introduced to the C-terminus of MBD2 and
consists of two parts: a tobacco etch virus (TEV) protease cleavage site and an avidin
biotinylation consensus sequence that can be selectively biotinylated (Figure 3.1.A,B). We
labeled this tag as the “Tavi” tag and the tagged allele as Mbd2

Tavi

. We also generated a separate

transgenic mouse line with BirA constitutively expressed from the Rosa26 locus (R26
(Johnson et al., manuscript in preparation). Therefore, MBD2

Tavi

BirA/+

)

protein can be specifically

biotinylated in the presence of BirA (Figure 3.1.A,B). We can detect and pull down biotinylated
endogenous MBD2 proteins using streptavidin-conjugated beads (Figure 3.1.C). Treatment with
TEV protease cleaves off the biotinylated tag from the MBD2 protein (Figure 3.1.D). This set of
transgenic mice allows us to detect and experimentally manipulate endogenous MBD2 with high
specificity and reproducibility.
Two previously described isoforms of MBD2, MBD2a and MBD2b (Hendrich and Bird,
1998), carry the Tavi tag (Figure 3.2.A). These isoforms arise from alternative translation start
sites from the same transcript that is expressed in adult somatic tissues (Hendrich and Bird,
1998). MBD2a, but not MBD2b, includes a N-terminal GR repeat region. Post-translational
methylation of the GR repeat has been shown to affect MBD2a function by reducing its affinity for
DNA and the NuRD complex (Tan and Nakielny, 2006). MBD2

Tavi

also includes a transcriptional

repression domain (TRD) that interacts with the NuRD complex (Boeke et al., 2000). Another
isoform, MBD2c, is expressed exclusively in the testes and ESCs (Hendrich and Bird, 1998; Lu et
al., 2014). MBD2c has an alternatively spliced C terminus that does not include the Tavi tag and
is not depicted in Figure 3.2.A. Mice heterozygous or homozygous for Mbd2

Tavi

are viable and

-/-

fertile similar to littermate controls. In contrast to Mbd2 mice that have reduced body weight
(Figure 2.2.A), Mbd2

Tavi/Tavi

mice with or without BirA expression show equivalent body weight to
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wildtype and R26

BirA/+

littermates (Figure 3.2.B) and we have not observed any gross phenotypic

abnormalities during routine handling. Therefore, biotinylation of MBD2

Tavi

does not appear to

impair MBD2 function.
We then used fluorophore-conjugated streptavidin to examine MBD2

Tavi

expression by

western blot (Figure 3.2.C). A representative commercial antibody to MBD2 (and others, data not
shown) recognizes several unknown proteins that do not differ between wildtype (WT) and Mbd2
/-

-

(KO) adult brain lysate (denoted by *), demonstrating invalidity of the stated antibody. In

contrast, streptavidin detects three biotinylated MBD2
Mbd2

Tavi/Tavi

; R26

BirA/+

Tavi

isoforms with high specificity in

mice, but not in mice expressing BirA without MBD2

addition to the predicted MBD2a
slightly smaller than MBD2a

Tavi

Tavi

and MBD2b

Tavi

Tavi

(R26

BirA/+

). In

isoforms, we observed a third MBD2 isoform

that has been previously detected but not described in detail (Ng

et al., 1999). This isoform has the C-terminal Tavi tag and is biotinylated in the presence of BirA.
Given the consistency and reproducibility of this isoform in different tissues and time points
(Figure 3.9), it is unlikely to be a degradation product of MBD2a

Tavi

. Therefore, we designated this

novel isoform as MBD2d. It includes exon 6 where the Tavi tag is inserted and may occur through
alternative splicing or translation start site usage (Figure 3.2.A). Direct comparison of proteins
detected by the MBD2 antibody versus streptavidin (Figure 3.2.C, merged image) demonstrates
the specificity and robustness of this biotin-tagging approach to identify MBD2 isoforms.
In order to directly compare MBD2 to MBD1 in vivo, we employed the same approach
and generated mice expressing gene replacement alleles for MBD1

Tavi

(Figure 3.3.A) and also for

MeCP2 (Johnson et al., in preparation). Murine Mbd1 has three reported alternatively spliced
isoforms that have two or three CxxC zinc finger DNA-binding domains in addition to a
transcriptional repression domain (TRD) (Jørgensen et al., 2004). MBD1a and MBD1b both carry
the Tavi tag, but MBD1c has an alternatively spliced C-terminus that does not include the Tavi tag
(Fig. 5A). Mbd1

Tavi/Tavi

; R26

BirA/+

mice are viable and fertile with no gross phenotypic abnormalities

observed during routine handling. Using western blots, we found that an antibody against MBD1
detects several cross-reacting proteins in postnatal day 7 (P7) brain lysate, comparing Mbd1 null
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(KO) to WT mice (Figure 3.3.B, denoted by *) (Zhao et al., 2003). All three isoforms of MBD1,
MBD1a

Tavi

, MBD1b

Tavi

and untagged MBD1d, are visible in R26

BirA/+

and Mbd1

Tavi/Tavi

mice when compared to Mbd1 null mice using this antibody. In contrast to R26

BirA/+

; R26

BirA/+

mice and

Mbd1 null mice, streptavidin detects two specific proteins corresponding to biotinylated MBD1a
and MBD1b

Tavi

in lysate from Mbd1

Tavi/Tavi

; R26

BirA/+

Tavi

mice. Streptavidin also detects a 75kDa

endogenously biotinylated protein that is close in size to untagged MBD1d (denoted by *). The
merged image demonstrates that streptavidin specifically detects the two biotin-tagged MBD1

Tavi

isoforms that are also recognized by the MBD1 antibody (yellow bands) (Figure 3.3.B). In
summary, this biotin-tagging approach represents a powerful tool to study multiple isoforms of
endogenous MBD proteins, overcoming antibody limitations.

Streptavidin-mediated pulldown of biotinylated MBD2

Tavi

detects multiple isoforms of

MBD2 in several tissues
We first sought to compare our streptavidin-mediated approach to antibodies in the
detection of biotinylated MBD2
from adult Mbd2

Tavi/Tavi

biotinylated MBD2

Tavi

; R26

Tavi

BirA/+

. We examined protein lysate from two tissues, brain and lung,

, R26

and MeCP2

Tavi

BirA/+

, and MeCP2

Tavi/y

; R26

BirA/+

mice in order to compare

to mice that do not express any Tavi-tagged proteins. We

should detect only endogenously biotinylated proteins in lysate from R26

BirA/+

mice and therefore

can reliably distinguish biotinylated Tavi-tag proteins from background. We used streptavidin
pulldown to enrich for biotinylated proteins and detected each protein with streptavidin and
antibodies raised against MBD2 or MeCP2, respectively (Figure 3.4).
We observed that a commercial antibody to MBD2 detects multiple non-specific protein
species in the brain and one notable non-specific protein in the lung that is close in size to MBD2
(Figure 3.4.A,C; denoted by *). However, streptavidin-mediated pulldown of biotinylated MBD2
reveals that this antibody detects only MBD2a

Tavi

Tavi

, and, furthermore, that this band is only

detectable upon streptavidin-mediated enrichment of MBD2

Tavi

in both brain and lung (Figure

3.4.A,C; note yellow band in merged image). The cross-reacting bands that are visible in the input
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samples are depleted upon streptavidin-mediated enrichment of MBD2

Tavi

. In contrast,

streptavidin reveals the three biotinylated isoforms of MBD2 described above in addition to a
constitutively expressed endogenous biotinylated protein of 75kDa (denoted by *). Therefore, we
conclude that our approach to detect biotinylated MBD2

Tavi

in vivo is significantly more robust and

reliable than detection with antibodies alone.
In contrast, an antibody raised against MeCP2 detects endogenous MeCP2 and
biotinylated MeCP2

Tavi

with high specificity in protein lysate from both brain and lung (Figure

3.4.B,D). We found that streptavidin detects a constitutively expressed, endogenously biotinylated
protein of approximately 75kDa that is close is size to MeCP2 which is also enriched after
streptavidin pulldown (Figure 3.4.B,D; denoted by *). By examining the merged image, it is
apparent that both biotinylated MeCP2
but only MeCP2

Tavi

Tavi

and MBD2

Tavi

are enriched by streptavidin pulldown,

is detected by the MeCP2 antibody (Figure 3.4.B,D; note yellow band in

merged image).
We also validated the specific enrichment of biotinylated MBD2

Tavi

and MeCP2

Tavi

by

streptavidin pulldown using an additional reagent. We used an antibody raised against the
biotinylation consensus sequence for BirA (labeled Avi) to detect the Tavi tag of MBD2
MeCP2

Tavi

Tavi

and

in addition to streptavidin to detect biotinylated proteins. This approach allowed us to

simultaneously detect MBD2

Tavi

and MeCP2

Tavi

using the same reagents for a direct comparison

of enrichment and expression levels. We performed streptavidin pulldown using protein lysate
from four tissues, brain, lung, small intestine, and colon, from adult Mbd2
R26

BirA/+

, and MeCP2

Tavi/y

; R26

BirA/+

Tavi/Tavi

; R26

mice in order to compare biotinylated MBD2

Tavi

BirA/+

,

and MeCP2

Tavi

to mice that do not express any Tavi-tagged proteins (Figure 3.5). This comparison allowed us to
assess the presence of multiple isoforms of MBD2 in different tissues, and also served as a
preliminary analysis of MBD protein spatial expression.
We found that streptavidin and the Avi antibody detect three isoforms of MBD2

Tavi

in all

tissues examined here. The Avi antibody also detects several cross-reacting proteins that vary
between tissues, must notably a band at 50kDa in the brain and colon that partially obscures
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MBD2a

Tavi

and MBD2d

Tavi

(Figure 3.5.A,D). Streptavidin also detects several endogenously

biotinylated proteins, including one at 75kDa that partially obscures MeCP2

Tavi

in blots with brain,

lung, and colon lysate (Figure 3.5.A,B,D). Despite these complications, it is apparent that MBD2
and MeCP2 carry the Tavi-tag and are biotinylated, as demonstrated by the merged signals using
two methods of detection, the Avi antibody and streptavidin (yellow bands, merged images). We
also observed that MeCP2 expression is not detectable in the small intestine, even after
enrichment for MeCP2

Tavi

three isoforms of MBD2

with streptavidin pulldown (Figure 3.5.C). Additionally, we found that all

Tavi

appear to be equivalently expressed in these four tissues, which we

later re-evaluated with further experiments (Figure 3.9). These additional verifications
demonstrate the necessity for a novel affinity-tagging approach in order to study MBD2 functions
in vivo. This approach also allows for the enrichment and detection of biotinylated MBD2
MeCP2

Tavi

Tavi

and

in parallel.

Streptavidin-mediated pulldown of biotinylated MBD2

Tavi

reveals distinct binding partners

for MBD2 and MeCP2 in vivo and ubiquitous MBD2-NuRD interactions
Our initial analysis of MBD2

Tavi

and MeCP2

Tavi

expression while verifying the biotinylation

of each protein showed that these proteins are co-expressed in several tissues, including the
brain, lung and colon (Figure 3.5). Despite being co-expressed and having similar DNA-binding
properties, the MBD proteins have distinct functions that may be conferred through interactions
with distinct protein complexes in vivo (Baubec et al., 2013; Nan et al., 1998; Zhang et al., 1999).
However, for MBD2 these interactions have only been verified using cell culture systems and the
dynamics of these interactions in vivo have not been fully explored. Therefore, in order to verify
MBD2 and co-repressor interactions in vivo, we performed streptavidin-mediated co-pulldown
experiments with MBD2
and MeCP2

Tavi/y

; R26

Tavi

BirA/+

and MeCP2

Tavi

using brain and lung lysate from Mbd2

, respectively, and R26

BirA/+

Tavi/Tavi

; R26

BirA/+

adult mice. We assessed interactions

between MBD2 and the NuRD that have been studied in cultured cells and interactions between
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MeCP2 and the NCoR and SIN3A co-repressor complexes (Boeke et al., 2000; Ebert et al., 2013;
Lyst et al., 2013; Nan et al., 1998; Zhang et al., 1999).
We detected interaction between MeCP2

Tavi

and two core components of the NCoR

complex, TBLR1 and HDAC3. We also detected interaction between MeCP2

Tavi

and HDAC1,

which associates with NCoR and SIN3A, and SIN3A itself in both brain and lung (Figure 3.6.A,B).
We found that MBD2

Tavi

had a strong association with components of the NuRD complex,

including HDAC1, HDAC2 and MTA2 in both tissues. Interestingly, we found that MBD2 shows
stronger association with HDAC1 compared to MeCP2 under these pulldown conditions. We also
observed a weak interaction between MBD2
2000). Neither MeCP2

Tavi

nor MBD2

Tavi

Tavi

and SIN3A, as has been reported (Boeke et al.,

interacted with LaminB1, as expected (Baubec et al.,

2013).
This approach also allowed us to determine if there are tissue-specific interactions
between the MBD2, MeCP2 and co-repressor complexes. To analyze this question more closely,
we also examined MBD2 interactions with NuRD in the colon in addition to the brain and lung of
adult mice (Figure 3.6.C). These tissues are representative of cell types with MBD2 and MBD3
co-expression (brain), MBD2 expression but not MBD3, or MBD2 expression with lowly
detectable MBD3 expression (Figures 3.8 and 3.9). We found essentially identical patterns of
interaction for MeCP2

Tavi

and MBD2

interactions between MBD2

Tavi

Tavi

in the brain and lung. Furthermore, we observed similar

and components of the NuRD complex in the brain, lung and

colon. This evidence suggests that these interactions are ubiquitous and may not have tissue or
cell type specificity. These findings also raise important questions for the interactions between
MBD2 and NuRD in tissues where MBD3 is not expressed, specifically the lung and colon.
Because all isoforms of MBD2 carry the Tavi tag, we were unable to distinguish which
isoforms were interacting with NuRD by streptavidin pulldown of MBD2

Tavi

. It has been reported

that modifications to the N terminus of MBD2a can affect NuRD association (Tan and Nakielny,
2006).Therefore, we wanted to test which isoforms of MBD2 interact with NuRD in vivo. We
performed co-immunoprecipitation with antibodies against two NuRD components, CHD4 (also
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known as Mi2-β) and HDAC1 with brain lysate from adult Mbd2

Tavi/Tavi

3.6.D). Unexpectedly, we found that all three isoforms of MBD2
with CHD4 and HDAC1. MBD2d
to MBD2a

Tavi

and MBD2b

Tavi

Tavi

Tavi

; R26

BirA/+

mice (Figure

are co-immunoprecipitated

showed weaker interaction with CHD4 and HDAC1 compared

, but the lower expression of this isoform makes quantitative

interpretation difficult. In addition, all three MBD2

Tavi

isoforms have significantly weaker interaction

with CHD4 than HDAC1 under these conditions. We determined that we were not disrupting
endogenous protein complex interactions by detecting CHD4 and HDAC1 interactions with other
NuRD complex proteins, including HDAC2 and MTA2, and HDAC1 interaction with SIN3A. We
conclude that in vivo MBD2 is associated with the NuRD complex in the brain. Additional
experiments may reveal whether or under what circumstances MBD2a may have reduced
interactions with NuRD in vivo, as has been reported (Tan and Nakielny, 2006).

MBD2

Tavi

is depleted at genomic loci with chromatin marks associated with transcriptional

silencing
Due to the limitations of antibodies for MBD2, previous attempts to perform chromatin
immunoprecipitation (ChIP) for MBD2 have mainly relied on tagged alleles over expressed in
cultured cells (Baubec et al., 2013; Günther et al., 2013; Menafra et al., 2014). These previous
studies generally showed that MBD2 is localized at methylated CpG islands at transcription start
sites, promoters, and exons. Interestingly, MBD2 binding is highly dependent on mCG density
and is consequentially not enriched at highly methylated, low-density sites such as introns and
intergenic regions. MBD2 and NuRD are also found at some actively transcribed loci, suggesting
that more complex transcriptional regulation may be occurring beyond simple transcriptional
repression associated with DNA methylation.
We wanted to determine if MBD2 shows similar patterns of localization in vivo by using
streptavidin to perform ChIP for MBD2

Tavi

in adult cortex tissue. Using ChIP followed by

quantitative PCR analysis, we examined MBD2 enrichment at two constitutively expressed loci,
the promoters of Gapdh and Actb. We also assessed two transcriptionally repressed or gene poor
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regions, including intra-cisternal A-type particle (IAP) elements and a gene desert region on
chromosome 6. IAP elements are high-copy number long terminal repeat (LTR) transposons that
are found throughout the genome and transcriptionally silenced by methylation (Walsh et al.,
1998). Although these sites are methylated, the mCG density is low and therefore MBD2 is not
strongly enriched at IAP elements or other repetitive elements (Baubec et al., 2013).
In order to assess the chromatin state at each site, we first performed ChIP-qPCR for
histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 acetylation (H3K27ac),
both of which are associated with transcriptional activation and open chromatin (Shlyueva et al.,
2014). As expected, we determined that H3K4me3 and H3K27ac are enriched at the promoters
of Gapdh and Actb relative to the transcriptionally repressed IAP elements and gene desert loci
(Figure 3.7.A). We then used streptavidin to perform ChIP-qPCR for MBD2
(Figure 3.7.B). We determined that MBD2

Tavi

Tavi

at the same loci

is enriched at the transcriptionally silent or gene-

poor regions at IAP elements and in the gene desert region of chromosome 6 and is relatively
depleted at the promoters of Gapdh and Actb. Streptavidin also binds to endogenously
biotinylated proteins, although these proteins are not predicted to be chromatin-binding proteins
and therefore are unlikely to interfere with MBD2

Tavi

ChIP (de Boer et al., 2003).

In order to verify the specificity or the streptavidin ChIP approach for MBD2

Tavi

, we

repeated the ChIP experiment with an additional pre-treatment with TEV protease before
performing the ChIP. This pre-treatment cleaves the C-terminal biotinylation consensus sequence
from the coding sequence of MBD2

Tavi

, and therefore should give no ChIP signal after streptavidin

ChIP. We determined that pre-treatment with TEV protease effectively abolishes the ChIP signal
for MBD2

Tavi

at all loci (Figure 3.7.B), thereby demonstrating the specificity of this approach.

Distinct spatiotemporal expression patterns of endogenous MBD2 in contrast to MBD1,
MeCP2 and MBD3
Together with published studies (Cook et al., 2015; Sansom et al., 2003; Wang et al.,
2013), our results support a role for MBD2 in tissues or organs outside the brain, in notable
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contrast to MeCP2 and MBD1 (Chapter 2). In order to better understand MBD2 functions in vivo,
we sought to characterize where and when MBD2 is expressed in comparison to other MBD
proteins. This has previously been challenging because, even with reliable antibodies, the
variable immunoreactivity of each antibody makes comparison of the expression levels for
different MBD proteins difficult. In contrast, our biotin-affinity tag approach allows for direct,
quantitative comparison of expression levels of MBD2 and MBD1. To better understand where
and when MBD2 functions in vivo, we analyzed the expression patterns of MBD2, MBD1,
MeCP2, and MBD3 across eight different tissues and two developmental time points, P7 and
P42. We took advantage of the Tavi-tagged alleles of MBD2 and MBD1 to reliably determine the
expression level of each protein and compared their expression side-by-side using quantitative
western blots. This approach allowed us to obtain a comprehensive view of endogenous MBD
spatiotemporal expression patterns at the protein level.
Using MBD2

Tavi

mice with constitutively expressed BirA (Mbd2

Tavi/Tavi

; R26

BirA/+

), we

analyzed the expression of three Tavi-tagged isoforms of MBD2 (MBD2a, MBD2b, and MBD2d)
using two complementary reagents. First, we used an antibody raised against the biotinylation
consensus sequence for BirA (labeled Avi) to detect the Tavi tag of MBD2
streptavidin to detect biotinylated MBD2

Tavi

Tavi

. We also used

. In order to exclude cross-reacting proteins

recognized by the Avi antibody and also exclude endogenously biotinylated proteins, we first
used these reagents with protein lysate from R26

BirA/+

animals that do not express any Tavi alleles

(Figure 3.8.A,B). The Avi antibody detects several cross-reacting proteins, most notably a 50kDa
protein that is highly expressed in the brain at both P7 and P42 and a weaker cross-reacting band
at 37kDa at P7. Several endogenous biotinylated proteins are also detected by streptavidin in the
molecular size around MBD2, particularly a 37kDa protein in the heart, liver, kidney and small
intestine at P42 (Figure 3.8.A,B; denoted by *).
Western blot analysis of protein lysate from Mbd2

Tavi/Tavi

; R26

BirA/+

animals showed that all

three isoforms of MBD2 are partially obscured by the cross-reacting bands detected by the Avi
antibody, particularly in the brain (Figure 3.8.C,D). However, MBD2a
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Tavi

and MBD2b

Tavi

are clearly

detected by streptavidin in multiple tissues at both P7 and P42. By examining the merged images
from the streptavidin and Avi antibody signals (yellow bands), we concluded that the three
isoforms of MBD2

Tavi

are expressed highly in multiple tissues including the heart, lung, liver,

kidney and colon at P7 and P42. MBD2d

Tavi

appears to be expressed at a lower level than the 2a

and 2b isoforms in all tissues examined, particularly at P42. These isoforms are expressed in the
brain, but at a lower level compared than other tissues. Interestingly, all MBD2

Tavi

isoforms are

not expressed in spleen or small intestine at P7, but become up-regulated in these tissues at P42
(Figure 3.8.C,D).
We next sought to place MBD2 spatiotemporal expression patterns into the context of the
MBD family. Therefore, we surveyed MBD1, MeCP2 and MBD3 expression in the same set of
tissues and time points included in our MBD2 study. We used the Tavi-tag system to analyze
MBD1 expression. First, we identified cross-reacting proteins detected by the Avi antibody and
endogenously biotinylated proteins by analyzing protein lysate from R26

BirA/+

animals (Figure

3.9.A,B). At the molecular size around MBD1, the Avi antibody detected only a minor crossreacting band at 75kDa in the kidney at P42 (denoted by *). Several endogenous biotinylated
proteins are detected by streptavidin, particularly a 75kDa protein with significant expression in all
tissues examined at P7 and P42 (denoted by *) (Figure 3.9.A,B).
We then used Mbd1

Tavi/Tavi

; R26

BirA/+

mice to perform western blots with streptavidin and

the Avi antibody to detect biotinylated MBD1

Tavi

expression (Figure 3.9.C,D). Streptavidin and the

Avi antibody both detect biotinylated MBD1a

Tavi

and MBD1b

Tavi

. In order to examine the untagged

MBD1d isoform, we also performed western blots with an antibody against MBD1 and included
brain lysate from Mbd1 null mice to specifically identify MBD1 isoforms (Figure 3.9.C,D). The
MBD1 antibody detects the untagged MBD1d isoform in addition to the two biotinylated Tavitagged isoforms (MBD1 antibody and streptavidin merged images, note red unbiotinylated
MBD1d band). We found that at P7, the three MBD1 isoforms are all highly expressed in the
brain, consistent with a previously reported role for MBD1 in neural stem cells (Liu et al., 2010).
Notably, MBD1 is barely detectable in non-neuronal tissues at P7. In addition, the expression of
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all MBD1 isoforms is significantly reduced in P42 brains compared to P7 while remaining nearly
undetectable in other tissues.
We then assessed MeCP2 and MBD3 expression in P7 and P42 wildtype animals using
antibodies against each protein (Figure 3.10). The specificity and reliability of these antibodies
allowed us to complete the expression survey. Consistent with previous findings (Shahbazian et
al., 2002), we found that MeCP2 is highly expressed in the brain at P7 and P42, but is also
expressed relatively highly in the lung and colon. Developmentally, MeCP2 expression is upregulated in the heart and liver but down-regulated in the lung, kidney and colon in adult tissues,
while remaining consistently high in the brain (Figure 3.10.A,B). Strikingly, we found that MBD3 is
highly expressed in the brain with weakly detectable expression in the colon at P7 with
undetectable expression in all other tissues examined (Figure 3.10.C). Similarly to MBD1 (Figure
3.9.D), MBD3 is significantly downregulated in the brain at P42 while remaining undetectable in
all other tissues with the exception of the colon (Figure 3.10.D). These findings are in notable
contrast to the expression patterns of MBD2, which is widely expressed in multiple tissue types.
Our side-by-side comparison of MBD expression levels reveals that MBD2 is distinct from MBD1,
MeCP2, and MBD3 in that it is highly expressed across multiple non-neuronal tissues. In contrast,
MBD1, MeCP2, and MBD3 are highly enriched in the brain, consistent with their well-described
neuronal functions (Allan et al., 2008; Guy et al., 2001). Our findings on the spatiotemporal
expression patterns of the MBD proteins are summarized in Figure 3.11.
Our biotin-tagging approach also allows for direct quantitative comparison of MBD2
and MBD1

Tavi

protein expression by measuring the streptavidin signal, an approach that is not

possible with different antibodies. We quantified the relative expression of MBD2a
MBD1a

Tavi

Tavi

Tavi

and

by normalizing the streptavidin signal to the H3 antibody signal for the brain, lung, and

colon at P7 and P42, three tissues where both MBD2 and MBD1 expression were detected
(average of three representative western blots) (Figure 3.12). This analysis demonstrated that
MBD2a

Tavi

is expressed significantly higher in the lung and colon compared to the brain at both

developmental time points, P7 and P42 (Figure 3.12.A). In contrast, MBD1a
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Tavi

is expressed

significantly higher in the brain compared to the lung and colon at P7 and P42 (Figure 3.12.B).
We also assessed the temporal expression changes for MBD2a

Tavi

Tavi

specifically in

expression levels in the brain do not

Tavi

is significantly down-regulated at P42

compared to P7. In P42 brains, though the expression of MBD2a
MBD1a

and MBD1a

Tavi

the brain (Figure 3.12.C). We found that MBD2a
significantly change from P7 to P42, but MBD1a

Tavi

Tavi

is significantly higher than

, it is relatively lower than MeCP2 (Figure 3.12.C and 3.10.B). Together, the distinct

spatiotemporal expression patterns of MBD2 in comparison to MBD1 and MeCP2 appear to
underlie the distinct behavioral phenotypes observed in each individual MBD gene null mouse
model.

MBD2 is expressed widely throughout the brain and specifically in small intestine and
colon epithelial crypt cells in adult mice
In order to examine MBD2 spatial expression in more detail, we took advantage of the
Mbd2 null allele, which contains a LacZ allele that replaces the Mbd2 coding exon 2 (Hendrich et
-/-

al., 2001). Therefore, we were able to use Mbd2 mice with β-gal staining to visualize where
endogenous MBD2 is expressed. A similar approach has been used to determine MBD1
expression in the brain, as the Mbd1 null allele also contains a LacZ allele (Zhao et al., 2003). We
examined β-gal staining throughout the brain, including the olfactory bulb, prefrontal cortex,
-/-

striatum, hippocampus, and cerebellum in P60 wildtype and Mbd2 mice. We also used Nissl
staining of adjacent cryosections to visualize the anatomy of each region. In wildtype mice, no β-/-

gal staining is visible, as expected (Figure 3.13.A). In Mbd2 mice, we observed β-gal staining
throughout the brain, which implies that MBD2 is endogenously expressed throughout all brain
regions examined here (Figure 3.13.B). Certain regions such as the hippocampus and the
cerebellum show intense staining, but this is reflective of higher cell density rather than increased
MBD2 expression as increased staining intensity is also observed with Nissl staining. These
results corroborate our findings that MBD2 is expressed in the adult mouse brain using western
blots to detect MBD2

Tavi

expression (Figure 3.8).
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We also extended our analysis of MBD2 spatial expression to the gastrointestinal tract,
as there is evidence that the regulation of DNA methylation is essential in the maintenance of
epithelial crypt cells (Sheaffer et al., 2014). Additionally, MBD2 has been proposed to affect
tumorigenesis in colorectal cancer models (Sansom et al., 2003). We used the same β-gal
-/-

staining strategy with Mbd2 mice as for the brain and examined MBD2 expression in the
-/-

jejunum of the small intestine and the colon of P60 wildtype and Mbd2 mice. We found that
MBD2 is expressed specifically in the crypt epithelial cells in the small intestine and colon, which
house proliferating undifferentiated stem cells (Figure 3.14.A) (Humphries and Wright, 2008; Tan
and Barker, 2014). We also verified the spatial expression of MBD2 by fractioning epithelial cells
from the small intestine into villi and crypt populations and isolating colon crypt epithelial cells
from R26

BirA/+

and Mbd2

Tavi/Tavi

; R26

BirA/+

mice for western blot analysis. Using the anti-Avi

antibody and streptavidin to detect MBD2

Tavi

by western blotting, we determined that MBD2 is

expressed specifically in the crypt cellular populations of the small intestine and colon with
undetectable expression in small intestine villi (Figure 3.14.B). Together, this evidence suggests
that in the gastrointestinal tract MBD2 may have a specific role in proliferating crypt epithelial
stem cells.

DISCUSSION

In this study, we describe a novel biotin-tagging system for MBD2 and MBD1 and
demonstrate the utility of this system for the study of MBD functions in vivo. We found that an
affinity-tagged allele of MBD2 allows for the detection and immunoprecipitation of MBD2 in order
to examine different protein isoforms, in vivo binding partners, chromatin localization, and
spatiotemporal expression patterns. We found that MBD2 interacts with a distinct set of protein
partners compared to MeCP2 in vivo, and is anti-correlated with the presence of activating
histone marks at certain genomic loci. We also found that MBD2 is highly expressed in many
tissues and that MBD2 expression increases significantly in spleen and small intestine in adult
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mice. In contrast, MBD1, MeCP2, and MBD3 are primarily expressed in the brain. This study
provides new genetic tools and identifies new areas for future studies of MBD function in vivo.
To investigate the in vivo function and expression of MBD2 in context of the MBD protein
family, we used a biotin-tagging approach that we also applied to MBD1 (Figures 3.2 and 3.3).
This approach advantageously allows for the precise detection of MBD2 from multiple tissues in
vivo, while avoiding unreliable antibodies that are especially problematic for MBD2. We were also
able to identify multiple isoforms of MBD2 that are not recognized by MBD2 antibodies alone
(Figure 3.4). It is especially important to differentiate between the isoforms of MBD2 in vivo, as
there is strong evidence that different isoforms of MBD2 have different interactions with the NuRD
complex and different functions, particularly in ESCs (Lu et al., 2014; Tan and Nakielny, 2006).
The MBD2d isoform has been observed in HeLa cells expressing endogenous MBD2 and is
consistently identified in all tissues examined in this study (Figure 3.8). Therefore, it is unlikely to
be a simple protein degradation product due to technical artifacts and may represent a cleavage
event or post-translational modification of MBD2a. This isoform is also unlikely to arise from an
alternatively transcribed or spliced transcript because previous examination of MBD2 in cDNA
libraries identified only the transcripts corresponding to MBD2a/b and MBD2c (Figure 3.2.A)
(Hendrich and Bird, 1998).
Previous studies have established that MBD2 is a key component of the NuRD complex,
while MeCP2 is associated with the NCoR/SMRT and SIN3A co-repressor complexes, amongst
other functions (Lyst et al., 2013; Nan et al., 1998; Ng et al., 1999; Zhang et al., 1999). However,
in the case of MBD2, these results are exclusively from cultured cells and little is known about
MBD2 in vivo functions. The Tavi-tag approach we developed allowed us to determine that MBD2
is associated with NuRD in vivo, and under these conditions has stronger interactions with
HDAC1 than MeCP2 (Figure 3.6.A,B). We found essentially equivalent results in the brain, lung,
and colon, which suggests that the interactions of MBD2 with NuRD are ubiquitous. There is
evidence that post-translational modifications of MBD2a specifically affect NuRD interactions
(Tan and Nakielny, 2006). However, our co-immunoprecipitation results do not support this as we
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found that all isoforms of MBD2 are associated with the NuRD complex (Figure 3.6.D). It is
possible that this specific post-translational modification does not occur in the brain in vivo, or that
there are additional regulatory mechanisms determining MBD2 interactions with NuRD.
Previous work on the genome-wide binding patterns of MBD2 have been limited to
cultured cells, often with over-expressed alleles of MBD2, similar to studies of MBD2 binding
partners (Baubec et al., 2013; Günther et al., 2013; Menafra et al., 2014). We used the Tavi-tag
approach to perform ChIP-qPCR for MBD2 to better understand where MBD2 is localized in vivo.
Previous studies have found that MBD2 is localized at areas of high mCG density, but is also
associated with active transcription. The localization of MBD2 to actively transcribed sites may
depend on interactions with NuRD (Baubec et al., 2013). We found that MBD2

Tavi

shows reduced

binding at the enhancers of constitutively active genes that have activating histone marks
compared to gene-poor inactive regions (Figure 3.7). This result supports previously published
findings. However, in order to have a complete understanding of MBD2 function additional loci
must be examined. The NuRD complex and other co-repressors may function as modulators of
transcriptional activity instead of just repressors, which is supported by ChIP-seq data (Baubec et
al., 2013; Reynolds et al., 2013). Therefore, it would be informative to compare MBD2 binding at
constitutively active genes to genes that have more active modulation of their expression, such as
lowly expressed or cell-type specific genes. Additionally, MBD2 binding and mCG density in vivo
could be examined to determine if MBD2 binds to DNA in a mCG-density dependent manner, as
has been shown in ESCs (Baubec et al., 2013).
We also used the Tavi-tag approach to quantitatively analyze the different spatiotemporal
expression patterns of MBD2 and MBD1 and compared these results to parallel analysis of
MeCP2 and MBD3 using antibodies (Figures 3.8-12). This strategy allowed us to perform a sideby-side, quantitative comparison of MBD2 and MBD1 expression, while avoiding the use of
unreliable antibodies for MBD2. Our spatiotemporal expression survey demonstrates that MBD2
is distinct from MBD1, MeCP2, and MBD3 as it is highly expressed in many tissues instead of
being primarily expressed in the brain. We also observed that the three isoforms of MBD2 do not
82

show appreciable differences in expression levels between tissues or temporally, and instead are
co-expressed consistently.
In order to gain a more precise spatial map of MBD2 expression in the brain, we
-/-

performed β-gal staining in Mbd2 mice (Figure 3.13). Our results show that MBD2 is expressed
constitutively throughout all regions of the brain examined. This result is congruent with our
western blot data that MBD2 is expressed constitutively when examined at the resolution of
western blots with whole tissue lysate (Figure 3.8). The finding that MBD3 is nearly exclusively
expressed in the brain result is especially striking, as MBD3 and MBD2 form mutually exclusive
complexes with the NuRD complex (Le Guezennec et al., 2006). A recent study found that MBD3,
but not MBD2, interacts with a brain-specific NuRD component CHD5, as opposed to CHD4
(Potts et al., 2011). This finding further supports the hypothesis that NuRD-related functions in the
brain may be primarily mediated by MBD3 and not MBD2. To extend this hypothesis, it is possible
that in peripheral tissues MBD2 is the primary component of NuRD where MBD3 is not
expressed. Our results show that MBD2 interacts with NuRD in a ubiquitous fashion across three
tissues with variable MBD3 expression (Figure 3.6). Because MBD3 is not expressed or
undetectable in these tissues, we hypothesize that NuRD primarily interacts with MBD2 in these
cell types.
Our finding that MBD2 expression increases significantly in the spleen and small intestine
from P7 to P42 is intriguing in the context of previous studies on the role of MBD2 in immunity
and the small intestine (Figure 3.8.C,D) (Berger et al., 2007; Cook et al., 2015; Phesse et al.,
2008; Sansom et al., 2003; Wang et al., 2013; Zhong et al., 2014). Precise temporal control of
methylation and demethylation is essential for the development and differentiation of both T cells
(Sellars et al., 2015) and intestinal epithelial crypt cells (Sheaffer et al., 2014), indicating that
MBD2 may contribute to the interpretation of DNA methylation in these tissues. For example,
MBD2 has a role in T cell development that is partially dependent on the methylation status of
critical genes such as Foxp3 (Lal et al., 2009; Wang et al., 2013). MBD2 can also indirectly affect
T cell activation and differentiation through its functions in dendritic cells (Cook et al., 2015).
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Interestingly, both MeCP2 and MBD1 have also been implicated in innate and adaptive immunity
(Cronk et al., 2015; Theoharides et al., 2015; Waterfield et al., 2014) indicating that MBD family
proteins may have a wider role in these systems. However, although it is apparent that NuRD is
essential for lymphocyte development, a precise role for MBD3 in these processes has not been
identified (Dege and Hagman, 2014b).
In the intestine, loss of MBD2 is linked to altered gene expression (Berger et al., 2007).
MBD2 has also been identified as a potential target for cancer therapeutic intervention. Loss of
MBD2 is protective against tumorigenesis in a mouse model of colorectal cancer by
downregulating Wnt signaling (Phesse et al., 2008; Sansom et al., 2003). In addition, MBD2
contributes to silencing of aberrantly hypermethylated tumor suppressor genes linked to colon
cancer (Martin et al., 2008). Our results show that MBD2 is upregulated in the adult small
intestine compared to expression at P7 (Figure 3.8.C,D). More specifically, we used parallel
approaches to show that MBD2 is expressed in the proliferating, undifferentiated crypt stem cells
of the small intestine and colon, and is not detectable in the differentiated epithelial villi cells of
the small intestine (Figure 3.14). These results indicate that MBD2 may have a role specifically in
undifferentiated, proliferating cells in this tissue. MBD3 has an essential role in maintaining gene
expression programs and cell proliferation in the colon (Aguilera et al., 2011). MBD2 may have
similar functions in the gastrointestinal tract. However, it is important to note that the histology of
-/-

the small intestine and colon in Mbd2 mice appears equivalent to wildtype in our preliminary
results and further work is required to characterize any MBD2-related phenotypes in this tissue.
The results of this work reveal many new directions for the study of MBD2 in vivo
functions. First, further investigation is necessary to characterize the MBD2d isoform we
observed in multiple tissues at young and adult time points and to determine if this isoform is
biologically relevant (Figure 3.8). For example, certain treatments to remove chemical
modifications may reveal if MBD2d is simply an unmodified form of MBD2a that consequentially
has a lower molecular weight. Additional work to investigate the in vivo binding partners of MBD2
is also required to determine the dynamics of interactions between NuRD and MBD2 or MBD3. A
84

previous study suggested that most NuRD is in complex with MBD3 and not MBD2 in mammalian
cells (Zhang et al., 1999). This may be the case in vivo in cell types where MBD2 and MBD3 are
co-expressed including the brain and colon, but it is unclear how these interactions may differ in
most peripheral tissues where MBD3 expression is very low.
The transgenic mice developed in this study could also be used to further examine MBD2
genome-wide localization patterns using streptavidin-mediated ChIP-seq. This approach would
allow for a more thorough characterization of MBD2 localization, especially in conjunction with
additional histone mark ChIP-seq analysis. These experiments may be combined with additional
ChIP-seq or gene expression analysis in Mbd2 null mice in order to examine how loss of MBD2
may affect the chromatin state and particularly histone acetylation. The Tavi-tag system can also
be modified to allow for cell-type specific biotinylation of the tagged proteins. With conditional
expression of BirA biotin ligase under control of a cell-type specific Cre recombinase, any of the
experiments described here may be performed in a cell-type specific manner. This approach may
be especially applicable to tissues such as the small intestine where MBD2 is expressed in a
distinct sub-population of the tissue (Figure 3.14).
In summary, our study describes the in vivo binding partners and spatiotemporal
expression patterns for MBD2 relative to the related proteins MBD1, MeCP2 and MBD3. We
found that MBD2 is associated with a unique set of co-factors compared to MeCP2 in vivo and
MBD2 localization to chromatin is anti-correlated with activating transcription marks. In contrast to
MBD1, MeCP2, and MBD3, MBD2 is widely expressed in non-neuronal peripheral tissues. Our
findings provide new insights into the functions of MBD2 and also provide genetic tools to
investigate these functions in vivo.
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CHAPTER 3 FIGURES

Figure 3.1. Schematic of biotin-affinity tagging approach.
Tavi/Tavi
(A) Mbd2
mice express an allele of MBD2 with a C-terminal biotinylation consensus
Tavi
sequence. (B) MBD2
is constitutively biotinylated in the presence of BirA biotin ligase in
Tavi/Tavi
BirA/+
Tavi
Mbd2
; R26
mice. (C) Biotinylated MBD2
can be pulled down with streptavidinconjugated beads for further downstream applications. (D) Treatment with TEV protease cleaves
Tavi
MBD2
between the endogenous protein coding sequence and C-terminal biotin consensus
sequence. Schematic diagrams are not to scale.
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Tavi

Figure 3.2. Development of Mbd2
knockin mice.
Tavi
(A) Targeting strategy for generating Mbd2
knockin mice. The Tavi tag is inserted into exon 6.
Tavi
Tavi
Two documented isoforms from alternative translation start sites, MBD2a
and MBD2b , are
expressed. A third newly found isoform, MBD2d, is also Tavi-tagged and expressed (GR, GR
Tavi/Tavi
Tavi/Tavi
repeat region; TRD, transcriptional repression domain). (B), Mbd2
(n = 8) and Mbd2
;
BirA/+
BirA/+
R26
(n = 7) mice have equivalent body weight to wildtype (+/+, n = 7) and R26
(n = 5)
mice (two-way ANOVA). Data are presented as mean ±SEM. (C) Detection of MBD2 isoforms in
-/the brain. An antibody against MBD2 detects cross-reacting bands in wildtype (WT) and Mbd2
Tavi
(KO) brain lysate. Three isoforms of MBD2
are specifically biotinylated and detected by
Tavi/Tavi
BirA/+
BirA/+
streptavidin in Mbd2
; R26
, but not R26
, brain lysate. Cross-reacting and
endogenously biotinylated proteins are denoted by *.
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Tavi

Figure 3.3. Development of Mbd1
knockin mice.
Tavi
(A) Targeting strategy for generating Mbd1
knockin mice. The Tavi tag is inserted into exon 15,
Tavi
Tavi
which is included in MBD1a
and MBD1b , but not in the alternatively spliced isoform MBD1d
(CxxC, CxxC zinc finger DNA-binding domain; TRD, transcriptional repression domain). (B) An
BirA/+
antibody against MBD1 detects three MBD1 isoforms that are present in R26
and
Tavi/Tavi
BirA/+
-/Tavi
Mbd1
; R26
, but not Mbd1 (KO), P7 brain lysate. Two MBD1
isoforms are
Tavi/Tavi
BirA/+
biotinylated and detected by streptavidin specifically in lysate from Mbd1
; R26
mice
(merged image, yellow bands). Cross-reacting and endogenously biotinylated proteins are
denoted by *.
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Figure 3.4. Streptavidin-mediated pulldown of biotinylated MBD2
of MBD2 with an antibody.
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Figure 3.4. Streptavidin-mediated pulldown of biotinylated MBD2
compared to detection
of MBD2 with an antibody.
Tavi
(A) Streptavidin pulldown of biotinylated MBD2
from brain lysate reveals three isoforms of
Tavi
Tavi
MBD2 . Only MBD2a
is detected by an antibody against MBD2 after enrichment. (B)
Tavi
Tavi
Streptavidin pulldown of MeCP2
from brain lysate shows specific detection of MeCP2
with
an antibody against MeCP2. Streptavidin detects an endogenously biotinylated protein at 75kDa
Tavi
that partially obscures MeCP2. (C) Streptavidin pulldown of biotinylated MBD2
from lung lysate
Tavi
Tavi
reveals three isoforms of MBD2 . Only MBD2a
is detected by an antibody against MBD2
Tavi
after enrichment. (D) Streptavidin pulldown of MeCP2
from lung lysate shows specific
Tavi
detection of MeCP2
with an antibody against MeCP2. Cross-reacting and endogenously
biotinylated proteins are denoted by *.
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Figure 3.5. Different isoforms of biotinylated MBD2
multiple tissues.
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Figure 3.5. Different isoforms of biotinylated MBD2
can be detected with streptavidin in
multiple tissues.
Tavi
(A) Streptavidin pulldown and western blot with of biotinylated MBD2
from brain lysate reveals
Tavi
Tavi
three isoforms of biotinylated MBD2 and biotinylated MeCP2 . In the brain, a non-specific
Tavi
Tavi
cross-reacting band detected by the Avi antibody partially obscures MBD2a
and MBD2d .
Tavi
MeCP2
is partially obscured by an endogenous biotinylated protein of 75kDa. (B) Biotinylated
Tavi
Tavi
isoforms of MBD2
and MeCP2
are detected by streptavidin and Avi antibody and enriched
Tavi
with streptavidin pulldown in lung lysate. (C) Three isoforms of MBD2
are detected by
streptavidin and Avi antibody and enriched with streptavidin pulldown in small intestine lysate.
Tavi
Tavi
MeCP2 is not detectable in the small intestine. (D) Three isoforms of MBD2
and MeCP2
are
detected by streptavidin and Avi antibody and enriched with streptavidin pulldown in colon lysate.
Cross-reacting and endogenously biotinylated proteins are denoted by *.
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Figure 3.6. Distinct in vivo binding partners of MBD2 and MeCP2 in the brain and lung and
ubiquitous MBD2-NuRD interactions across tissues.
Streptavidin pulldown and western blot from brain (A) and lung (B) lysate shows strong
Tavi
interactions between MBD2
and components of the NuRD complex, including HDAC1, HDAC2
Tavi
Tavi
and MTA2. MBD2
interacts weakly with SIN3A. MeCP2
interacts with the NCoR complex,
including TBLR1 and HDAC3, and weak interaction with HDAC1 and SIN3A. Neither protein
interacts with LaminB1 as expected. (C) MBD2 interacts with the NuRD complex in the colon
Tavi
similarly to the brain and lung. (D) Three isoforms of MBD2
are co-immunoprecipitated with
Tavi
components of the NuRD complex, including CHD4 and HDAC1. MBD2
shows weaker
interaction with CHD4 compared to HDAC1. Interactions between other components of the NuRD
complex, including HDAC2 and MTA2, and between HDAC1 and SIN3A were verified as controls.
Cross-reacting and endogenously biotinylated proteins are denoted by *.
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Figure 3.7. MBD2 is depleted at genomic loci with activating histone marks.
Tavi/Tavi
BirA/+
(A) ChIP-qPCR analysis in the cortex of adult Mbd2
; R26
mice for activating histone
marks H3K4me3 and H3K27ac shows enrichment at constitutively expressed loci, including the
Gapdh and Actb promoters, and relatively lower enrichment at transcriptionally inactive regions,
including IAP elements and a gene desert region of chromosome 6 (n = 3 biological replicates).
Tavi/Tavi
BirA/+
Tavi
(B) Streptavidin ChIP-qPCR in the cortex of adult Mbd2
; R26
mice shows MBD2
is
enriched at transcriptionally repressed repetitive and intergenic regions, and depleted at loci with
enrichment of activating histone marks including Gapdh and Actb promoters. Pre-treatment with
TEV protease cleaves the Tavi tag and returns the ChIP signal to background levels,
demonstrating specificity of streptavidin ChIP with Tavi-tagged MBD2 (n = 3 biological replicates).

94

Figure 3.8. Spatiotemporal expression of MBD2 at P7 and P42.
BirA/+
(A) and (B) Western blot analysis with lysate from R26
mice reveals cross-reacting proteins
detected by the Avi antibody and endogenously biotinylated proteins detected by streptavidin,
Tavi
Tavi
Tavi
Tavi
denoted by *. (C) and (D) Three isoforms of MBD2
(MBD2a , MBD2b
and MBD2d ) are
Tavi
biotinylated and detected by streptavidin and the Avi antibody. All isoforms of MBD2 are highly
expressed throughout the body at P7, but are not expressed in spleen and small intestine. All
Tavi
isoforms of MBD2
are highly expressed throughout the body at P42, with up-regulation in
spleen and small intestine compared to P7.
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Figure 3.9. Spatiotemporal expression of MBD1 at P7 and P42.
BirA/+
(A) and (B) Western blot analysis with lysate from R26
mice reveals cross-reacting proteins
detected by the Avi antibody and endogenously biotinylated proteins detected by streptavidin,
Tavi
Tavi
Tavi
denoted by *. (C) and (D) Two isoforms of MBD1
(MBD1a
and MBD1b ) are biotinylated
and detected by the Avi antibody and streptavidin. An antibody against MBD1 also detects
MBD1d, compared to Mbd1 null brain lysate (KO brain). All three isoforms are highly expressed in
the brain and show down-regulation at P42 compared to P7.

Figure 3.10. MeCP2 is consistently highly expressed in the brain while MBD3 is
downregulated in the adult brain.
(A) and (B), MeCP2 is highly expressed in the brain at P7 and P42 as detected by an antibody
against MeCP2 using lysate from wildtype animals. MeCP2 is also expressed in other tissues
including the lung and colon. (C) and (D), MBD3 is highly expressed as a doublet band in the
brain at P7 with lowly detectable expression at P42. MBD3 is also lowly detectable in the colon at
P7 and P42.
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Figure 3.11. Summary of MBD protein spatiotemporal expression patterns.
In the brain, MeCP2, MBD1, MBD2 and MBD3 are highly expressed at P7, but only MeCP2 and
MBD2 remain highly expressed at P42. In other tissues, MBD1 and MBD3 are undetectable with
the exception of the colon. MBD2 is highly expressed across all tissues examined, and is
upregulated in the spleen and small intestine at P42 compared to P7.
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Tavi

Tavi

Figure 3.12. Quantification of MBD2a
and MBD1a
expression levels.
Tavi
Tavi
Expression levels of biotinylated MBD2a
and MBD1a
were determined by normalizing the
fluorescence levels of streptavidin to H3 (average of three representative western blots). (A)
Tavi
MBD2a
is expressed significantly higher in the lung and colon compared to the brain at P7 and
Tavi
P42 (*P < 0.05, **P < 0.01, two-way ANOVA with Tukey’s test). (B) MBD1a
is expressed
significantly higher in the brain compared to the lung and colon at P7 and P42 (*P < 0.05, **P <
Tavi
0.01, two-way ANOVA with Tukey’s test). (C) MBD2a
expression in the brain does not
Tavi
significantly change from P7 to P42, but MBD1a
is significantly down-regulated in the brain at
Tavi
Tavi
P42 compared to P7. At P42, MBD2a
is expressed significantly higher than MBD1a
in the
brain (ns not significant, *P < 0.05, **P < 0.01, two-way ANOVA with Holm-Sidak multiple
comparison test). All data are presented as mean ±SEM.
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Figure 3.13. MBD2 expression throughout the adult brain is visualized with β-gal staining.
(A) Representative β-gal staining of brain regions from P60 wildtype mice shows no staining
(right). Nissl staining (left) allows for visualization of the tissue structure. (B) Representative β-gal
-/staining of brain regions from P60 Mbd2 mice shows that MBD2 is expressed throughout all
brain regions examined, including the olfactory bulb, cortex, striatum, hippocampus, and
cerebellum (right). Nissl staining (left) allows for visualization of the tissue structure. Scale bars
correspond to 500µm.

99

Figure 3.14. MBD2 is expressed specifically in epithelial crypt cells of the gastrointestinal
tract.
-/(A) Representative β-gal staining of the small intestine (SI) and colon in P60 wildtype and Mbd2
mice. There is no staining in wildtype animals, and staining primarily in the epithelial crypt cells of
-/Tavi
both tissues in Mbd2 mice. (B) Western blot analysis of spatial expression of MBD2
in the
small intestine and colon shows that MBD2 is primarily expressed in the epithelial crypt cells of
both tissues with no detectable expression in villi epithelial cells. Scale bars correspond to 50µm.
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CHAPTER 4: Discussion and Future Directions

In summary, I describe in Chapter 2 the results of the first thorough characterization of
Mbd2 null mice, with emphasis on behavioral phenotypes affected by related MBD proteins. In
Chapter 3, I present my work on the generation of two novel transgenic mice with biotin-tagged
endogenous MBD2 or MBD1. I also show the utilization of these mice to explore MBD2 functions
and spatiotemporal expression in the context of the MBD protein family. Together, this study
shows several unexpected findings and reveals new insights into MBD2 function in vivo. These
results elucidate new directions and provide novel genetic tools for further study of MBD2
functions.

Interpretation of Mbd2 null mice phenotypes
The majority of MBD proteins have been implicated in brain function in human disease
and mouse models. Of the MBD proteins, MeCP2, MBD1 and MBD3 are arguably the most
similar to MBD2 in terms of their DNA binding properties or co-repressor interactions (Baubec et
al., 2013; Le Guezennec et al., 2006). All of these MBD proteins, and also MBD5, which does not
bind to methylated DNA but is associated with heterochromatin, have been shown to directly
affect neuronal functions. All of these MBD protein null mice, with the exception of brain-specific
Mbd3 null mice which are perinatal lethal, also have notable behavioral deficits in addition to
underlying cellular phenotypes (Allan et al., 2008; Camarena et al., 2014; Guy et al., 2001; Knock
et al., 2015; Zhao et al., 2003). It is also well established that DNA methylation and co-repressor
protein activity, such as histone deacetylases associated with NuRD or the NCoR complexes, are
essential for brain function (Guan et al., 2009; Guo et al., 2011; McQuown et al., 2011). Due to
these findings, researchers in the MBD protein field have speculated that MBD2 may have similar
brain-related functions (Baubec and Schübeler, 2014; Du et al., 2015). Prior to my thesis work,
-/-

the only described behavioral or potentially brain-related phenotype of Mbd2 null (Mbd2 ) mice
was impaired pup nurturing and retrieval (Hendrich et al., 2001). This maternal behavior
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phenotype has been referenced to support a role for MBD2 in brain function and behavior,
although these phenotypes have complex etiologies (Du et al., 2015; Gammie, 2005).
-/-

With this evidence, it is surprising that we found Mbd2 mice are equivalent to wildtype
-/-

and heterozygous littermates in most behavioral tests. Mbd2 mice show subtle changes on
several behavioral tests and other measures, including home-cage hypoactivity, impaired nesting,
low body weight associated with hypophagia, altered hypothalamic peptide expression, and few
changes in striatal gene expression. These phenotypes are complex, multigenic, and
interdependent, and therefore interpretation of their etiologies is challenging. Additionally, these
phenotypes may be partially dependent on MBD2 functions in peripheral tissues. Specifically,
MBD2 has been shown to affect gene expression in the gastrointestinal tract and in multiple
immune cell types (Berger et al., 2007; Cook et al., 2015; Wang et al., 2013).
Assuming that loss of MBD2 does have effects in peripheral tissues, this further
complicates the interpretation of these phenotypes because these systems are interrelated. First,
the gastrointestinal system has an essential role in immune system homeostasis (Macdonald and
Monteleone, 2005). In addition, body weight is inexorably linked to energy homeostasis (Tou and
Wade, 2002), which could in turn affect activity levels to produce the hypoactivity and nesting
-/-

deficits we observed in Mbd2 mice. The results of the RNA-seq study to identify differentially
-/-

expressed genes (DEGs) in the striatum of Mbd2 mice support that immune and metabolic
phenotypes may be co-occurring to indirectly affect neuronal or behavioral outcomes. Two DEGs
with a greater than 2-fold change increase in expression are transthyretin (Ttr) and lipocalin2
(Lcn2), which are both linked to responses to inflammatory, nutritional, or neural injury stress
(Buxbaum and Reixach, 2009; Lee et al., 2009). Therefore, dysfunction in several systems upon
constitutive loss of MBD2 could have a synergistic effect on body weight, food intake, and activity
phenotypes.
The complexities of these phenotypes could be resolved with additional research.
Specifically, Mbd2 conditional null mice could be used to isolate tissue- or cell-type specific MBD2
functions. For example, by crossing a floxed-Mbd2 allele to a mouse expressing Villin-Cre
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recombinase (Madison et al., 2002) it would be possible delete Mbd2 exclusively from the entire
intestinal epithelium. Further examination of body weight, food intake and metabolic phenotypes
-/-

between this mouse and the constitutive Mbd2 mouse could reveal if low body weight is linked
directly to intestinal phenotypes. A similar approach could be taken to examine MBD2-related
phenotypes in lymphoid cell types. For instance, a mouse expressing Cre recombinase
specifically in FoxP3+ cells (Zhou et al., 2008) could be used to ablate MBD2 expression in Treg
cells. These cell-type specific approaches may be especially relevant to study MBD2 in immune
cell types, as MBD2 acts in multiple cell types that influence each other’s maturation and function,
such as CD4+ T cells and dendritic cells (Aoki et al., 2009; Cook et al., 2015).

Precedents for altered leptin or glucocorticoid receptor signaling in Mbd2 null mice
-/-

It is possible that the phenotypes observed in Mbd2 mice do have neuronal origins that
were not fully elucidated by the experiments described here. First, MBD2 may be affecting the
regulation of hypothalamic leptin signaling, which in turn could affect food intake, activity levels,
and body weight. We found that hypothalamic orexigenic and anorexigenic peptides showed
altered expression in Mbd2 mice, although our findings are not representative of a typical pattern
of misregulation associated with reduced body weight in other mouse models (Yang et al.,
2014a). Hypothalamic regulation of energy expenditure is regulated primarily by leptin and other
nutritional signaling (Myers et al., 2008). Transthyretin, which is significantly upregulated in the
-/-

striatum of Mbd2 mice, is also affected by leptin levels which supports that these mice may have
altered leptin signaling (Rendenbach et al., 2013). Previous studies have shown that MeCP2
affects hypothalamic gene expression and hypothalamic leptin signaling (Ben-Shachar et al.,
2009; Torres-Andrade et al., 2014). Furthermore, there is evidence that hypothalamic leptin
expression in response to diet-induced obesity is directly regulated through DNA methylation and
MBD2-related mechanisms (Shen et al., 2014). Therefore, additional experiments are warranted
-/-

to determine if leptin is misregulated in Mbd2 mice. It would also be critical to identify if any
leptin-related phenotypes are hypothalamic, other neuronal, or peripheral in origin.
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-/-

Another possible neuronal origin for Mbd2 phenotypes is the misregulation of
glucocorticoid receptor (GR) signaling. In this study, we hypothesized that altered striatal
-/-

dopamine signaling may underlie many of the phenotypes of Mbd2 mice, as highly similar
phenotypic profiles have been observed in mice with genetic or pharmacological disruption to this
system (Gammie et al., 2008; Henschen et al., 2013; Jager et al., 2014; Palmiter, 2008).
However, analysis of biogenic amine levels in the cortex and striatum showed that dopamine and
-/-

its metabolites are equivalent between wildtype and Mbd2 mice. An alternative, parallel
-/-

hypothesis is that altered GR signaling in Mbd2 mice could contribute to the maternal nurturing
-/-

deficits and possibly other observed phenotypes in Mbd2 mice (Hendrich et al., 2001).
Maternal licking and grooming behaviors drive increased expression of GR in the
hippocampus, which in turn affects the regulation of stress responses through the hypothalamic–
pituitary–adrenal (HPA) axis (Liu et al., 1997). Maternal behavior is strongly influenced by stress,
adverse events or other environmental cues and these behaviors can trans-generationally
influence maternal behavior of female offspring through epigenetic mechanisms (Francis et al.,
1999). The expression of GR in the hippocampus is regulated through methylation of the exon 17
promoter and recruitment of activating transcription factors, including nerve growth factorinducible protein A (NGFI-A). Epigenetic changes at the GR exon 17 promoter in response to
early environmental cues can persist into adulthood to affect stress responses (Weaver et al.,
2004).
A recent study showed that MBD2 expression is upregulated in the hippocampus in
response to maternal licking and grooming, and MBD2 is required for NGFI-A-dependent
activation of GR expression. Interestingly, the GR exon 17 promoter is generally silenced by DNA
methylation, but MBD2 and NGFI-A binding activates GR expression. This regulation appears to
be MBD2-specific, as MeCP2 was not found to interact with the GR exon 17 promoter (Weaver et
al., 2014). These findings evoke the similar mechanism of FoxP3 regulation in Treg cells, which is
generally silenced by DNA methylation but becomes demethylated and actively transcribed
dependent on MBD2 and TET-2 activity (Wang et al., 2013). However, it is unknown if activation
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of GR is concurrent with demethylation of the exon 17 promoter in a similar MBD2-dependent
-/-

manner. According to this model, a female Mbd2 mouse born to a heterozygous mother would
have an attenuated GR expression response to maternal behavior, leading to long-term
epigenetic changes at the GR locus. These epigenetic changes could in turn affect this Mbd2

-/-

female mouse’s own maternal nurturing behaviors, as has been observed in female rats whose
dams were exposed to environmental stress (Francis et al., 1999; Liu et al., 1997; Weaver et al.,
2004).
-/-

Furthermore, if GR signaling is altered in other cell types in Mbd2 mice, this
misregulation could have widespread phenotypic effects. Glucocorticoid signaling is regulated by
the HPA axis in response to stress and circadian signals through ubiquitously expressed GRs
(Kadmiel and Cidlowski, 2013). The specificity of glucocorticoid signaling throughout the body is
achieved by tightly regulated cell-type specific expression levels and post-translational
modification of different GR isoforms. The GR locus has multiple alternative first exons
corresponding to different cell-type specific isoforms, each with their own promoter that is
regulated through DNA methylation and transcription factor binding (Turner et al., 2010).
It is possible that MBD2 regulates methylation-dependent GR expression in other cell
types similarly to the hippocampus. GR signaling is systemic and has broad anti-inflammatory,
anti-proliferative, pro-apoptotic, and anti-angiogenic effects on nearly every organ or system in
the body. GR signaling has been shown to affect stress responses, inflammatory responses,
glucose and lipid regulation, and general systemic homeostasis (Kadmiel and Cidlowski, 2013).
-/-

Therefore, it is conceivable that reduced or altered GR signaling in Mbd2 mice could underlie
many of this mouse model’s subtle, non-specific phenotypes, including impaired nurturing,
hypoactivity, gene expression changes corresponding to stress or inflammation, and low body
weight.

Potential functional redundancy amongst MBD proteins
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Our results showed that loss of MBD2 surprisingly has only subtle effects on behavior
that may be related to non-neuronal, systemic phenotypes, which suggests that MBD2 may be
dispensable for brain function. However, our biochemical and spatiotemporal data show that
MBD2 is expressed at young and adult ages and interacts with the NuRD complex in the brain,
suggesting an active role. There are several possible models to address this discrepancy. First, it
is possible that MBD2 does impair neuronal functions, but these changes may be too subtle or in
too small a population of cells to produce robust changes in behavior. For example, loss of MBD2
-/-

affects maturation and proliferation of olfactory receptor neurons, but Mbd2 mice appear to have
unaffected olfactory ability (Macdonald et al., 2010). Another possibility is that MeCP2, which is
very highly expressed in the brain throughout development, is able to compensate for loss of
MBD2 in the brain. Alternatively, it has been proposed that the MBD family proteins may be
functionally redundant because transcriptional repression is generally maintained in single MBD
null models (Baubec and Schübeler, 2014).
Our findings, as they stand alone, support the model of compensation or functional
redundancy in regard to the role of MBD2 and other MBD proteins specifically in the brain. Our
data on the spatiotemporal expression of the MBD proteins shows that the brain is unique in
having relatively high levels of MeCP2, MBD1, MBD2 and MBD3 expression compared to other
tissues, particularly at younger ages. Therefore it is possible that loss of MBD2 alone in this
tissue may not cause severe disruptions. MeCP2, which is expressed very highly in the brain and
is essential for brain function (Guy et al., 2001; Skene et al., 2010), may be the predominant MBD
protein in this tissue and therefore could be able to compensate for loss of MBD2. Our copulldown results and previous studies show that MBD2 and MeCP2 have certain overlaps in their
co-repressor protein interactions. Specifically, MBD2 and MeCP2 both interact with HDAC1 and
SIN3A (Boeke et al., 2000; Nan et al., 1998) in addition to binding to DNA in a mCG-density
dependent manner (Baubec et al., 2013). However, MeCP2 would not necessarily be able to
compensate for all MBD2-specific functions with NuRD, as MeCP2 does not interact with all
members of this complex.
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However, genetic evidence argues that the MBD proteins are not able to fully
compensate for each other. Loss of each MBD protein produces distinct phenotypes in mice,
emphasizing the unique role for each MBD protein (Allan et al., 2008; Guy et al., 2001; Hendrich
et al., 2001). Loss of both MBD2 and MeCP2 decreases survivability compared to loss of MeCP2
alone (Martín Caballero et al., 2009). Similarly, loss of MBD2 in mice heterozygous for a Mbd3
null allele resulted in decreased viability compared to Mbd3 heterozygous mice with wildtype
MBD2 expression (Hendrich et al., 2001), indicating that MBD2 has other functions for which
MeCP2 and MBD3 are unable to compensate. There is currently no information on the phenotype
of mice null for both MBD1 and MBD2, which would help clarify any potential interactions
between these two MBD proteins. This has been difficult to achieve because the two genes are
less than 4 Mb apart on the same chromosome. A double null mouse for Mbd2 and Mbd3 would
also be informative, but may be impossible to achieve because constitutive loss of MBD3 is
embryonic lethal, while brain-specific ablation of MBD3 is perinatal lethal (Hendrich et al., 2001;
Knock et al., 2015).
The argument that the MBD proteins are functionally redundant at the molecular level is
most applicable to MBD2 and MBD3, which are very closely related both in their protein structure
and as components of the NuRD complex (Hendrich and Bird, 1998; Le Guezennec et al., 2006).
However, genetic and biochemical evidence suggests that MBD2 and MBD3 have quite distinct
properties, which argues against this model. Despite the high level of conservation between
MBD2 and MBD3, these proteins have entirely different DNA-binding capabilities, which is
reflected in their distinct genome-wide binding profiles in cell lines (Baubec et al., 2013; Günther
et al., 2013; Hashimoto et al., 2012a). MBD2 binds specifically to mCG and MBD3 binds with low
and equivalent affinity to unmodified or modified cytosines (Hashimoto et al., 2012a; Spruijt et al.,
2013). In studies of genome-wide localization, MBD2 is found at methylated CGIs at transcription
start sites, promoters, and exons, with low enrichment at low mCG-dense regions, such as
repetitive regions and intergenic sites (Baubec et al., 2013; Günther et al., 2013; Menafra et al.,
2014). MBD2 is also localized at unmethylated, active sites dependent on interactions with NuRD
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(Baubec et al., 2013). In contrast, MBD3 is found at more unmethylated sites with active
transcription compared to MBD2 (Günther et al., 2013). One example of MBD2-specific
transcriptional regulation occurs at the BRCA1-NBR2 locus in HeLa cells where MBD2, but not
MeCP2 or MBD1, is highly expressed and binds to a constitutively methylated regulatory region
(Auriol et al., 2005).
MBD2 and MBD3 also differ in their interactions with the NuRD complex, which could
result in different tissue-specific functions. MBD3/NuRD may be the primary form of NuRD in the
brain, as it is abundant in the cerebellum where it affects synaptic connectivity in addition to
regulating cortical neuronal differentiation (Knock et al., 2015; Yamada et al., 2014). MBD3 also
interacts with a brain-specific, alternate form of NuRD that incorporates CHD4 in place of CHD5.
This interaction is specific for MBD3, but it is not clear what the functional significance of the
CHD4/NuRD complex versus the CHD5/NuRD complex in the brain may be (Potts et al., 2011).
MBD2 has isoform-specific interactions with NuRD that could have important functional
consequences, particularly in ESCs (Baubec et al., 2013; Lu et al., 2014). MBD2 also has
isoform-specific interactions with different protein complexes that may affect NuRD interactions,
and different genome-wide localization (Baubec et al., 2013; Tan and Nakielny, 2006). However,
our results did not reveal a notable difference in binding to components of the NuRD complex
between MBD2 isoforms. This may be due to experimental limitations, which did not permit the
detection of subtle differences in NuRD interactions, or this mechanism may not occur in the brain
in vivo. It is not clear if the other binding partners for MBD2 represent specific, NuRDindependent functions, or if they serve to mediate the interactions between MBD2 and NuRD.
Either of these scenarios would necessarily indicate that any NuRD-independent MBD2 functions
are also dispensable for brain function. If MBD2 does have distinct functions independent of
NuRD, this again raises the question of why loss of MBD2 does not result in a more severe
phenotype.
Although our results fit the MBD protein functional redundancy model in the brain, they do
not support functional redundancy in peripheral tissues. We found that MBD2 is ubiquitously
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expressed across all tissues examined at adult ages, and most tissues at postnatal day 7.
MeCP2 is more widely expressed compared to MBD1 and MBD3, but is not co-expressed in all
tissues with MBD2 expression. MBD3 and MBD1 expression is undetectable in the peripheral
tissues examined, with the exception of the colon. Therefore, even if some level of functional
redundancy exists among these proteins, this cannot be occurring in tissues such as the spleen
or small intestine, where MBD2 is the only MBD protein expressed.
Our spatiotemporal expression profiling also raises important new questions about the in
vivo dynamics of the NuRD complex and MBD2 or MBD3. Biochemical evidence has shown that
MBD2 and MBD3 are mutually exclusive in the NuRD complex, and that the presence of the MBD
protein is necessary for NuRD complex formation and function (Le Guezennec et al., 2006;
Ramírez et al., 2012; Saito and Ishikawa, 2002). It is also apparent that the NuRD complex is
essential in many tissues and biological processes, including development and tumorigenesis
(Torchy et al., 2015). We found that MBD2 is associated with NuRD ubiquitously in three
representative tissues. Our expression data on MBD2 and MBD3 suggest that in adult peripheral
tissues, NuRD complex functions must depend primarily on MBD2, as MBD2 is highly expressed
but MBD3 is not detectable. Our expression data for MBD3 indicate that MBD3 may be acting at
early time points, particularly in the brain. This hypothesis is supported by mouse genetic studies
that show that a constitutive loss of MBD3 is embryonic lethal, while a brain-specific conditional
Mbd3 null allele is perinatal lethal with neuronal deficits (Hendrich et al., 2001; Knock et al.,
2015).
However, if MBD2 is indeed the primary acting MBD protein in adult peripheral tissues,
-/-

this model again poses the question of why Mbd2 mice show relatively subtle phenotypes. This
question can only be answered once the precise in vivo functions of MBD2 and the other MBD
proteins have been defined. It is clear from genetic, biochemical and expression evidence that
MBD2 has distinct properties from the other MBD proteins. Therefore, other explanations for the
-/-

absence of a relatively robust Mbd2 phenotype besides functional redundancy must be
considered.
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Models of MBD2 function and outstanding questions
An essential goal of the MBD protein field that remains unresolved is defining the precise
functions of these proteins. Surprisingly, attempts to identify specific methylated loci that show
direct transcriptional regulation by the MBD proteins have been mostly unsuccessful. Ablation of
the MBD encoding genes, including Mecp2, Mbd2, or Mbd3, produces many subtle transcriptional
changes without a clear tendency for aberrant upregulation that would be expected according to
models of MBD proteins being simple transcriptional repressors (Chahrour et al., 2008; Günther
et al., 2013). This is especially surprising in the case of MeCP2, because loss or mutation of this
gene has severe phenotypic consequences (Amir et al., 1999). For MeCP2, this inconsistency
may be due to the fact that this protein has many other proposed functions, such as chromatin
organization or stability, that may not necessarily correspond to large, consistent transcriptional
changes upon loss of MeCP2 (Maunakea et al., 2013; Pohodich and Zoghbi, 2015; Skene et al.,
2010). The picture is less clear for the other MBD proteins, including MBD2. The only described
functions for MBD2 involve interactions with NuRD or other transcriptional activators and
repressors, with no proposed major alternative functions (Angrisano et al., 2006; Ramírez et al.,
2012). However, there is increasing evidence that the functions of MBD2 with NuRD are more
dynamic and complex than originally realized when this protein complex was first identified
(Baubec et al., 2013; Feng and Zhang, 2001).
These questions are challenging to resolve because it is experimentally difficult to
distinguish between functions that are MBD2-specific rather than mediated by the NuRD complex
as a whole, while the role of MBD3 must also be considered. We anticipate that our
spatiotemporal expression results will aid in resolving this matter. Studying NuRD complex
formation and function in a tissue where MBD2 is exclusively expressed may provide insights into
MBD2-specific functions without the complication of MBD3/NuRD activity. Conversely, it would be
valuable to compare MBD2/NuRD function to MBD3/NuRD function in the brain of young animals,
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where these proteins are co-expressed, using conditional loss of MBD2 or MBD3 to examine
questions of how the NuRD complex forms and functions with either protein.
One possible model for these interactions in tissues with MBD2 and MBD3 co-expression
is that MBD3 is essential for NuRD formation and function, while MBD2 represents a more
transient member of NuRD that is required to fine-tune NuRD function, and thus may be
expendable. One study determined that most NuRD complexes contain MBD3 rather than MBD2
(Zhang et al., 1999), but this study was limited to cultured cells, and the dynamics of these
interactions in vivo have not been fully determined. This scenario is supported by the distinct
functions of MBD2 and MBD3 in ESCs. MBD3 is absolutely required for embryogenesis, while
complete ablation of MBD2 does not compromise survivability or fertility (Hendrich et al., 2001).
However, loss or overexpression of an individual isoform of MBD2 regulates the balance between
differentiation and proliferation of pluripotent cells (Lu et al., 2014).
The different isoforms of MBD2 introduce further complications into models of
MBD2/NuRD function. With a few important exceptions, most studies of MBD2 do not
acknowledge or distinguish between the multiple alternatively spliced or translated isoforms. A
recent study described opposing functions for MBD2a and MBD2c in the differentiation or
proliferation of ESCs (Lu et al., 2014). Biochemical evidence shows that MBD2a, MBD2b, and
MBD2c, which is only expressed in the testes and ESCs, have different interactions with NuRD
and other protein complexes and are recruited to DNA differently (Baubec et al., 2013; Lu et al.,
2014; Tan and Nakielny, 2006). These multiple forms of MBD2 may have distinct roles in other
cell types that have yet to be fully explored. Similarly to the situation in ESCs, it is possible that
complete deletion of MBD2 does not have large phenotypic effects, as we have observed.
Disrupting the balance of MBD2 isoform expression could be more detrimental to NuRD function
and therefore produce more robust phenotypes similarly to loss of MBD3.
Finally, another possible explanation for the absence of large transcriptional changes or
-/-

overt phenotypes in Mbd2 mice is combinatorial action or redundancy among transcriptional and
epigenetic regulatory mechanisms. There are multiple interdependent epigenetic mechanisms,
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such as histone modifications and nucleosome spacing, to safeguard chromatin and
transcriptional stability. This idea of epigenetic “resilience” means that multiple mechanisms of
transcriptional regulation can co-exist at a single locus, so that upon loss of one component, the
transcriptional program or epigenetic state is still maintained (Perissi et al., 2010). This concept is
especially relevant to induced pluripotent stem cells, which tend to maintain certain epigenetic
signatures even after reprogramming (Hochedlinger and Jaenisch, 2015). An example of MBD2
activity in this kind of regulation occurs at the Xist locus. Small amounts of aberrant Xist transcript
are detectable in the absence of MBD2, but not other MBD proteins. However, other silencing
mechanisms including HDAC activity were intact in Mbd2 null cells to partially maintain Xist
repression (Barr et al., 2007).
This model also allows for more dynamic responses at a single locus, which is supported
by evidence that DNA methylation and co-repressors such as NuRD may in fact modulate both
transcriptional activation and repression depending on the epigenomic context (Reynolds et al.,
2013; Suzuki and Bird, 2008). DNA methylation can be associated with active transcription,
possibly through the binding of activating transcription factors that bind specifically to methylated
DNA sequences, many with developmental or cell-type specificity (Spruijt et al., 2013).
Furthermore, the MBD proteins, including MBD2 and NuRD, are localized at many
transcriptionally active sites (Baubec et al., 2013; Günther et al., 2013). These findings argue for
a more dynamic picture of methylation-mediated transcriptional regulation than straightforward
repression by the MBD proteins and their corresponding co-repressor proteins (Reynolds et al.,
2013).
In conclusion, MBD2 is an integral part of the NuRD complex with many unanswered
questions regarding its molecular and biological functions. We have shown for the first time that
loss of MBD2 surprisingly produces few subtle phenotypes, in comparison to mice with loss of
other MBD proteins (Guy et al., 2001; Hendrich et al., 2001; Zhao et al., 2003). We also
introduced valuable genetic tools for the study of MBD2 in vivo. We generated two novel
transgenic mouse lines with endogenous biotin-tagged MBD2 or MBD1, which can be used for
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numerous experimental applications. We employed these mice to show that MBD2 is expressed
and associates with the NuRD complex ubiquitously, while the expression of other MBD proteins
is largely restricted to the brain. The spatiotemporal expression patterns of MBD2 support
potential functions in several peripheral tissues. These findings also address important questions
about functional redundancy amongst the MBD proteins as well as the dynamics of the NuRD
complex with MBD2 and MBD3 in vivo. Future investigations into MBD2 functions may have
important implications for the study of pluripotency, immunity and cancer.

113

BIBLIOGRAPHY
Agarwal, N., Hardt, T., Brero, A., Nowak, D., Rothbauer, U., Becker, A., et al. (2007). MeCP2
interacts with HP1 and modulates its heterochromatin association during myogenic
differentiation. Nucleic Acids Res. 35, 5402–5408. doi:10.1093/nar/gkm599.
Aguilera, C., Nakagawa, K., Sancho, R., Chakraborty, A., Hendrich, B., and Behrens, A. (2011).
c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor
complex. Nature 469, 231–235. doi:10.1038/nature09607.
Alabert, C., Bukowski-Wills, J.-C., Lee, S.-B., Kustatscher, G., Nakamura, K., de Lima Alves, F.,
et al. (2014). Nascent chromatin capture proteomics determines chromatin dynamics
during DNA replication and identifies unknown fork components. Nat. Cell Biol. 16, 281–
293. doi:10.1038/ncb2918.
Allan, A. M., Liang, X., Luo, Y., Pak, C., Li, X., Szulwach, K. E., et al. (2008). The loss of methylCpG binding protein 1 leads to autism-like behavioral deficits. Hum. Mol. Genet. 17,
2047–2057. doi:10.1093/hmg/ddn102.
Álvarez-Errico, D., Vento-Tormo, R., Sieweke, M., and Ballestar, E. (2014). Epigenetic control of
myeloid cell differentiation, identity and function. Nat. Rev. Immunol. 15, 7–17.
doi:10.1038/nri3777.
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., and Zoghbi, H. Y. (1999).
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding
protein 2. Nat. Genet. 23, 185–188. doi:10.1038/13810.
Angrisano, T., Lembo, F., Pero, R., Natale, F., Fusco, A., Avvedimento, V. E., et al. (2006).
TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves
transcriptional repression of methylated promoters. Nucleic Acids Res. 34, 364–372.
doi:10.1093/nar/gkj400.
Aoki, K., Sato, N., Yamaguchi, A., Kaminuma, O., Hosozawa, T., and Miyatake, S. (2009).
Regulation of DNA demethylation during maturation of CD4+ naive T cells by the
conserved noncoding sequence 1. J. Immunol. Baltim. Md 1950 182, 7698–7707.
doi:10.4049/jimmunol.0801643.
Auriol, E., Billard, L.-M., Magdinier, F., and Dante, R. (2005). Specific binding of the methyl
binding domain protein 2 at the BRCA1-NBR2 locus. Nucleic Acids Res. 33, 4243–4254.
doi:10.1093/nar/gki729.
Bader, S., Walker, M., McQueen, H. A., Sellar, R., Oei, E., Wopereis, S., et al. (2003). MBD1,
MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon
and lung cancers. Oncogene 22, 3506–3510. doi:10.1038/sj.onc.1206574.
Balada, E., Ordi-Ros, J., Serrano-Acedo, S., Martinez-Lostao, L., and Vilardell-Tarrés, M. (2007).
Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic
lupus erythematosus patients. J. Leukoc. Biol. 81, 1609–1616. doi:10.1189/jlb.0107064.
Ballas, N., Grunseich, C., Lu, D. D., Speh, J. C., and Mandel, G. (2005). REST and its
corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis.
Cell 121, 645–657. doi:10.1016/j.cell.2005.03.013.
114

Ballestar, E., Pile, L. A., Wassarman, D. A., Wolffe, A. P., and Wade, P. A. (2001). A Drosophila
MBD family member is a transcriptional corepressor associated with specific genes. Eur.
J. Biochem. FEBS 268, 5397–5406.
Barr, H., Hermann, A., Berger, J., Tsai, H.-H., Adie, K., Prokhortchouk, A., et al. (2007). Mbd2
contributes to DNA methylation-directed repression of the Xist gene. Mol. Cell. Biol. 27,
3750–3757. doi:10.1128/MCB.02204-06.
Basta, J., and Rauchman, M. (2015). The nucleosome remodeling and deacetylase complex in
development and disease. Transl. Res. 165, 36–47. doi:10.1016/j.trsl.2014.05.003.
Baubec, T., Colombo, D. F., Wirbelauer, C., Schmidt, J., Burger, L., Krebs, A. R., et al. (2015).
Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic
methylation. Nature 520, 243–247. doi:10.1038/nature14176.
Baubec, T., Ivánek, R., Lienert, F., and Schübeler, D. (2013). Methylation-dependent and independent genomic targeting principles of the MBD protein family. Cell 153, 480–492.
doi:10.1016/j.cell.2013.03.011.
Baubec, T., and Schübeler, D. (2014). Genomic patterns and context specific interpretation of
DNA methylation. Curr. Opin. Genet. Dev. 25, 85–92. doi:10.1016/j.gde.2013.11.015.
Baylin, S. B., and Jones, P. A. (2011). A decade of exploring the cancer epigenome - biological
and translational implications. Nat. Rev. Cancer 11, 726–734. doi:10.1038/nrc3130.
Baymaz, H. I., Fournier, A., Laget, S., Ji, Z., Jansen, P. W. T. C., Smits, A. H., et al. (2014).
MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpGbinding domain. Proteomics. doi:10.1002/pmic.201400013.
Benayed, R., Gharani, N., Rossman, I., Mancuso, V., Lazar, G., Kamdar, S., et al. (2005).
Support for the Homeobox Transcription Factor Gene< i> ENGRAILED 2</i> as an
Autism Spectrum Disorder Susceptibility Locus. Am. J. Hum. Genet. 77, 851–868.
Ben-Shachar, S., Chahrour, M., Thaller, C., Shaw, C. A., and Zoghbi, H. Y. (2009). Mouse
models of MeCP2 disorders share gene expression changes in the cerebellum and
hypothalamus. Hum. Mol. Genet. 18, 2431–2442. doi:10.1093/hmg/ddp181.
Berger, J., Sansom, O., Clarke, A., and Bird, A. (2007). MBD2 is required for correct spatial gene
expression in the gut. Mol. Cell. Biol. 27, 4049–4057. doi:10.1128/MCB.02023-06.
Billard, L.-M., Magdinier, F., Lenoir, G. M., Frappart, L., and Dante, R. (2002). MeCP2 and MBD2
expression during normal and pathological growth of the human mammary gland.
Oncogene 21, 2704–2712. doi:10.1038/sj.onc.1205357.
Bissonnette, J. M., Schaevitz, L. R., Knopp, S. J., and Zhou, Z. (2014). Respiratory phenotypes
are distinctly affected in mice with common Rett syndrome mutations MeCP2 T158A and
R168X. Neuroscience 267, 166–176. doi:10.1016/j.neuroscience.2014.02.043.
Blattler, A., and Farnham, P. J. (2013). Cross-talk between Site-specific Transcription Factors
and DNA Methylation States. J. Biol. Chem. 288, 34287–34294.
doi:10.1074/jbc.R113.512517.

115

Boeke, J., Ammerpohl, O., Kegel, S., Moehren, U., and Renkawitz, R. (2000). The minimal
repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds
directly to Sin3A. J. Biol. Chem. 275, 34963–34967. doi:10.1074/jbc.M005929200.
de Boer, E., Rodriguez, P., Bonte, E., Krijgsveld, J., Katsantoni, E., Heck, A., et al. (2003).
Efficient biotinylation and single-step purification of tagged transcription factors in
mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100, 7480–7485.
doi:10.1073/pnas.1332608100.
Bourc’his, D., Xu, G. L., Lin, C. S., Bollman, B., and Bestor, T. H. (2001). Dnmt3L and the
establishment of maternal genomic imprints. Science 294, 2536–2539.
doi:10.1126/science.1065848.
Bromberg-Martin, E. S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in motivational
control: rewarding, aversive, and alerting. Neuron 68, 815–834.
doi:10.1016/j.neuron.2010.11.022.
Buxbaum, J. N., and Reixach, N. (2009). Transthyretin: the servant of many masters. Cell. Mol.
Life Sci. 66, 3095–3101. doi:10.1007/s00018-009-0109-0.
Cai, Y., Geutjes, E.-J., de Lint, K., Roepman, P., Bruurs, L., Yu, L.-R., et al. (2014). The NuRD
complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor
genes. Oncogene 33, 2157–2168. doi:10.1038/onc.2013.178.
Camarena, V., Cao, L., Abad, C., Abrams, A., Toledo, Y., Araki, K., et al. (2014). Disruption of
Mbd5 in mice causes neuronal functional deficits and neurobehavioral abnormalities
consistent with 2q23.1 microdeletion syndrome. EMBO Mol. Med. 6, 1003–1015.
doi:10.15252/emmm.201404044.
Campbell, P. M., Bovenzi, V., and Szyf, M. (2004). Methylated DNA-binding protein 2 antisense
inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo.
Carcinogenesis 25, 499–507. doi:10.1093/carcin/bgh045.
Cedar, H., and Bergman, Y. (2009). Linking DNA methylation and histone modification: patterns
and paradigms. Nat. Rev. Genet. 10, 295–304. doi:10.1038/nrg2540.
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., et al. (2008). MeCP2, a
key contributor to neurological disease, activates and represses transcription. Science
320, 1224–1229. doi:10.1126/science.1153252.
Chatagnon, A., Bougel, S., Perriaud, L., Lachuer, J., Benhattar, J., and Dante, R. (2009). Specific
association between the methyl-CpG-binding domain protein 2 and the hypermethylated
region of the human telomerase reverse transcriptase promoter in cancer cells.
Carcinogenesis 30, 28–34. doi:10.1093/carcin/bgn240.
Chatagnon, A., Perriaud, L., Nazaret, N., Croze, S., Benhattar, J., Lachuer, J., et al. (2011).
Preferential binding of the methyl-CpG binding domain protein 2 at methylated
transcriptional start site regions. Epigenetics Off. J. DNA Methylation Soc. 6, 1295–1307.
doi:10.4161/epi.6.11.17875.
Cheh, M. A., Millonig, J. H., Roselli, L. M., Ming, X., Jacobsen, E., Kamdar, S., et al. (2006). En2
null mice display neurobehavioral and neurochemical alterations relevant to autism
spectrum disorder. Brain Res. 1116, 166–176. doi:10.1016/j.brainres.2006.07.086.
116

Chen, T., and Dent, S. Y. R. (2014). Chromatin modifiers and remodellers: regulators of cellular
differentiation. Nat. Rev. Genet. 15, 93–106. doi:10.1038/nrg3607.
Chen, T., Ueda, Y., Dodge, J. E., Wang, Z., and Li, E. (2003). Establishment and maintenance of
genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b.
Mol. Cell. Biol. 23, 5594–5605.
Conti, V., Gandaglia, A., Galli, F., Tirone, M., Bellini, E., Campana, L., et al. (2015). MeCP2
Affects Skeletal Muscle Growth and Morphology through Non Cell-Autonomous
Mechanisms. PLOS ONE 10, e0130183. doi:10.1371/journal.pone.0130183.
Cook, P. C., Owen, H., Deaton, A. M., Borger, J. G., Brown, S. L., Clouaire, T., et al. (2015). A
dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by
dendritic cells. Nat. Commun. 6, 6920. doi:10.1038/ncomms7920.
Crawley, J. N. (2007). What’s wrong with my mouse?: behavioral phenotyping of transgenic and
null mice. 2nd ed. Hoboken, N.J: Wiley-Interscience.
Cronk, J. C., Derecki, N. C., Ji, E., Xu, Y., Lampano, A. E., Smirnov, I., et al. (2015). Methyl-CpG
Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to
Inflammatory Stimuli. Immunity 42, 679–691. doi:10.1016/j.immuni.2015.03.013.
Csankovszki, G., Nagy, A., and Jaenisch, R. (2001). Synergism of Xist Rna, DNA Methylation,
and Histone Hypoacetylation in Maintaining X Chromosome Inactivation. J. Cell Biol. 153,
773–784. doi:10.1083/jcb.153.4.773.
Cukier, H. N., Lee, J. M., Ma, D., Young, J. I., Mayo, V., Butler, B. L., et al. (2012). The expanding
role of MBD genes in autism: identification of a MECP2 duplication and novel alterations
in MBD5, MBD6, and SETDB1. Autism Res. Off. J. Int. Soc. Autism Res. 5, 385–397.
doi:10.1002/aur.1251.
Cukier, H. N., Rabionet, R., Konidari, I., Rayner-Evans, M. Y., Baltos, M. L., Wright, H. H., et al.
(2010). Novel variants identified in methyl-CpG-binding domain genes in autistic
individuals. Neurogenetics 11, 291–303. doi:10.1007/s10048-009-0228-7.
Deacon, R. M. (2006). Assessing nest building in mice. Nat. Protoc. 1, 1117–1119.
doi:10.1038/nprot.2006.170.
Deaton, A. M., and Bird, A. (2011). CpG islands and the regulation of transcription. Genes Dev.
25, 1010–1022. doi:10.1101/gad.2037511.
Dege, C., and Hagman, J. (2014a). Mi-2/NuRD chromatin remodeling complexes regulate B and
T-lymphocyte development and function. Immunol. Rev. 261, 126–140.
doi:10.1111/imr.12209.
Dege, C., and Hagman, J. (2014b). Mi-2/NuRD chromatin remodeling complexes regulate B and
T-lymphocyte development and function. Immunol. Rev. 261, 126–140.
doi:10.1111/imr.12209.
Derks, S., Bosch, L. J. W., Niessen, H. E. C., Moerkerk, P. T. M., van den Bosch, S. M.,
Carvalho, B., et al. (2009). Promoter CpG island hypermethylation- and H3K9me3 and
H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC)
117

gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal
region 18q21. Carcinogenesis 30, 1041–1048. doi:10.1093/carcin/bgp073.
Desai, M. A., Webb, H. D., Sinanan, L. M., Scarsdale, J. N., Walavalkar, N. M., Ginder, G. D., et
al. (2015). An intrinsically disordered region of methyl-CpG binding domain protein 2
(MBD2) recruits the histone deacetylase core of the NuRD complex. Nucleic Acids Res.
43, 3100–3113. doi:10.1093/nar/gkv168.
Devailly, G., Grandin, M., Perriaud, L., Mathot, P., Delcros, J.-G., Bidet, Y., et al. (2015).
Dynamics of MBD2 deposition across methylated DNA regions during malignant
transformation of human mammary epithelial cells. Nucleic Acids Res.
doi:10.1093/nar/gkv508.
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., et al. (2013). STAR:
ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21.
doi:10.1093/bioinformatics/bts635.
Domcke, S., Bardet, A. F., Adrian Ginno, P., Hartl, D., Burger, L., and Schübeler, D. (2015).
Competition between DNA methylation and transcription factors determines binding of
NRF1. Nature 528, 575–579. doi:10.1038/nature16462.
Dos Santos, R. L., Tosti, L., Radzisheuskaya, A., Caballero, I. M., Kaji, K., Hendrich, B., et al.
(2014). MBD3/NuRD Facilitates Induction of Pluripotency in a Context-Dependent
Manner. Cell Stem Cell. doi:10.1016/j.stem.2014.04.019.
Du, Q., Luu, P.-L., Stirzaker, C., and Clark, S. J. (2015). Methyl-CpG-binding domain proteins:
readers of the epigenome. Epigenomics, 1–23. doi:10.2217/epi.15.39.
Eberl, H. C., Spruijt, C. G., Kelstrup, C. D., Vermeulen, M., and Mann, M. (2013). A Map of
General and Specialized Chromatin Readers in Mouse Tissues Generated by Label-free
Interaction Proteomics. Mol. Cell 49, 368–378. doi:10.1016/j.molcel.2012.10.026.
Ebert, D. H., Gabel, H. W., Robinson, N. D., Kastan, N. R., Hu, L. S., Cohen, S., et al. (2013).
Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with
NCoR. Nature 499, 341–345. doi:10.1038/nature12348.
Endele, S., Rosenberger, G., Geider, K., Popp, B., Tamer, C., Stefanova, I., et al. (2010).
Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors
cause variable neurodevelopmental phenotypes. Nat. Genet. 42, 1021–1026.
doi:10.1038/ng.677.
Fairless, A. H., Shah, R. Y., Guthrie, A. J., Li, H., and Brodkin, E. S. (2011). Deconstructing
Sociability, An Autism-Relevant Phenotype, in Mouse Models. Anat. Rec. Adv. Integr.
Anat. Evol. Biol. 294, 1713–1725. doi:10.1002/ar.21318.
Fearon, E., Cho, K., Nigro, J., Kern, S., Simons, J., Ruppert, J., et al. (1990). Identification of a
chromosome 18q gene that is altered in colorectal cancers. Science 247, 49–56.
doi:10.1126/science.2294591.
Feng, J., Zhou, Y., Campbell, S. L., Le, T., Li, E., Sweatt, J. D., et al. (2010). Dnmt1 and Dnmt3a
maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat.
Neurosci. 13, 423–430. doi:10.1038/nn.2514.
118

Feng, Q., and Zhang, Y. (2001). The MeCP1 complex represses transcription through preferential
binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15, 827–
832. doi:10.1101/gad.876201.
Filion, G. J. P., Zhenilo, S., Salozhin, S., Yamada, D., Prokhortchouk, E., and Defossez, P.-A.
(2006). A family of human zinc finger proteins that bind methylated DNA and repress
transcription. Mol. Cell. Biol. 26, 169–181. doi:10.1128/MCB.26.1.169-181.2006.
Francis, D., Diorio, J., Liu, D., and Meaney, M. J. (1999). Nongenomic transmission across
generations of maternal behavior and stress responses in the rat. Science 286, 1155–
1158.
Fujita, H., Fujii, R., Aratani, S., Amano, T., Fukamizu, A., and Nakajima, T. (2003a). Antithetic
Effects of MBD2a on Gene Regulation. Mol. Cell. Biol. 23, 2645–2657.
doi:10.1128/MCB.23.8.2645-2657.2003.
Fujita, N., Watanabe, S., Ichimura, T., Ohkuma, Y., Chiba, T., Saya, H., et al. (2003b). MCAF
mediates MBD1-dependent transcriptional repression. Mol. Cell. Biol. 23, 2834–2843.
Fujita, N., Watanabe, S., Ichimura, T., Tsuruzoe, S., Shinkai, Y., Tachibana, M., et al. (2003c).
Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic
complex for DNA methylation-based transcriptional repression. J. Biol. Chem. 278,
24132–24138. doi:10.1074/jbc.M302283200.
Gabel, H. W., Kinde, B., Stroud, H., Gilbert, C. S., Harmin, D. A., Kastan, N. R., et al. (2015).
Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature
522, 89–93. doi:10.1038/nature14319.
Gammie, S. C. (2005). Current models and future directions for understanding the neural
circuitries of maternal behaviors in rodents. Behav. Cogn. Neurosci. Rev. 4, 119–135.
doi:10.1177/1534582305281086.
Gammie, S. C., Edelmann, M. N., Mandel-Brehm, C., D’Anna, K. L., Auger, A. P., and Stevenson,
S. A. (2008). Altered dopamine signaling in naturally occurring maternal neglect. PloS
One 3, e1974. doi:10.1371/journal.pone.0001974.
Gao, H., Lukin, K., Ramírez, J., Fields, S., Lopez, D., and Hagman, J. (2009). Opposing effects of
SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming
by EBF and Pax5. Proc. Natl. Acad. Sci. U. S. A. 106, 11258–11263.
doi:10.1073/pnas.0809485106.
Gaskill, B. N., Karas, A. Z., Garner, J. P., and Pritchett-Corning, K. R. (2013). Nest Building as an
Indicator of Health and Welfare in Laboratory Mice. J. Vis. Exp. doi:10.3791/51012.
Gnanapragasam, M. N., Scarsdale, J. N., Amaya, M. L., Webb, H. D., Desai, M. A., Walavalkar,
N. M., et al. (2011). p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are
critical for globin gene silencing by the MBD2-NuRD complex. Proc. Natl. Acad. Sci. U. S.
A. 108, 7487–7492. doi:10.1073/pnas.1015341108.
Goffin, D., Allen, M., Zhang, L., Amorim, M., Wang, I.-T. J., Reyes, A.-R. S., et al. (2012). Rett
syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP
responses. Nat. Neurosci. 15, 274–283. doi:10.1038/nn.2997.
119

Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., et al. (2009).
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–
60. doi:10.1038/nature07925.
Günther, K., Rust, M., Leers, J., Boettger, T., Scharfe, M., Jarek, M., et al. (2013). Differential
roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to
exon sequences. Nucleic Acids Res. 41, 3010–3021. doi:10.1093/nar/gkt035.
Guo, J. U., Ma, D. K., Mo, H., Ball, M. P., Jang, M.-H., Bonaguidi, M. A., et al. (2011). Neuronal
activity modifies the DNA methylation landscape in the adult brain. Nat. Neurosci. 14,
1345–1351. doi:10.1038/nn.2900.
Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., et al. (2014). Distribution, recognition and
regulation of non-CpG methylation in the adult mammalian brain. Nat. Neurosci. 17, 215–
222. doi:10.1038/nn.3607.
Gu, P., Xu, X., Le Menuet, D., Chung, A. C.-K., and Cooney, A. J. (2011). Differential recruitment
of methyl CpG-binding domain factors and DNA methyltransferases by the orphan
receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem
Cells Dayt. Ohio 29, 1041–1051. doi:10.1002/stem.652.
Guy, J., Hendrich, B., Holmes, M., Martin, J. E., and Bird, A. (2001). A mouse Mecp2-null
mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322–
326. doi:10.1038/85899.
Hashimoto, H., Liu, Y., Upadhyay, A. K., Chang, Y., Howerton, S. B., Vertino, P. M., et al.
(2012a). Recognition and potential mechanisms for replication and erasure of cytosine
hydroxymethylation. Nucleic Acids Res. 40, 4841–4849. doi:10.1093/nar/gks155.
Hashimoto, H., Zhang, X., and Cheng, X. (2012b). Excision of thymine and 5-hydroxymethyluracil
by the MBD4 DNA glycosylase domain: structural basis and implications for active DNA
demethylation. Nucleic Acids Res. 40, 8276–8284. doi:10.1093/nar/gks628.
Hendrich, B., Abbott, C., McQueen, H., Chambers, D., Cross, S., and Bird, A. (1999). Genomic
structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and
Mbd4 genes. Mamm. Genome Off. J. Int. Mamm. Genome Soc. 10, 906–912.
Hendrich, B., and Bird, A. (1998). Identification and characterization of a family of mammalian
methyl-CpG binding proteins. Mol. Cell. Biol. 18, 6538–6547.
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V. A., and Bird, A. (2001). Closely related proteins
MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes
Dev. 15, 710–723. doi:10.1101/gad.194101.
Hendrich, B., and Tweedie, S. (2003). The methyl-CpG binding domain and the evolving role of
DNA methylation in animals. Trends Genet. 19, 269–277. doi:10.1016/S01689525(03)00080-5.
Henschen, C. W., Palmiter, R. D., and Darvas, M. (2013). Restoration of dopamine signaling to
the dorsal striatum is sufficient for aspects of active maternal behavior in female mice.
Endocrinology 154, 4316–4327. doi:10.1210/en.2013-1257.

120

He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., et al. (2011). Tet-mediated formation of 5carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307.
doi:10.1126/science.1210944.
Heyward, F. D., and Sweatt, J. D. (2015). DNA Methylation in Memory Formation: Emerging
Insights. The Neuroscientist 21, 475–489. doi:10.1177/1073858415579635.
Hochedlinger, K., and Jaenisch, R. (2015). Induced Pluripotency and Epigenetic Reprogramming.
Cold Spring Harb. Perspect. Biol. 7, a019448. doi:10.1101/cshperspect.a019448.
Holik, A. Z., Young, M., Krzystyniak, J., Williams, G. T., Metzger, D., Shorning, B. Y., et al.
(2014). Brg1 Loss Attenuates Aberrant Wnt-Signalling and Prevents Wnt-Dependent
Tumourigenesis in the Murine Small Intestine. PLoS Genet. 10, e1004453.
doi:10.1371/journal.pgen.1004453.
Hosokawa, H., Tanaka, T., Suzuki, Y., Iwamura, C., Ohkubo, S., Endoh, K., et al. (2013).
Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell
identity. Proc. Natl. Acad. Sci. U. S. A. 110, 4691–4696. doi:10.1073/pnas.1220865110.
Howerton, A. R., Roland, A. V., and Bale, T. L. (2014). Dorsal raphe neuroinflammation promotes
dramatic behavioral stress dysregulation. J. Neurosci. Off. J. Soc. Neurosci. 34, 7113–
7123. doi:10.1523/JNEUROSCI.0118-14.2014.
Humphries, A., and Wright, N. A. (2008). Colonic crypt organization and tumorigenesis. Nat. Rev.
Cancer 8, 415–424. doi:10.1038/nrc2392.
Hutchins, A. S., Artis, D., Hendrich, B. D., Bird, A. P., Scott, P., and Reiner, S. L. (2005). Cutting
edge: a critical role for gene silencing in preventing excessive type 1 immunity. J.
Immunol. Baltim. Md 1950 175, 5606–5610.
Hutchins, A. S., Mullen, A. C., Lee, H. W., Sykes, K. J., High, F. A., Hendrich, B. D., et al. (2002).
Gene silencing quantitatively controls the function of a developmental trans-activator.
Mol. Cell 10, 81–91.
Ichimura, T., Watanabe, S., Sakamoto, Y., Aoto, T., Fujita, N., and Nakao, M. (2005).
Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family
proteins. J. Biol. Chem. 280, 13928–13935. doi:10.1074/jbc.M413654200.
Illingworth, R., Kerr, A., Desousa, D., Jørgensen, H., Ellis, P., Stalker, J., et al. (2008). A novel
CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS
Biol. 6, e22. doi:10.1371/journal.pbio.0060022.
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., et al. (2011). Tet proteins can
convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333,
1300–1303. doi:10.1126/science.1210597.
Jager, J., O’Brien, W. T., Manlove, J., Krizman, E. N., Fang, B., Gerhart-Hines, Z., et al. (2014).
Behavioral Changes and Dopaminergic Dysregulation in Mice Lacking the Nuclear
Receptor Rev-erbα. Mol. Endocrinol. 28, 490–498. doi:10.1210/me.2013-1351.
Jeffery, L., and Nakielny, S. (2004). Components of the DNA methylation system of chromatin
control are RNA-binding proteins. J. Biol. Chem. 279, 49479–49487.
doi:10.1074/jbc.M409070200.
121

Jirkof, P. (2014). Burrowing and nest building behavior as indicators of well-being in mice. J.
Neurosci. Methods 234, 139–146. doi:10.1016/j.jneumeth.2014.02.001.
Jørgensen, H. F., Ben-Porath, I., and Bird, A. P. (2004). Mbd1 is recruited to both methylated and
nonmethylated CpGs via distinct DNA binding domains. Mol. Cell. Biol. 24, 3387–3395.
Kadmiel, M., and Cidlowski, J. A. (2013). Glucocorticoid receptor signaling in health and disease.
Trends Pharmacol. Sci. 34, 518–530. doi:10.1016/j.tips.2013.07.003.
Kaji, K., Caballero, I. M., MacLeod, R., Nichols, J., Wilson, V. A., and Hendrich, B. (2006). The
NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat. Cell
Biol. 8, 285–292. doi:10.1038/ncb1372.
Kaji, K., Nichols, J., and Hendrich, B. (2007). Mbd3, a component of the NuRD co-repressor
complex, is required for development of pluripotent cells. Dev. Camb. Engl. 134, 1123–
1132. doi:10.1242/dev.02802.
Kanai, Y., Ushijima, S., Nakanishi, Y., and Hirohashi, S. (1999). Reduced mRNA expression of
the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem.
Biophys. Res. Commun. 264, 962–966. doi:10.1006/bbrc.1999.1613.
Kernohan, K. D., Vernimmen, D., Gloor, G. B., and Bérubé, N. G. (2014). Analysis of neonatal
brain lacking ATRX or MeCP2 reveals changes in nucleosome density, CTCF binding
and chromatin looping. Nucleic Acids Res. 42, 8356–8368. doi:10.1093/nar/gku564.
Kersh, E. N. (2006). Impaired Memory CD8 T Cell Development in the Absence of Methyl-CpGBinding Domain Protein 2. J. Immunol. 177, 3821–3826.
doi:10.4049/jimmunol.177.6.3821.
Kim, T.-K., and Shiekhattar, R. (2015). Architectural and Functional Commonalities between
Enhancers and Promoters. Cell 162, 948–959. doi:10.1016/j.cell.2015.08.008.
Knock, E., Pereira, J., Lombard, P. D., Dimond, A., Leaford, D., Livesey, F. J., et al. (2015). The
methyl binding domain 3/nucleosome remodelling and deacetylase complex regulates
neural cell fate determination and terminal differentiation in the cerebral cortex. Neural
Develop. 10, 13. doi:10.1186/s13064-015-0040-z.
Komori, H. K., Hart, T., LaMere, S. A., Chew, P. V., and Salomon, D. R. (2015). Defining CD4 T
cell memory by the epigenetic landscape of CpG DNA methylation. J. Immunol. Baltim.
Md 1950 194, 1565–1579. doi:10.4049/jimmunol.1401162.
Laget, S., Joulie, M., Le Masson, F., Sasai, N., Christians, E., Pradhan, S., et al. (2010). The
human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind
methylated DNA. PloS One 5, e11982. doi:10.1371/journal.pone.0011982.
Lai, A. Y., and Wade, P. A. (2011). Cancer biology and NuRD: a multifaceted chromatin
remodelling complex. Nat. Rev. Cancer 11, 588–596. doi:10.1038/nrc3091.
Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E. P., et al. (2009). Epigenetic
regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol.
Baltim. Md 1950 182, 259–273.

122

Lee, M. R., Prasain, N., Chae, H.-D., Kim, Y.-J., Mantel, C., Yoder, M. C., et al. (2013).
Epigenetic regulation of NANOG by miR-302 cluster-MBD2 completes induced
pluripotent stem cell reprogramming. Stem Cells Dayt. Ohio 31, 666–681.
doi:10.1002/stem.1302.
Lee, S., Park, J.-Y., Lee, W.-H., Kim, H., Park, H.-C., Mori, K., et al. (2009). Lipocalin-2 Is an
Autocrine Mediator of Reactive Astrocytosis. J. Neurosci. 29, 234–249.
doi:10.1523/JNEUROSCI.5273-08.2009.
Le Guezennec, X., Vermeulen, M., Brinkman, A. B., Hoeijmakers, W. A. M., Cohen, A., Lasonder,
E., et al. (2006). MBD2/NuRD and MBD3/NuRD, two distinct complexes with different
biochemical and functional properties. Mol. Cell. Biol. 26, 843–851.
doi:10.1128/MCB.26.3.843-851.2006.
Lei, W., Luo, Y., Lei, W., Luo, Y., Yan, K., Zhao, S., et al. (2009). Abnormal DNA methylation in
CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and
dermatomyositis. Scand. J. Rheumatol. 38, 369–374. doi:10.1080/03009740902758875.
Lewis, J. D., Meehan, R. R., Henzel, W. J., Maurer-Fogy, I., Jeppesen, P., Klein, F., et al. (1992).
Purification, sequence, and cellular localization of a novel chromosomal protein that binds
to Methylated DNA. Cell 69, 905–914. doi:10.1016/0092-8674(92)90610-O.
Li, E., Beard, C., and Jaenisch, R. (1993). Role for DNA methylation in genomic imprinting.
Nature 366, 362–365. doi:10.1038/366362a0.
Li, H., Yamagata, T., Mori, M., Yasuhara, A., and Momoi, M. Y. (2005). Mutation analysis of
methyl-CpG binding protein family genes in autistic patients. Brain Dev. 27, 321–325.
doi:10.1016/j.braindev.2004.08.003.
Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., et al. (2013).
Global epigenomic reconfiguration during mammalian brain development. Science 341,
1237905. doi:10.1126/science.1237905.
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., et al. (2009).
Human DNA methylomes at base resolution show widespread epigenomic differences.
Nature 462, 315–322. doi:10.1038/nature08514.
Liu, C. C., Ou, T. T., Wu, C. C., Li, R. N., Lin, Y. C., Lin, C. H., et al. (2011). Global DNA
methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus
20, 131–136. doi:10.1177/0961203310381517.
Liu, C., Teng, Z.-Q., Santistevan, N. J., Szulwach, K. E., Guo, W., Jin, P., et al. (2010). Epigenetic
regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation.
Cell Stem Cell 6, 433–444. doi:10.1016/j.stem.2010.02.017.
Liu, D., Diorio, J., Tannenbaum, B., Caldji, C., Francis, D., Freedman, A., et al. (1997). Maternal
care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal
responses to stress. Science 277, 1659–1662.
Lopez-Serra, L., Ballestar, E., Ropero, S., Setien, F., Billard, L.-M., Fraga, M. F., et al. (2008).
Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of
methyl-CpG-binding domain proteins. Oncogene 27, 3556–3566.
doi:10.1038/sj.onc.1211022.
123

Luo, M., Ling, T., Xie, W., Sun, H., Zhou, Y., Zhu, Q., et al. (2013). NuRD blocks reprogramming
of mouse somatic cells into pluripotent stem cells. Stem Cells Dayt. Ohio 31, 1278–1286.
doi:10.1002/stem.1374.
Lu, X., Kovalev, G. I., Chang, H., Kallin, E., Knudsen, G., Xia, L., et al. (2008). Inactivation of
NuRD component Mta2 causes abnormal T cell activation and lupus-like autoimmune
disease in mice. J. Biol. Chem. 283, 13825–13833. doi:10.1074/jbc.M801275200.
Lu, Y., Loh, Y.-H., Li, H., Cesana, M., Ficarro, S. B., Parikh, J. R., et al. (2014). Alternative
Splicing of MBD2 Supports Self-Renewal in Human Pluripotent Stem Cells. Cell Stem
Cell. doi:10.1016/j.stem.2014.04.002.
Lyst, M. J., Ekiert, R., Ebert, D. H., Merusi, C., Nowak, J., Selfridge, J., et al. (2013). Rett
syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT corepressor. Nat. Neurosci. 16, 898–902. doi:10.1038/nn.3434.
Macdonald, J. L., Verster, A., Berndt, A., and Roskams, A. J. (2010). MBD2 and MeCP2 regulate
distinct transitions in the stage-specific differentiation of olfactory receptor neurons. Mol.
Cell. Neurosci. 44, 55–67. doi:10.1016/j.mcn.2010.02.003.
Macdonald, T. T., and Monteleone, G. (2005). Immunity, inflammation, and allergy in the gut.
Science 307, 1920–1925. doi:10.1126/science.1106442.
Madison, B. B., Dunbar, L., Qiao, X. T., Braunstein, K., Braunstein, E., and Gumucio, D. L.
(2002). Cis elements of the villin gene control expression in restricted domains of the
vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem.
277, 33275–33283. doi:10.1074/jbc.M204935200.
Magdinier, F., and Wolffe, A. P. (2001). Selective association of the methyl-CpG binding protein
MBD2 with the silent p14/p16 locus in human neoplasia. Proc. Natl. Acad. Sci. U. S. A.
98, 4990–4995. doi:10.1073/pnas.101617298.
Marhold, J., Kramer, K., Kremmer, E., and Lyko, F. (2004). The Drosophila MBD2/3 protein
mediates interactions between the MI-2 chromatin complex and CpT/A-methylated DNA.
Dev. Camb. Engl. 131, 6033–6039. doi:10.1242/dev.01531.
Martín Caballero, I., Hansen, J., Leaford, D., Pollard, S., and Hendrich, B. D. (2009). The methylCpG binding proteins Mecp2, Mbd2 and Kaiso are dispensable for mouse
embryogenesis, but play a redundant function in neural differentiation. PloS One 4,
e4315. doi:10.1371/journal.pone.0004315.
Martin, V., Jørgensen, H. F., Chaubert, A. S. B., Berger, J., Barr, H., Shaw, P., et al. (2008).
MBD2-mediated transcriptional repression of the p14ARF tumor suppressor gene in
human colon cancer cells. Pathobiol. J. Immunopathol. Mol. Cell. Biol. 75, 281–287.
doi:10.1159/000151708.
Maunakea, A. K., Chepelev, I., Cui, K., and Zhao, K. (2013). Intragenic DNA methylation
modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell
Res. 23, 1256–1269. doi:10.1038/cr.2013.110.
Maunakea, A. K., Nagarajan, R. P., Bilenky, M., Ballinger, T. J., D’Souza, C., Fouse, S. D., et al.
(2010). Conserved role of intragenic DNA methylation in regulating alternative promoters.
Nature 466, 253–257. doi:10.1038/nature09165.
124

McQuown, S. C., Barrett, R. M., Matheos, D. P., Post, R. J., Rogge, G. A., Alenghat, T., et al.
(2011). HDAC3 is a critical negative regulator of long-term memory formation. J.
Neurosci. Off. J. Soc. Neurosci. 31, 764–774. doi:10.1523/JNEUROSCI.5052-10.2011.
Meehan, R. R., Lewis, J. D., McKay, S., Kleiner, E. L., and Bird, A. P. (1989). Identification of a
mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58,
499–507. doi:10.1016/0092-8674(89)90430-3.
Meissner, A. (2010). Epigenetic modifications in pluripotent and differentiated cells. Nat.
Biotechnol. 28, 1079–1088. doi:10.1038/nbt.1684.
Mellén, M., Ayata, P., Dewell, S., Kriaucionis, S., and Heintz, N. (2012). MeCP2 binds to 5hmC
enriched within active genes and accessible chromatin in the nervous system. Cell 151,
1417–1430. doi:10.1016/j.cell.2012.11.022.
Menafra, R., Brinkman, A. B., Matarese, F., Franci, G., Bartels, S. J. J., Nguyen, L., et al. (2014).
Genome-Wide Binding of MBD2 Reveals Strong Preference for Highly Methylated Loci.
PLoS ONE 9, e99603. doi:10.1371/journal.pone.0099603.
Mian, O. Y., Wang, S. Z., Zhu, S. Z., Gnanapragasam, M. N., Graham, L., Bear, H. D., et al.
(2011). Methyl-binding domain protein 2-dependent proliferation and survival of breast
cancer cells. Mol. Cancer Res. MCR 9, 1152–1162. doi:10.1158/1541-7786.MCR-110252.
Mitra, P., Xie, R.-L., Medina, R., Hovhannisyan, H., Zaidi, S. K., Wei, Y., et al. (2003).
Identification of HiNF-P, a Key Activator of Cell Cycle-Controlled Histone H4 Genes at the
Onset of S Phase. Mol. Cell. Biol. 23, 8110–8123. doi:10.1128/MCB.23.22.81108123.2003.
Mo, A., Mukamel, E. A., Davis, F. P., Luo, C., Henry, G. L., Picard, S., et al. (2015). Epigenomic
Signatures of Neuronal Diversity in the Mammalian Brain. Neuron 86, 1369–1384.
doi:10.1016/j.neuron.2015.05.018.
Morey, L., Brenner, C., Fazi, F., Villa, R., Gutierrez, A., Buschbeck, M., et al. (2008). MBD3, a
component of the NuRD complex, facilitates chromatin alteration and deposition of
epigenetic marks. Mol. Cell. Biol. 28, 5912–5923. doi:10.1128/MCB.00467-08.
Müller, H. M., Fiegl, H., Goebel, G., Hubalek, M. M., Widschwendter, A., Müller-Holzner, E., et al.
(2003). MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast
tissue and its association with oestrogen receptor status. Br. J. Cancer 89, 1934–1939.
doi:10.1038/sj.bjc.6601392.
Müller-Tidow, C., Kügler, K., Diederichs, S., Klümpen, S., Möller, M., Vogt, U., et al. (2001). Loss
of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer.
Br. J. Cancer 85, 1168–1174. doi:10.1054/bjoc.2001.2041.
Musselman, C. A., Ramirez, J., Sims, J. K., Mansfield, R. E., Oliver, S. S., Denu, J. M., et al.
(2012). Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4
ATPase is required for CHD4-mediated repression. Proc. Natl. Acad. Sci. 109, 787–792.
doi:10.1073/pnas.1113655109.

125

Myers, M. G., Cowley, M. A., and Münzberg, H. (2008). Mechanisms of leptin action and leptin
resistance. Annu. Rev. Physiol. 70, 537–556.
doi:10.1146/annurev.physiol.70.113006.100707.
Nan, X., Campoy, F. J., and Bird, A. (1997). MeCP2 is a transcriptional repressor with abundant
binding sites in genomic chromatin. Cell 88, 471–481.
Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., et al. (1998).
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone
deacetylase complex. Nature 393, 386–389. doi:10.1038/30764.
Ng, H. H., Jeppesen, P., and Bird, A. (2000). Active repression of methylated genes by the
chromosomal protein MBD1. Mol. Cell. Biol. 20, 1394–1406.
Ng, H. H., Zhang, Y., Hendrich, B., Johnson, C. A., Turner, B. M., Erdjument-Bromage, H., et al.
(1999). MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase
complex. Nat. Genet. 23, 58–61. doi:10.1038/12659.
Nicholson, T. B., Chen, T., and Richard, S. (2009). The physiological and pathophysiological role
of PRMT1-mediated protein arginine methylation. Pharmacol. Res. 60, 466–474.
doi:10.1016/j.phrs.2009.07.006.
Noh, K.-M., Wang, H., Kim, H. R., Wenderski, W., Fang, F., Li, C. H., et al. (2015). Engineering of
a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and
Phenotypic Features of Mouse ESCs. Mol. Cell 59, 89–103.
doi:10.1016/j.molcel.2015.05.017.
Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999). DNA methyltransferases Dnmt3a and
Dnmt3b are essential for de novo methylation and mammalian development. Cell 99,
247–257.
Otabi, H., Goto, T., Okayama, T., Kohari, D., and Toyoda, A. (2015). Subchronic and mild social
defeat stress alter mouse nest building behavior. Behav. Processes.
doi:10.1016/j.beproc.2015.10.018.
Palmiter, R. D. (2008). Dopamine Signaling in the Dorsal Striatum Is Essential for Motivated
Behaviors. Ann. N. Y. Acad. Sci. 1129, 35–46. doi:10.1196/annals.1417.003.
Panayotis, N., Ghata, A., Villard, L., and Roux, J.-C. (2011). Biogenic amines and their
metabolites are differentially affected in the Mecp2-deficient mouse brain. BMC Neurosci.
12, 47. doi:10.1186/1471-2202-12-47.
Parry, L., and Clarke, A. R. (2011). The Roles of the Methyl-CpG Binding Proteins in Cancer.
Genes Cancer 2, 618–630. doi:10.1177/1947601911418499.
Pasciuto, E., Borrie, S. C., Kanellopoulos, A. K., Santos, A. R., Cappuyns, E., D’Andrea, L., et al.
(2015). Autism Spectrum Disorders: Translating human deficits into mouse behavior.
Neurobiol. Learn. Mem. doi:10.1016/j.nlm.2015.07.013.
Pastor, W. A., Aravind, L., and Rao, A. (2013). TETonic shift: biological roles of TET proteins in
DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14, 341–356.
doi:10.1038/nrm3589.
126

Pastor, W. A., Pape, U. J., Huang, Y., Henderson, H. R., Lister, R., Ko, M., et al. (2011).
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473,
394–397. doi:10.1038/nature10102.
Perissi, V., Jepsen, K., Glass, C. K., and Rosenfeld, M. G. (2010). Deconstructing repression:
evolving models of co-repressor action. Nat. Rev. Genet. 11, 109–123.
doi:10.1038/nrg2736.
Phesse, T. J., Parry, L., Reed, K. R., Ewan, K. B., Dale, T. C., Sansom, O. J., et al. (2008).
Deficiency of Mbd2 attenuates Wnt signaling. Mol. Cell. Biol. 28, 6094–6103.
doi:10.1128/MCB.00539-08.
Pohodich, A. E., and Zoghbi, H. Y. (2015). Rett syndrome: disruption of epigenetic control of
postnatal neurological functions. Hum. Mol. Genet. doi:10.1093/hmg/ddv217.
Pontes, T. B., Chen, E. S., Gigek, C. O., Calcagno, D. Q., Wisnieski, F., Leal, M. F., et al. (2014).
Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. Tumour
Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 35, 3447–3453. doi:10.1007/s13277-0131455-y.
Potts, R. C., Zhang, P., Wurster, A. L., Precht, P., Mughal, M. R., Wood, W. H., et al. (2011).
CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates
expression of neuronal genes. PloS One 6, e24515. doi:10.1371/journal.pone.0024515.
Prokhortchouk, A., Hendrich, B., Jørgensen, H., Ruzov, A., Wilm, M., Georgiev, G., et al. (2001).
The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional
repressor. Genes Dev. 15, 1613–1618. doi:10.1101/gad.198501.
Prokhortchouk, A., Sansom, O., Selfridge, J., Caballero, I. M., Salozhin, S., Aithozhina, D., et al.
(2006). Kaiso-deficient mice show resistance to intestinal cancer. Mol. Cell. Biol. 26, 199–
208. doi:10.1128/MCB.26.1.199-208.2006.
Rais, Y., Zviran, A., Geula, S., Gafni, O., Chomsky, E., Viukov, S., et al. (2013). Deterministic
direct reprogramming of somatic cells to pluripotency. Nature 502, 65–70.
doi:10.1038/nature12587.
Ramírez, J., Dege, C., Kutateladze, T. G., and Hagman, J. (2012). MBD2 and multiple domains of
CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol. Cell.
Biol. 32, 5078–5088. doi:10.1128/MCB.00819-12.
Reed, D. R., Lawler, M. P., and Tordoff, M. G. (2008). Reduced body weight is a common effect
of gene null in mice. BMC Genet. 9, 4. doi:10.1186/1471-2156-9-4.
Reese, B. E., Bachman, K. E., Baylin, S. B., and Rountree, M. R. (2003). The methyl-CpG
binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1.
Mol. Cell. Biol. 23, 3226–3236.
Rendenbach, C., Ganswindt, S., Seitz, S., Barvencik, F., Huebner, A. K., Baranowsky, A., et al.
(2013). Increased Expression of Transthyretin in Leptin-Deficient ob/ob Mice is not
Causative for Their Major Phenotypic Abnormalities. J. Neuroendocrinol. 25, 14–22.
doi:10.1111/j.1365-2826.2012.02366.x.

127

Reynolds, N., Latos, P., Hynes-Allen, A., Loos, R., Leaford, D., O’Shaughnessy, A., et al. (2012).
NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity
and lineage commitment. Cell Stem Cell 10, 583–594. doi:10.1016/j.stem.2012.02.020.
Reynolds, N., O’Shaughnessy, A., and Hendrich, B. (2013). Transcriptional repressors:
multifaceted regulators of gene expression. Dev. Camb. Engl. 140, 505–512.
doi:10.1242/dev.083105.
Robinson, M. D., McCarthy, D. J., and Smyth, G. K. (2010). edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. Bioinforma. Oxf. Engl. 26,
139–140. doi:10.1093/bioinformatics/btp616.
Roloff, T. C., Ropers, H. H., and Nuber, U. A. (2003). Comparative study of methyl-CpG-binding
domain proteins. BMC Genomics 4, 1.
Saito, M., and Ishikawa, F. (2002). The mCpG-binding domain of human MBD3 does not bind to
mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J. Biol. Chem. 277,
35434–35439. doi:10.1074/jbc.M203455200.
Sansom, O. J. (2004). Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and
migration. Genes Dev. 18, 1385–1390. doi:10.1101/gad.287404.
Sansom, O. J., Berger, J., Bishop, S. M., Hendrich, B., Bird, A., and Clarke, A. R. (2003).
Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34, 145–147.
doi:10.1038/ng1155.
Sapkota, Y., Mackey, J. R., Lai, R., Franco-Villalobos, C., Lupichuk, S., Robson, P. J., et al.
(2014). Assessing SNP-SNP interactions among DNA repair, modification and
metabolism related pathway genes in breast cancer susceptibility. PloS One 8, e64896.
doi:10.1371/journal.pone.0064896.
Sarraf, S. A., and Stancheva, I. (2004). Methyl-CpG binding protein MBD1 couples histone H3
methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol. Cell
15, 595–605. doi:10.1016/j.molcel.2004.06.043.
Schoch, H., and Abel, T. (2014). Transcriptional co-repressors and memory storage.
Neuropharmacology 80, 53–60. doi:10.1016/j.neuropharm.2014.01.003.
Schübeler, D. (2015). Function and information content of DNA methylation. Nature 517, 321–
326. doi:10.1038/nature14192.
Schultz, M. D., He, Y., Whitaker, J. W., Hariharan, M., Mukamel, E. A., Leung, D., et al. (2015).
Human body epigenome maps reveal noncanonical DNA methylation variation. Nature.
doi:10.1038/nature14465.
Schwartz, M. W. (2005). Diabetes, Obesity, and the Brain. Science 307, 375–379.
doi:10.1126/science.1104344.
Sekimata, M., Takahashi, A., Murakami-Sekimata, A., and Homma, Y. (2001). Involvement of a
novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methylCpG-binding protein, MBD2. J. Biol. Chem. 276, 42632–42638.
doi:10.1074/jbc.M107048200.
128

Sellars, M., Huh, J. R., Day, K., Issuree, P. D., Galan, C., Gobeil, S., et al. (2015). Regulation of
DNA methylation dictates Cd4 expression during the development of helper and cytotoxic
T cell lineages. Nat. Immunol. 16, 746–754. doi:10.1038/ni.3198.
Shahbazian, M. D., Antalffy, B., Armstrong, D. L., and Zoghbi, H. Y. (2002). Insight into Rett
syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with
neuronal maturation. Hum. Mol. Genet. 11, 115–124.
Sheaffer, K. L., Kim, R., Aoki, R., Elliott, E. N., Schug, J., Burger, L., et al. (2014). DNA
methylation is required for the control of stem cell differentiation in the small intestine.
Genes Dev. 28, 652–664. doi:10.1101/gad.230318.113.
Shen, W., Wang, C., Xia, L., Fan, C., Dong, H., Deckelbaum, R. J., et al. (2014). Epigenetic
modification of the leptin promoter in diet-induced obese mice and the effects of N-3
polyunsaturated fatty acids. Sci. Rep. 4, 5282. doi:10.1038/srep05282.
Shih, H.-Y., Sciumè, G., Poholek, A. C., Vahedi, G., Hirahara, K., Villarino, A. V., et al. (2014).
Transcriptional and epigenetic networks of helper T and innate lymphoid cells. Immunol.
Rev. 261, 23–49. doi:10.1111/imr.12208.
Shlyueva, D., Stampfel, G., and Stark, A. (2014). Transcriptional enhancers: from properties to
genome-wide predictions. Nat. Rev. Genet. 15, 272–286. doi:10.1038/nrg3682.
Shukeir, N., Pakneshan, P., Chen, G., Szyf, M., and Rabbani, S. A. (2006). Alteration of the
methylation status of tumor-promoting genes decreases prostate cancer cell
invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66, 9202–9210.
doi:10.1158/0008-5472.CAN-06-1954.
Skene, P. J., Illingworth, R. S., Webb, S., Kerr, A. R. W., James, K. D., Turner, D. J., et al. (2010).
Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the
chromatin state. Mol. Cell 37, 457–468. doi:10.1016/j.molcel.2010.01.030.
Smith, Z. D., and Meissner, A. (2013). DNA methylation: roles in mammalian development. Nat.
Rev. Genet. 14, 204–220. doi:10.1038/nrg3354.
Spruijt, C. G., Gnerlich, F., Smits, A. H., Pfaffeneder, T., Jansen, P. W. T. C., Bauer, C., et al.
(2013). Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives.
Cell 152, 1146–1159. doi:10.1016/j.cell.2013.02.004.
Spruijt, C. G., and Vermeulen, M. (2014). DNA methylation: old dog, new tricks? Nat. Struct. Mol.
Biol. 21, 949–954. doi:10.1038/nsmb.2910.
Stefanska, B., Suderman, M., Machnes, Z., Bhattacharyya, B., Hallett, M., and Szyf, M. (2013).
Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by
methylated DNA-binding protein MBD2. Carcinogenesis 34, 2738–2749.
doi:10.1093/carcin/bgt273.
Stroud, H., Feng, S., Morey Kinney, S., Pradhan, S., and Jacobsen, S. E. (2011). 5Hydroxymethylcytosine is associated with enhancers and gene bodies in human
embryonic stem cells. Genome Biol. 12, R54. doi:10.1186/gb-2011-12-6-r54.
Sunyer, B., Patil, S., Höger, H., and Luber, G. (2007). Barnes maze, a useful task to assess
spatial reference memory in the mice. Protoc. Exch. doi:10.1038/nprot.2007.390.
129

Suzuki, M. M., and Bird, A. (2008). DNA methylation landscapes: provocative insights from
epigenomics. Nat. Rev. Genet. 9, 465–476. doi:10.1038/nrg2341.
Szulwach, K. E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., et al. (2011). 5-hmC-mediated
epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14,
1607–1616. doi:10.1038/nn.2959.
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., et al. (2009).
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL
partner TET1. Science 324, 930–935. doi:10.1126/science.1170116.
Talkowski, M. E., Mullegama, S. V., Rosenfeld, J. A., van Bon, B. W. M., Shen, Y., Repnikova, E.
A., et al. (2011). Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a
single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am.
J. Hum. Genet. 89, 551–563. doi:10.1016/j.ajhg.2011.09.011.
Tan, C. P., and Nakielny, S. (2006). Control of the DNA methylation system component MBD2 by
protein arginine methylation. Mol. Cell. Biol. 26, 7224–7235. doi:10.1128/MCB.00473-06.
Tan, D. W.-M., and Barker, N. (2014). “Intestinal Stem Cells and Their Defining Niche,” in Current
Topics in Developmental Biology (Elsevier), 77–107. Available at:
http://linkinghub.elsevier.com/retrieve/pii/B9780124160224000032 [Accessed December
2, 2015].
Tatematsu, K. I., Yamazaki, T., and Ishikawa, F. (2000). MBD2-MBD3 complex binds to hemimethylated DNA and forms a complex containing DNMT1 at the replication foci in late S
phase. Genes Cells Devoted Mol. Cell. Mech. 5, 677–688.
Theoharides, T. C., Athanassiou, M., Panagiotidou, S., and Doyle, R. (2015). Dysregulated brain
immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. J.
Neuroimmunol. 279, 33–38. doi:10.1016/j.jneuroim.2014.12.003.
Thomson, J. P., Skene, P. J., Selfridge, J., Clouaire, T., Guy, J., Webb, S., et al. (2010). CpG
islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 464,
1082–1086. doi:10.1038/nature08924.
Torchy, M. P., Hamiche, A., and Klaholz, B. P. (2015). Structure and function insights into the
NuRD chromatin remodeling complex. Cell. Mol. Life Sci. CMLS 72, 2491–2507.
doi:10.1007/s00018-015-1880-8.
Torres-Andrade, R., Moldenhauer, R., Gutierrez-Bertin, N., Soto-Covasich, J., Mancilla-Medina,
C., Ehrenfeld, C., et al. (2014). The increase in body weight induced by the lacking of
Mecp2 is associated with altered leptin-signalling in the hypothalamus. Exp. Physiol.
doi:10.1113/expphysiol.2014.079798.
Tou, J. C. L., and Wade, C. E. (2002). Determinants affecting physical activity levels in animal
models. Exp. Biol. Med. Maywood NJ 227, 587–600.
Tsoi, L. C., Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., et al. (2012).
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
Nat. Genet. 44, 1341–1348. doi:10.1038/ng.2467.

130

Turner, J. D., Alt, S. R., Cao, L., Vernocchi, S., Trifonova, S., Battello, N., et al. (2010).
Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.
Biochem. Pharmacol. 80, 1860–1868. doi:10.1016/j.bcp.2010.06.037.
Unoki, M., Nishidate, T., and Nakamura, Y. (2004). ICBP90, an E2F-1 target, recruits HDAC1 and
binds to methyl-CpG through its SRA domain. Oncogene 23, 7601–7610.
doi:10.1038/sj.onc.1208053.
Wade, P. A., Gegonne, A., Jones, P. L., Ballestar, E., Aubry, F., and Wolffe, A. P. (1999). Mi-2
complex couples DNA methylation to chromatin remodelling and histone deacetylation.
Nat. Genet. 23, 62–66. doi:10.1038/12664.
Walsh, C. P., Chaillet, J. R., and Bestor, T. H. (1998). Transcription of IAP endogenous
retroviruses is constrained by cytosine methylation. Nat. Genet. 20, 116–117.
Wang, L., Liu, Y., Han, R., Beier, U. H., Thomas, R. M., Wells, A. D., et al. (2013). Mbd2
promotes foxp3 demethylation and T-regulatory-cell function. Mol. Cell. Biol. 33, 4106–
4115. doi:10.1128/MCB.00144-13.
Waterfield, M., Khan, I. S., Cortez, J. T., Fan, U., Metzger, T., Greer, A., et al. (2014). The
transcriptional regulator Aire coopts the repressive ATF7ip-MBD1 complex for the
induction of immunotolerance. Nat. Immunol. 15, 258–265. doi:10.1038/ni.2820.
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D’Alessio, A. C., Sharma, S., Seckl, J. R., et al.
(2004). Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847–854.
doi:10.1038/nn1276.
Weaver, I. C. G., Hellstrom, I. C., Brown, S. E., Andrews, S. D., Dymov, S., Diorio, J., et al.
(2014). The methylated-DNA binding protein MBD2 enhances NGFI-A (egr-1)-mediated
transcriptional activation of the glucocorticoid receptor. Philos. Trans. R. Soc. B Biol. Sci.
369, 20130513–20130513. doi:10.1098/rstb.2013.0513.
Yamada, T., Yang, Y., Hemberg, M., Yoshida, T., Cho, H. Y., Murphy, J. P., et al. (2014).
Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic
connectivity in the mammalian brain. Neuron 83, 122–134.
doi:10.1016/j.neuron.2014.05.039.
Yang, L., Gilbert, M. L., Zheng, R., and McKnight, G. S. (2014a). Selective Expression of a
Dominant-Negative Type Ια PKA Regulatory Subunit in Striatal Medium Spiny Neurons
Impairs Gene Expression and Leads to Reduced Feeding and Locomotor Activity. J.
Neurosci. 34, 4896–4904. doi:10.1523/JNEUROSCI.3460-13.2014.
Yang, M., and Crawley, J. N. (2009). “Simple Behavioral Assessment of Mouse Olfaction,” in
Current Protocols in Neuroscience, eds. J. N. Crawley, C. R. Gerfen, M. A. Rogawski, D.
R. Sibley, P. Skolnick, and S. Wray (Hoboken, NJ, USA: John Wiley & Sons, Inc.).
Available at: http://doi.wiley.com/10.1002/0471142301.ns0824s48 [Accessed July 3,
2015].
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., and Liang, G. (2014b). Gene
body methylation can alter gene expression and is a therapeutic target in cancer. Cancer
Cell 26, 577–590. doi:10.1016/j.ccr.2014.07.028.

131

Yi, C.-X., and Tschop, M. H. (2012). Brain-gut-adipose-tissue communication pathways at a
glance. Dis. Model. Mech. 5, 583–587. doi:10.1242/dmm.009902.
Yildirim, O., Li, R., Hung, J.-H., Chen, P. B., Dong, X., Ee, L.-S., et al. (2011). Mbd3/NURD
complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic
stem cells. Cell 147, 1498–1510. doi:10.1016/j.cell.2011.11.054.
Yoder, J. A., and Bestor, T. H. (1998). A candidate mammalian DNA methyltransferase related to
pmt1p of fission yeast. Hum. Mol. Genet. 7, 279–284.
Yoshida, T., Hazan, I., Zhang, J., Ng, S. Y., Naito, T., Snippert, H. J., et al. (2008). The role of the
chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage
differentiation. Genes Dev. 22, 1174–1189. doi:10.1101/gad.1642808.
Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, D. (1999).
Analysis of the NuRD subunits reveals a histone deacetylase core complex and a
connection with DNA methylation. Genes Dev. 13, 1924–1935.
Zhao, X., Ueba, T., Christie, B. R., Barkho, B., McConnell, M. J., Nakashima, K., et al. (2003).
Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and
hippocampal function. Proc. Natl. Acad. Sci. U. S. A. 100, 6777–6782.
doi:10.1073/pnas.1131928100.
Zhong, J., Yu, Q., Yang, P., Rao, X., He, L., Fang, J., et al. (2014). MBD2 regulates TH17
differentiation and experimental autoimmune encephalomyelitis by controlling the
homeostasis of T-bet/Hlx axis. J. Autoimmun. doi:10.1016/j.jaut.2014.05.006.
Zhou, X., Jeker, L. T., Fife, B. T., Zhu, S., Anderson, M. S., McManus, M. T., et al. (2008).
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J. Exp.
Med. 205, 1983–1991. doi:10.1084/jem.20080707.
Zhou, Z., Hong, E. J., Cohen, S., Zhao, W.-N., Ho, H.-Y. H., Schmidt, L., et al. (2006). Brainspecific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription,
dendritic growth, and spine maturation. Neuron 52, 255–269.
doi:10.1016/j.neuron.2006.09.037.
Zhu, D., Hunter, S. B., Vertino, P. M., and Meir, E. G. V. (2011). Overexpression of MBD2 in
Glioblastoma Maintains Epigenetic Silencing and Inhibits the Antiangiogenic Function of
the Tumor Suppressor Gene BAI1. Cancer Res. 71, 5859–5870. doi:10.1158/00085472.CAN-11-1157.
Zhu, Y., Brown, H. N., Zhang, Y., Holford, T. R., and Zheng, T. (2005). Genotypes and
haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent
upon menopausal status. Breast Cancer Res. BCR 7, R745–752. doi:10.1186/bcr1283.
Zhu, Y., Harrison, D. J., and Bader, S. A. (2004). Genetic and epigenetic analyses of MBD3 in
colon and lung cancer. Br. J. Cancer 90, 1972–1975. doi:10.1038/sj.bjc.6601776.

132

